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INTERROGATING DUX4 MRNA 3’END FORMATION 
  
Natoya Janeen Peart, B.S 
 
Advisory Professor: Eric J. Wagner, Ph.D. 
 
Double Homeobox 4, Dux4, is the leading candidate gene for Facioscapulohumeral 
Dystrophy (FSHD). FSHD is the third most common muscular dystrophy, and is 
characterized by progressive muscle weakness primarily in the upper body. In individuals 
diagnosed with FSHD, Dux4 is inappropriately expressed in somatic cells due to two 
conditions. The first is hypomethylation of the subtelomeric D4Z4 repeats on chromosome 4. 
Each D4Z4 repeat on chromosome 4 is 3.3kb in length and contains the open reading frame 
for Dux4. Hypomethylation of the D4Z4 repeats primarily occurs due to contraction of the 
repeats from 11-100 (typical numbers in the healthy population) to between 1 and 10 
repeats. Concomitant with the hypomethylation of the D4Z4 repeats on chromosome 4 is a 
single nucleotide polymorphism in the flanking DNA that generates a non-consensus 
polyadenylation signal (PAS). This PAS allows for the productive transcription of a 
polyadenylated Dux4 mRNA from the terminal D4Z4 repeat. Dux4 is anemically expressed 
in patient somatic cells, but contributes to FSHD pathology due to Dux4-dependent cellular 
reprogramming.  
We aim to understand what regulatory elements facilitate the cleavage and 
polyadenylation (CPA) of the Dux4 mRNA beyond the non-consensus PAS and to 
determine if inefficient CPA underlies the poor expression of Dux4 in patient cells. We 
viii 
 
designed a transcriptional read-through reporter to assay cleavage and polyadenylation in 
cells and confirm that additional cis elements are required for CPA of Dux4 besides the non-
consensus PAS. This element is located outside the region where cis regulatory elements 
for CPA are usually present. Moreover, the element which lies downstream of the PAS, is 
within a degenerate repeat region, called β-satellite DNA. Using the knowledge gained from 
characterizing Dux4 mRNA 3′end formation, we designed antisense oligonucleotides 
(ASOs) to impair the production of polyadenylated Dux4. Prior to antagonizing Dux4 CPA, 
we demonstrate, in proof of principle experiments that ASOs directed toward required CPA 
regulatory elements can impair gene expression, and may redirect polyadenylation. Finally, 
the work presented here lays the foundation for us to impair Dux4 CPA in reporter driven 
assays and patient cells; and to exploit currently available deep sequencing technology to 
determine the specificity of PAS-directed ASOs.  
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Chapter 1 : Eukaryotic RNA Processing 
Whatever begins, also ends? 
-Seneca the Younger 
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What is RNA Processing? 
Ribonucleic Acid (RNA) is one the three major macromolecules important for life. In 
eukaryotes, genetic material is stored in the deoxyribonucleic acid (DNA) and then 
transmitted as RNA in response to stimuli, to catalyze reactions, regulate gene expression, 
influence cell structure, and regulate cell behavior, in part through the translation of the RNA 
into a protein. There are many types of RNA molecules and they serve important roles in the 
eukaryotic cell. Here, I will provide background on RNA processing by focusing on RNA 
transcribed by RNA Polymerase II (RNAPII). Specifically, I will focus on the maturation and 
metabolism of the RNA accomplished through processing of the 3′ end in order to remove it 
from the template DNA and package it for stability in the nucleus and ultimately cytoplasm.  
Nuclear 3′ end RNA Processing 
RNA polymerase II (RNAPII) is a large multi-subunit and tightly regulated enzyme 
responsible for producing messenger RNA (mRNA), and several non-coding RNA (ncRNA) 
including some microRNAs (miRNAs), small nucleolar RNAs (snoRNAs) and small nuclear 
RNAs (snRNAs). Post translational modifications which regulate the function of RNAPII 
occur on the highly conserved C-terminal domain (CTD) and take the form of various 
phosphorylation events which facilitate initiation, elongation and termination of transcription 
(Hampsey, 1998; Jeronimo et al., 2013; Mayfield et al., 2016). For initiation of transcription, 
RNAPII associates with various factors ranging from the general transcription factors (for 
initiation of transcription of mRNAs) to specific transcription factors such as small nuclear 
RNA activating protein complex (for transcription initiation of snRNAs) (Chen and Wagner, 
2010; Gupta et al., 2016). Following the initiation of transcription and the synthesis of 
nascent RNA, all RNA transcripts have a 5′ triphosphate. Typically, RNAPII transcripts 
undergo additional modification to protect the RNA, by addition of an inverted N7-
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methylguanosine (m7G) to the 5′ terminus of the RNA (Byszewska et al., 2014), which ‘caps’ 
the RNA. Subsequent to capping and during the elongation of the RNA transcript, additional 
processing occurs co-transcriptionally to yield a mature RNA product. For example, the 
majority of eukaryotic mRNAs are spliced to remove introns. However, some RNA 
processing events occur post-transcriptionally depending on the type RNA molecule. For 
example, the m7G cap of several RNAPII substrates, such as spliceosomal snRNAs and 
snoRNAs, undergo additional methylation to form 2,2,7-trimethyl Guanosine (TMG), which 
occurs cytoplasmically and in a few instances in the nucleus (Jády et al., 2004; Seto et al., 
1999; Webb and Zakian, 2008).  
Regardless of their specific downstream function, all RNAPII transcripts must be 
separated from the polymerase and DNA template and protected to avoid non-regulated 
degradation. Unsurprisingly, given the diversity of RNAPII transcripts, the process of 
separating the RNA transcript from the DNA template and RNAPII, as well as protecting the 
3′ terminus of the RNA transcript (here referred to as 3′ end processing) is complex and 
tightly regulated. The mechanism of 3’ end processing can be thought of as a two-step 
event involving first cleavage of the nascent RNA followed by additional modification to 
stabilize the processed transcript. The purpose of cleaving RNAPII transcripts is two-fold.  
First, to release the nascent transcript from the polymerase promoting further modification 
and second  to promote termination of RNAPII through the action of exonucleases (such as 
Xrn2) on the downstream RNA product (Rosonina et al., 2006). The 3′ terminus of the 
transcripts are further modified to stabilize the transcript through the activity of polyA 
polymerase (in the case of mRNA) or by exonucleases to generate a stable secondary 
structure at the 3’ end (in the case of histone mRNA and non-coding RNA).  The process of 
3’ end processing is governed by cis elements and trans acting factors.  Moreover, the 
diversity of RNAPII transcripts means that the regulatory elements of 3′ end processing of 
these transcripts vary tremendously (for reviews see (Legendre and Gautheret, 2003; Peart 
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et al., 2013; Tian and Graber, 2012; Wilusz and Spector, 2010)) .  Below, I provide a brief 
discussion on the cis elements and trans factors that govern many of the RNAPII 3’ end 
processing events including coding RNA (both polyadenylated and non-polyadenylated) and 
non-coding RNA (including snRNA, telomerase RNA, and long non-coding RNA). 
  
The 3’ end formation of non-coding RNA: snRNA 3′end formation is not an integrated tail 
The majority of the Uridine rich small nuclear RNAs (snRNAs) are transcribed by 
RNAPII and are ~60-200 nucleotides in length (Peart et al., 2013). These snRNAs are 
packaged into RNA protein complexes called small nuclear ribonucleoproteins (snRNPs) 
and they facilitate splicing of pre-mRNAs or promote the 3′ end formation of replication 
dependent histone mRNA. In metazoans, transcription of the snRNAs by RNAPII requires 
the small nuclear activating protein complex at the promoter (Jawdekar and Henry, 2008; 
Yoon et al., 1995).This is relevant because the accurate and precise 3′ end formation of the 
RNAPII-transcribed snRNAs is intimately connected to promoter identity as well as the 
distance between the site of termination and the promoter (Hernandez and Weiner, 1986; 
Ramamurthy et al., 1996). The 3′ end formation of the snRNAs is dependent on recognition 
of, not only the correct promoter, but also the 3′box downstream of the gene body and 
specific phosphorylation of the CTD of RNA PII (Figure 1.1A). Together the cis regulatory 
elements allow for the recruitment of a protein complex (Chen and Wagner, 2010; Peart et 
al., 2013), which is responsible for cleaving the snRNA.  
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Figure 1.1. snRNA 3′ end processing in humans and S. cerevisiae. (A). The 3′ end formation 
of the RNAPII transcribed snRNA in humans requires a snRNA specific promoter and 
conserved downstream element, the 3′ box located proximal to the end of the mature 
snRNA. The snRNA promoter is recognized by the small nuclear activating protein complex 
(SNAPc), and with the presence of the general transcription proteins recruits RNAPII. Along 
with the RNAPII, a multi-subunit complex, Integrator, located on the CTD of the polymerase 
is brought in close proximity to the nascent RNA. The snRNA is cleaved by a heterodimer of 
subunits 9 and 11 of the Integrator complex. (B). S. cerevisiae does not have integrator 
proteins and instead the snRNAs are either polyadenylated using the cleavage and 
polyadenylation factors to cleave the RNA and add a poly (A) tail. Another pathway, involves 
endonucleolytic cleavage of a stem loop structure in the pre-snRNA by the RNase, Rnt1. 
Subsequently, the snRNA can be further trimmed to generate the final 3′ terminus. 
Alternatively, the snRNA 3′ end formation uses the Nrd1/Nab3/Sen1 termination pathway to 
cause the release of the nascent RNA from the polymerase.   
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In metazoans, snRNA 3′ end formation is accomplished by a large multi-protein 
complex, termed the Integrator complex (Baillat et al., 2005). The Integrator complex is 
comprised of ~14 subunits, which play different but as yet unresolved roles in snRNA 
transcription and termination (Baillat et al., 2005; Chen and Wagner, 2010; Chen et al., 
2012). The subunits responsible for cleaving the snRNA are Integrator subunit 9 and 
Integrator subunit 11, and following the cleavage by these subunits the snRNA is released 
from the DNA template (Figure 1.1A). Several of the Integrator subunits display reciprocal 
dependency, in that depletion of one subunit leads to the depletion of another (Albrecht and 
Wagner, 2012), however the functional relevance of this observation for snRNA 3′ end 
formation is not straightforward. The RNA binding partner within the complex is unknown 
resulting in a black box for how Integrator positions the RNA for cleavage; and while it is 
known that the Integrator associates with the CTD of RNAPII, during snRNA transcription, 
the sequence of events leading to the recruitment of the Integrator complex to facilitate 
cleavage of the snRNA remains nebulous (Baillat and Wagner, 2015). However, the identity 
of the protein complex, as well as the cis requirements for snRNA 3′ end formation is not 
conserved between metazoans and fungi (Peart et al., 2013). 
In certain fungi, such as Saccharomyces cerevisiae, the cleavage and subsequent 3′ 
end of the Uridine rich snRNA is accomplished through several distinct processes, which 
may act as a failsafe to ensure the production of the snRNA (reviewed by (Peart et al., 
2013)). The snRNAs in S. cerevisiae are processed at the 3′ terminus utilizing 
endonucleolytic cleavage, exonucleolytic trimming and tailing. One pathway, uses 
endonucleolytic cleavage of S. cerevisiae snRNA by Rnt1, a double strand specific RNase 
III, which cuts the stem loop of pre-snRNA to release a transcript with an unprotected 3′ OH. 
This pre-snRNA is then trimmed by the exonuclease, like the RNA Exosome or Rex1. 
Alternate pathways use transcription termination by means of the Nrd1/Nab3/Sen1 pathway, 
or likely involve the cleavage and polyadenylation factor complex (Peart et al., 2013). 
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U2snRNA in yeast can be polyadenylated utilizing the components of the cleavage and 
polyadenylation machinery, although some of the factors were dispensable for processing 
(Abou Elela and Ares, 1998; Morlando et al., 2002). Still, snRNAs in S. cerevisiae also use 
the polyadenylation independent Nrd1/Nab3/Sen1 pathway, which has some functional 
interconnections with the cleavage and polyadenylation machinery (Porrua and Libri, 2015). 
Nrd1 and Nab3 are RNA binding proteins, and Sen1 is a helicase; the three proteins can 
associate with a phosphorylated RNAPII CTD, and play an important role in termination of 
RNA PII transcription (Arndt and Reines, 2015). Thus, utilization of this pathway effectively 
couples transcription termination with RNA 3′end formation. Despite the different complexes 
required for 3′ end formation of snRNA in fungi and vertebrates, the subsequent fate of the 
snRNAs is similar.  
  
The 3’ end formation of non-coding RNA: telomerase RNA 3′end formation, means to an 
end. 
The telomerase RNA is transcribed by RNAPII in vertebrates and fungi and forms the 
RNA component of the telomerase enzyme, which maintains the length of the telomere. The 
sequence of the telomerase RNA varies, and only few of the critical secondary structure 
elements are highly conserved (Rubtsova et al., 2012). Variability in the conservation of 
several elements, reflects the diversity in how the RNA is processed despite the end result 
from all species being the formation of the ribonucleoprotein telomerase. Like the snRNAs, 
the telomerase RNA also harbors a hypermethylated m7G in Homo sapiens, 
Schizosaccharomyces pombe and Saccharomyces cerevisiae (Jády et al., 2004; Seto et al., 
1999; Webb and Zakian, 2008). While significant inroads have been made in identifying and 
characterizing the 3′ end formation of several RNAPII transcripts, most notably mRNA which 
will be discussed later and snRNAs, this compendium of knowledge is less generalized and 
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congruent for telomerase RNA. The insights that have been gathered over the past few 
years for the formation of 3′ end formation of telomerase RNA (hereafter referred to as TER 
for simplicity) show great diversity between fungi and vertebrates (Rubtsova et al., 2012).  
In H. sapiens, and presumably other vertebrates the formation of the 3′ terminus of 
TER is dependent on a highly conserved domains, CR7 and box H/ACA (Figure 1.2A) 
(Mitchell et al., 1999; Theimer et al., 2007). This domain combination is a unique feature to 
vertebrate TER (Chen and Greider, 2004). The H/ACA motif is a feature of a class of 
snoRNAs and the 3′ end processing is likely analogous (Balakin et al., 1996; Mitchell et al., 
1999), however the precise mechanism is yet to be delineated. While heterologous 
expression of the human TER in S. cerevisiae indicates that it 3′ end processing is 
dependent on several protein factors that mediate processing of yeast H/ACA snRNAs (Dez 
et al., 2001), the additional requirement of the CR7 domain for 3′ processing (Fu and Collins, 
2003) of the human TER suggests that novel factors are in play. 
In yeast, the 3′ terminus of TER is defined after the Sm binding site (Figure 1.2A) 
(Gunisova et al., 2009). However, the different yeast species process the 3′ terminus 
differently, two case examples, S. pombe and S. cerevisiae using will be presented.  
In S. cerevisiae there are also two forms of TER, a polyadenylated and non-
polyadenylated form, the former being a minor species. The major non-polyadenylated 
species ultimately forms the RNA component of the TER. Rather than being processed from 
the longer polyadenylated species (Chapon et al., 1997), the non-polyadenylated TER 
appears to be processed independently (Noël et al., 2012). The TER of S. cerevisiae has 
multiple 3′ end processing signals, one of which is dependent on the Nrd1/Nab3 termination 
pathway (Noël et al., 2012). The other appears to utilize the canonical pathway for cleaving 
and polyadenylation. Polyadenylated TER production is dependent on the Cleavage Factor 
and PolyA polymerase (Chapon et al., 1997), which are essential factors for cleavage and 
polyadenylation of mRNA in budding yeast. This observation has created a model where the 
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polyadenylated form of TER appears to be generated from transcriptional read-through, but 
what its functional role is or whether it is further processed is unclear. To create the non-
polyadenylation form of TER, it is thought that the Nrd1/Nab3 protein complex binds to a 
terminator sequence in TER and facilitates termination of TER. An intriguing idea posited 
suggests that presence of non-polyadenylated and polyadenylated forms of TER in several 
yeast species (although the 3′ end formation process is accomplished through different 
means) is a kind of precautionary measure to ensure the production of the required RNA 
(Noël et al., 2012). Interestingly, this Nrd1/Nab3 dependence for TER 3′ end processing did 
not show a dependency on the Sen1 helicase. This may be analogous to the some of the 
functional redundancy of snRNA 3′ end processing in S. cerevisiae (Peart et al., 2013). In 
both humans and S. cerevisiae the precise exonuclease that trims the mature TER or the 
endonuclease which cleaves the TER from the DNA template after the cleavage site is 
demarcated by the interacting protein is unclear.  
Two models for the formation of mature TER are possible. Non-polyadenylated TER 
and polyadenylated TER in both humans and S. cerevisiae may be differentially processed, 
utilizing different endonucleases corresponding to the cis elements present. Alternatively, 
the polyadenylated forms of TER may also be a precursor for the mature TER (Chapon et 
al., 1997). It has led to the speculation that nuclear exosome may play a role in this process, 
where, in S. cerevisiae the Sm site in the TER likely bound by Sm proteins marks the 
termination site to which the exosome trims the polyadenylated precursor (Figure 1.2B) (Coy 
et al., 2013).   
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Figure 1.2. Yeast and Human Telomerase RNA 3′ end processing. (A). Signals required for 
Telomerase 3′ end formation in humans and yeast. Efficient TER 3′ end processing in 
humans requires a CR7 loop (indicated by red box) and H/ACA box, the human TER is not 
polyadenylated. Yeast TER may be polyadenylated, however, mature TER incorporated into 
the telomerase do not necessarily require poly(A) tails.  The 3′ terminus of yeast TER share 
a Sm site (posited to act as a boundary element), X indicates additional cis elements used 
by different yeast genus to generate mature TER. (B). 3′ end formation of TER in S. 
cerevisiae uses two distinct pathways to generate mature TER.  S. cerevisiae uses 
Nrd1/Nab3 termination complex to terminate transcription and release the nascent TER. The 
Sm protein bound TER is protected from exonucleolytic degradation. Alternatively, the  
Cleavage and Polyadenylation (CPF) proteins are recruited to cleave the nascent TER 
which is subsequently polyadenylated. C. The TER in yeast of the genus 
Schizosaccharomyces contain a suboptimal intron. An incomplete splicing reaction, 
dependent modulated by stringency of snRNP binding to the splice regulators, 5′  or 3′ splice 
site (SS) and branch point (BP). The Sm binding site, bound by Sm proteins, is also required 
for the generation of mature TER. The first transesterification reaction of splicing is 
completed, by exon ligation is suppressed and the 3′ exon and lariat are discarded. The Sm 
proteins (white circles) promote the trimethylation of the m7G cap of the TER, and then are 
replaced by the Lsm proteins (yellow circles). 
  
13 
 
Like in S. cerevisiae, the mature TER of S. pombe that forms a subunit of telomerase 
is the non-polyadenylated form, however in S. pombe, the 3′ end formation of TER uses the 
spliceosome, to cleave the mature TER from the polyadenylated precursor (Figure 1.2C) 
(Box et al., 2008). The spliceosome is a large ribonucleoprotein complex that typically 
removes introns from pre-mRNAs, by catalyzing transesterification reactions, which excise 
an intron, and ligate the flanking exons (Matera and Wang, 2014; Smith et al., 2008). An 
analysis of the polyadenylated TER in S. pombe revealed that a small portion had an 
internal deletion of 56 nucleotides, closer analysis of this deletion revealed that the TER 
contained an intron. Intriguingly, removal of this intron or substituting a heterologous 
efficiently spliced intron resulted in a decrease in the mature form TER (Box et al., 2008).  
The 5′ splice site is recognized by the U1snRNP  (Box et al., 2008) which is the first step of 
canonical splicing reactions in eukaryotes (Smith et al., 2008). However, in contrast to the 
canonical splicing reactions with two transesterification, completion of only the first 
transesterification reaction is required for generation of mature TER (Box et al., 2008).The 5′ 
splice site in TER overlaps with the Sm binding site and it was subsequently demonstrated 
that Sm protein binding is critical for spliceosomal cleavage (Tang et al., 2012) and thus Sm 
protein binding may impair the second transesterification reaction. Subsequent to the 
spliceosomal cleavage, the Sm proteins are replaced by Lsm proteins which stabilize the 
mature TER (Tang et al., 2012). Spliceosomal cleavage is conserved in yeast of the genus 
Schizosaccharomyces (Kannan et al., 2015) and possibly in other yeast as splice sites were 
detected in TER genes in several yeast of the genus Candida (Gunisova et al., 2009). A 
significant contribution to impairment of the complete splicing reaction in the TER is a 
distortion of the kinetics of splicing due to the suboptimality of the intron ((Kannan et al., 
2013, 2015) and reviewed (Peart et al., 2013)). 
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The 3’ end formation of non-coding RNA: A NEAT trick  
The nuclear enriched abundant transcripts, NEAT1 and NEAT2 are mammalian 
conserved polyadenylated long non-coding RNA (lncRNA) (Hutchinson et al., 2007). NEAT1 
is a structural lncRNA essential for paraspeckles in the nucleus of mammalian cells 
(Sunwoo et al., 2009). Paraspeckles are subnuclear compartments suggested to control 
gene expression by retaining certain RNA molecules in the nucleus. They may also serve as 
marker for loss of pluripotency (reviewed by (Bond and Fox, 2009; Yamazaki and Hirose, 
2015)). NEAT2, also known as MALAT1 for metastasis-associated lung adenocarcinoma 
transcript 1, is a long lived lncRNA that is frequently associated with several cancers, and 
plays inconclusive roles in modulating mRNA splicing and influencing gene activation 
(Gutschner et al., 2013). Both NEAT1 and NEAT2 are polyadenylated, however, they also 
undergo additional processing to generate a triple helical structure at the 3′ terminus which 
is essential for stabilization ((Brown et al., 2012; Wilusz et al., 2012). NEAT1 is transcribed 
as two isoforms Menε (a polyadenylated ~3.2kb  lncRNA) and Menβ (a non-polyadenylated 
~23kb lncRNA), while NEAT2 is processed to generate the nuclear retained MALAT1 and a 
cytoplasmic short-lived mascRNA (Wilusz et al., 2008, 2012).  Menβ and Malat1 do not have 
canonical polyadenosine tails, instead they have an encoded run of adenosines at the 3′ 
ends (cleavage of the RNA occurs after the run of encoded adenosines). The polyadenosine 
tails at the 3′ ends are both short, however, the transcripts are surprising stable (Sunwoo et 
al., 2009; Wilusz et al., 2008). The presence of adenosine stretch in the template DNA and 
the lack of signals for cleavage and polyadenylation near the 3′ ends revealed a novel 
method of processing the 3′ ends of an RNAPII transcript. Illumination of this process was 
possible due to presence of small non-coding RNA, mascRNA. The mascRNA structurally 
resembles a transfer RNA as it is predicted to adopt a cloverleaf fold and has a CCA 
modification at the 3′ end. The 5′ end of mascRNA corresponds to the 3′ end of the Malat1 
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lncRNA, and production of mascRNA was dependent on Malat1 production. This led to the 
speculation, which was proven, that the 3′ ends of the Malat1 lncRNA is processed by 
endoribonuclease, RNase P (Wilusz et al., 2008). RNase P cleaves Malat1 and Menε/β 
downstream after the encoded adenosine stretch to generate an lncRNA with a short tail, 
upstream of the tRNA like fold. The downstream product of the cleavage in the case of 
mascRNA is further processed at its 3′ terminus by RNase Z, prior to the addition of the 
CCA (Figure 1.3). It remains unclear if the process occurs co-transcriptionally or post 
transcriptionally (that is, if the process occurs prior to a canonical cleavage and 
polyadenylation event or on an already cleaved and polyadenylated transcript) (Sunwoo et 
al., 2009; Wilusz et al., 2008).  
The stability of Menε/β and Malat1 given their short adenosine tails was surprising. 
Located near the 3′ end of the Menε/β and Malat1 RNA there is a conserved A and U rich 
tract similar to an element called the expression and nuclear retention element (ENE) found 
in the stable nuclear retained polyadenylated RNAs from Kaposi's sarcoma-associated 
herpesvirus (Brown et al., 2012).  It was further demonstrated by two independent groups 
that the RNA adopts a triple helical fold due to the presence of the U/A rich motif (Brown et 
al., 2012; Wilusz et al., 2012).  
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Figure 1.3. 3′ end processing of NEAT lncRNA transcripts. The precursor NEAT lncRNA 
may be polyadenylated. The mature NEAT is generated following cleavage by the 
endonuclease RNase P between an A/U rich region and a clover like structure. Cleavage 
generates a small tRNA-like RNA, which is further processed at its 3′ end by RNase Z, and 
stabilized by the addition of a CCA tail by the CCA adding enzyme. The upstream cleavage 
product is stabilized due to the formation of triple helix structure in the RNA because of the 
A/U rich stretches near the 3′ terminus. Triple helix bonds are Hoogsteen (broken lines 
between A/U blocks) and Watson crick (solid lines between A/U blocks).    
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The 3’ end formation of Coding RNA: To cleave and polyadenylate 
Coding mRNA can be broken down into two categories: those that contain a long 
adenylated 3’ tail and those that lack this feature. In contrast to the majority of mRNAs that 
are polyA tailed, the 3′ end of mature replication dependent histone mRNA is not 
polyadenylated, rather polyadenylated histone mRNA is aberrant and thought to be 
produced by inefficient 3’ end formation. Remarkably, the process of accomplishing this task 
is highly complex and tightly regulated. The core machinery responsible for 3′ end formation 
of the coding RNAPII transcripts are the cleavage and polyadenylation specificity factors 
(CPSF). 
In the simplest instance, the cleavage and polyadenylation (CPA) is dependent on 
the recognition of several cis regulatory elements – a polyadenylation signal (PAS), a 
cleavage site (CS), an upstream sequence element (USE), and a downstream sequence 
element (DSE). These cis elements are recognized and bound by the CPSF complex, the 
cleavage stimulation factor complex (CstF) and the cleavage factor complex (CF). The PAS 
is typically AAUAAA, and the DSE is typically U/GU rich in metazoans (Figure 1.4A). 
However, this general and simple assumption of cis element organization seems to be quite 
rare in mammals (Tian and Graber, 2012). Many mRNAs do not utilize AAUAAA as the 
PAS, or possess a readily identifiable DSE, or USE, and a few even lack these elements 
altogether. To add a further level of complexity, several mRNAs possess multiple PASs 
(Beaudoing et al., 2000; Tian et al., 2005), so the process of selecting a cleavage site must 
be and is highly regulated.  I discuss some of the implications, and processes here.  
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Figure 1.4. The 3′ end processing of mRNA in yeast and humans, and human replication 
dependent histone mRNA. (A) cis regulatory elements for (i) polyadenylated mRNA in 
humans (ii) polyadenylated mRNA in yeast, and (iii) non-polyadenylated histone mRNA in 
humans. Canonical elements for polyadenylation of mRNA in humans are an upstream 
sequence element (USE), a polyadenylation signal (PAS) a cleavage site (CS) and a U-rich 
downstream sequence element. The elements for CPA in yeast are a U-rich efficiency 
element (EE), an A rich positioning element (PE) and a cleavage site. The cis elements for 
3′ end formation of the replication dependent histone mRNA in humans are structural and 
sequence specific. First is the requirement for a stem loop and second is the requirement for 
histone downstream element (HDE). (B) The cis elements of mRNA 3′ end formation are 
recognized by several trans acting factors.  Shown are some of the proteins that are shared 
by all three mRNA processing events. (i) and (iii) human  mRNA 3′ end processing both use 
the CPSF proteins 73 and 100 for cleavage supported by the scaffold protein Symplekin. In 
yeast (ii) the orthologues of these proteins Ysh1, Ydh1 and Pta, respectively, facilitated the 
cleavage of the mRNA. In yeast the PE is recognized and bound by RNA-15, an orthologue 
of human CstF64 that binds the DSE in the human pre-mRNA transcript.  The PAS in 
humans is bound by WDR33. (iii). In the replication dependent histone  mRNA, the HDE 
base pairs with the U7 snRNP, and the stem loop binding protein (SLBP) binds the histone 
stem together recruiting the CPSF proteins.   
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CPA is reliant on several cis elements, key is the hexameric PAS; but how is the 
hexamer, for example AAUAAA, functionally characterized as a signal for polyadenylation? 
There is typically an enrichment of uridines in  the immediate vicinity of  an identifiable 
hexanucleotide PAS (Legendre and Gautheret, 2003). In addition, the site of cleavage and 
subsequent tailing is biased toward CA or UA dinucleotide (Derti et al., 2012; Li and Du, 
2013; Sheets et al., 1990). The complex of proteins regulating CPA was initially purified in 
the late 20th century through a series of biochemical purifications and additional proteins 
have since been shown to play a role in this process (reviewed and references within (Shi 
and Manley, 2015; Xiang et al., 2014)). The Uridine stretches in the RNA are bound by the 
CF and CstF complexes, while the hexamer PAS, in the case of AAUAAA, is bound by the 
CPSF protein WDR33 (Figure 1.3B) (Chan et al., 2014; Schönemann et al., 2014). The 
mRNA is then cleaved by the endonuclease CPSF73 (Dominski, 2010; Mandel et al., 2006), 
which forms a stable core with CPSF100 and Symplekin ((Xiang et al., 2014). Although 
there are differences in the stringency of requirement for certain elements or factors 
depending on the context of the gene expression, these factors work together to facilitate 
efficient cleavage and polyadenylation the mRNA.  
The trans acting factors required for cleavage and polyadenylation are highly 
conserved across fungi and metazoans (Tian and Graber, 2012; Xiang et al., 2014; Yang 
and Doublié, 2011). In S. cerevisiae the cis regulatory elements which mediate cleavage 
and polyadenylation are less defined, but no less critical for CPA. The elements required 
and sufficient for CPA in S. cerevisiae are an efficiency element, a positioning element, a 
cleavage site, and an enrichment of uridines around the cleavage site (Figure 1.2A) (Guo 
and Sherman, 1996; Tian and Graber, 2012). While several of the protein machinery are 
similar, there are differences in the binding specificities which likely reflect the differences in 
how sites of polyadenylation are determined in metazoans compared to fungi. For example, 
the A-rich positioning element in yeast which is analogous to the mammalian 
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polyadenylation signal is recognized by a homologue of the human CstF protein 64. In 
humans, CstF64 is found downstream of the site of polyadenylation at the U/GU rich DSE 
(Figure 1.2B). However, both human and yeast cis elements for CPA are enriched for 
uridines (reviewed in (Tian and Graber, 2012; Xiang et al., 2014)).  
The process known as alternative cleavage and polyadenylation (APA) describes 
how one gene uses two or more different PAS, without necessarily changing the coding 
region to generate different mRNAs. Regulation of polyadenylation site affects the length of 
the 3′ untranslated region (UTR), thus can affect mRNA behavior. As a consequence of 
APA, mRNA localization, stability and translatability can be changed (Mayr, 2016). These 
changes can have drastic effects contributing to disease pathologies (Ogorodnikov et al., 
2016), nonetheless, APA is not an aberrant occurrence in the cell. Rather, cell type can 
affect the APA, for example the mRNAs in the brain tend to have longer UTRs, utilizing more 
distal PAS compared to other cells  (Mayr, 2016).  Regulation of APA utilizes multiple trans 
acting factors, many of which are part of the core CPA machinery. The mechanisms and 
signaling cascades that affect the choice of polyadenylation site are still being unveiled, 
which contributes to understanding of general gene expression regulation, but also 
introduces new therapeutic targets (Klerk et al., 2012; Masamha et al., 2014, 2016).   
 
The 3’ end formation of Coding RNA : To cleave and not polyadenylate 
Similar to the other mRNAs in metazoans, the replication dependent histone mRNA 
depends on the CPSF machinery to remove the nascent RNA from the DNA template. 
However, of this large multiprotein complex, only a subset of proteins is required. 
Specifically, the cleavage factor including CPSF73 and 100 and the scaffold Symplekin. As 
mentioned previously, in higher metazoans such as humans, the histone mRNA is not 
polyadenylated; in its place, a stable stem loop at the 3′ terminus protects the transcript from 
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decay. In addition to CPSF73 and CPSF100, which cleave the transcript, histone mRNA 3′ 
end formation also requires the U7 snRNP and stem loop binding protein (SLBP). The U7 
snRNP and SLBP recognize the cis regulatory elements of the histone gene including a 
histone downstream element (HDE) and stem loop respectively (Figure 1.3A/B) (Dominski 
and Marzluff, 2007; Marzluff et al., 2008).  Additional trans acting factor facilitate the 
recruitment of the CPSF machinery and distinguishes histone mRNA 3′ end formation from 
the canonical mRNA cleavage and polyadenylation (reviewed (Dominski and Marzluff, 2007; 
Köhn and Hüttelmaier, 2016; Marzluff et al., 2008; Romeo and Schümperli, 2016)).  
 
Significance: All’s well that ends well. 
The nuclear processing of the 3′ end of RNAPII transcripts affects their localization, 
(whether they are exported, retained or decayed). The 3′ end of the RNAPII transcript is 
subject to regulation to control transcript fate, affecting the behavior and stability. For 
example, polyadenylated mRNAs are exported to the cytoplasm and once there, removal or 
shortening of this protective features at the 3′ terminus subjects the mRNA to decay, impairs 
translation of the mRNA into protein, or can lead to sequestration of the mRNA (Weill et al., 
2012).  
As there are many distinct types of RNAPII transcripts, regulation of the process by 
which the 3′ ends of the transcripts are formed, is critical because it dictates the behavior of 
the RNA. The redundancies within the pathway, the fail-safes and stopgaps present, 
demonstrate that appropriate 3′ end formation of the transcript is critical for cell 
homeostasis. The implications of dysregulated RNA 3’ end processing is evident in several 
diseases, dyskeratosis congenita, muscular dystrophy, cancer amongst others (Chen and 
Greider, 2004; Danckwardt et al., 2008; Ogorodnikov et al., 2016). However, not only is the 
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understanding of the 3′ end formation of RNA important for understanding disease etiology 
and designing strategies for intervention, but also to contribute to the body of science which 
governs how we understand how we work. The 3′ end formation of RNA can serve as a 
signal for the termination of transcription for RNAPII, which is important given the myriad of 
RNAPII transcripts so that the genome of increasingly complex organisms can be partitioned 
(Kuehner et al., 2011). 
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Chapter 2 : Introduction to Facioscapulohumeral Dystrophy 
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Overview of Facioscapulohumeral Dystrophy 
Facioscapulohumeral dystrophy (FSHD) is a progressive debilitating muscle 
disorder. The prevalence of FSHD varies according to the population surveyed; however, 
since the use of genetic testing the average prevalence is approximately 6.4 per 100000 
persons, with the highest incidence and prevalence to date reported in the Dutch population 
(Deenen et al., 2014). FSHD was first characterized in late 1800s but the molecular 
mechanism was not realized until the 1990s when the disease was associated with the 
reduction in D4Z4 microsatellite repeats on chromosome 4 below a threshold number of 10 
(healthy individuals contain 10-100 D4Z4 repeats) (van Deutekom et al., 1993; Wijmenga et 
al., 1992). However, it was not until the last decade that significant inroads have been made 
in delineating the molecular etiology of the disease (Lemmers et al., 2010a, 2012; Snider et 
al., 2010). 
Clinical Features 
The clinical features of FSHD are highly heterogeneous, and range from mild to 
severe. Severe FSHD may lead to wheelchair dependency, and may involve mental 
retardation (Tawil and Van Der Maarel, 2006). However, more often individuals with FSHD 
may present with hearing loss and retinal telangiectasia, the latter occasionally progressing 
to Coats Disease (Tawil and Van Der Maarel, 2006). Disease severity has been correlated 
with age, where severe cases of FSHD referred to as infantile onset FSHD lead to 
progressive muscle strength degeneration and other organ functional diminution. The 
relative severity of the disease is also often associated with the size of the D4Z4 
contractions, with smaller fragments, 1-3 repeats, associated with severe cases (Tawil and 
Van Der Maarel, 2006). Interestingly, one recent study showed that the severe cases of 
FSHD associated with smaller D4Z4 fragments were more often observed in patients that 
26 
 
had de novo FSHD, which arise without a previous family history of the disease (Nikolic et 
al., 2016). FSHD patients, in most cases display asymmetric muscle weakness, and facial 
drooping. FSHD is a rare muscular dystrophy that does not present cardiac involvement, 
although, there are case studies of FSHD patients presenting with epilepsy(Chen et al., 
2013b; Funakoshi et al., 1998; Saito et al., 2007). One of the more prevailing features of 
FSHD is chronic pain and fatigue (further reading for clinical features of FSHD (Mul et al., 
2016; Tawil and Van Der Maarel, 2006; Tawil et al., 2015)). As a consequence of the high 
clinical variability and the occasionally subtle phenotypes the incidence and prevalence of 
FSHD is posited to be underestimated (Deenen et al., 2014).  
Molecular Features 
 
FSHD is primarily an autosomal dominant disorder, however there is a high 
incidence of de novo mutations engendering disease (Sacconi et al., 2015; Tawil et al., 
2014). FSHD is mainly associated with contractions of the D4Z4 repeats on subtelomeric 
region of chromosome 4 (van Deutekom et al., 1993; Wijmenga et al., 1992). In spite of the 
similarities of the q arm of chromosomes 4 and 10 (over 98%) (van Geel et al., 2002), early 
characterization of the FSHD exclusively linked the disease to chromosome 4q, in particular 
the 4qA allele (de Greef et al., 2009; Lemmers et al., 2004, 2007; van Overveld et al., 2003; 
Wang et al., 2011). A single D4Z4 repeat is 3.2 kb in length and is thought to contain a 
single promoter and open reading frame encoding Dux4 (see below) but the lack of a 
cleavage and polyadenylation signal within the repeat prevents production of a Dux4 mRNA. 
Approximately 95% of the cases of FSHD have contracted D4Z4 alleles (Statland 
and Tawil, 2014), However, patients have been clinically diagnosed with FSHD and bear no 
contractions of the D4Z4 repeats. Instead, these patients, classified as FSHD2, have 
reduced repressive methylation marks on their D4Z4 repeats thereby de-repressing this 
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genomic region similar to what is observed to occur as a consequence of D4Z4 contraction 
in FSHD1 (van der Maarel et al., 2012; Statland and Tawil, 2014). Concomitant with the 
repression of the D4Z4 repeats, FSHD is predicated by single nucleotide polymorphisms 
(SNP) present within the region flanking the D4Z4 repeat on telomeric side that is specific to 
the 4qA allele (Lemmers et al., 2007, 2010a). The 4qA allele is distinguished, from the 4qB 
or 4qC allele, because of the presence of a truncated terminal D4Z4 repeat, pLAM, and β-
satellite repeat region (Lemmers et al., 2007, 2010b). The 4qA and 4qB alleles are the most 
predominant within the population, within which the most common haplotypes are A161, 
A166 B163, and B168 (Lemmers et al., 2010b); however, only the 4qA161 haplotype is 
associated with FSHD, as it contains a SNP that generate a non-consensus polyadenylation 
signal (PAS), AUUAAA, in the pLAM region (Lemmers et al., 2010a). The PAS allows for 
productive transcription of the Dux4 gene from the terminal D4Z4 repeat (Figure 2.1). 
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Figure 2.1. Schematic of the D4Z4 Repeats and the FSHD Locus. (A) Chromosome 
alignment of showing similarity between 4qA, 4qB and 10qA, with only the 4qA allele being 
associated with FSHD, with 4qB lacking pLAM and β-satellite sequences. D4Z4 repeats 
represented by gray overlapping triangles representing repressed state, with repeats 
numbering >10, pLAM and β-satellite are indicated by red and white boxes respectively. (B) 
Specific haplotype of FSHD afflicted individual. Transcriptional derepression as a 
consequence of reduction in number of D4Z4 repeats to 1-10, or mutation in modifier 
29 
 
proteins. The 4qA161 haplotype, contains a SNP generating non-consensus PAS, 
AUUAAA. The presence of the PAS allows for productive transcription 
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There is evident, incomplete penetrance of the disease associated with both the SNP 
generating a non-consensus PAS and the contraction of the D4Z4 repeats (Scionti et al., 
2012). For example, there are individuals who display reduction in the number of D4Z4 
repeats or hypomethylation of the D4Z4 repeats in the presence of the permissive haplotype 
who are asymptomatic (Lemmers et al., 2012; Scionti et al., 2012) Moreover, although there 
is a general correlation between repeat length with disease severity, this is not absolute 
(Nikolic et al., 2016; Sacconi et al., 2013; Scionti et al., 2012). These observations support 
the hypothesis that genetic modifiers exist that can affect the D4Z4 locus in trans.  An 
example of such a modifier is the gene SMCHD1 (structural maintenance of chromosomes 
flexible hinge domain containing 1). Individuals with FSHD2 can have the epigenetic state of 
their D4Z4 repeat maintained in the hypomethylated state due to haploinsuffiency of 
SMCHD1 (Lemmers et al., 2012). Recently, heterozygous mutations in DNA 
methyltransferase 3B (DNMT3B) were reported to also derepress the D4Z4 repeats; and are 
posited to contribute to FSHD2 in the absence of SMCHD1 mutations (van den Boogaard et 
al., 2016). Intriguingly, the disease displays a strong reliance of the epigenetic state of the 
D4Z4 repeats, with one group reporting that mutations in the SMCDH1 ‘modified’ the FSHD 
disease severity when coupled with contracted D4Z4 repeats (Sacconi et al., 2013). 
 
Model System for FSHD Investigation 
Currently there is no established animal model for FSHD, although, several animals 
have been generated to study aspects of FSHD (Jones et al., 2016; Lek et al., 2015). The 
majority of the shortcomings of the various animal models may be related to the degree of 
divergence seen between D4Z4 repeats in ape primate and other mammals. Indeed, 
transgenic mice animals containing the D4Z4 repeats fail to completely recapitulate the 
disease (Krom et al., 2013). Several candidate genes located in the vicinity of the D4Z4 
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repeat region have been used to generate animal models of FSHD (Dandapat et al., 2014, 
2016; Gabellini et al., 2006; Jones et al., 2016; Mitsuhashi et al., 2012). For example, one of 
the longstanding candidate genes of FSHD, FRG1, has been used to generate mice that 
presents some of the features of the disease (Gabellini et al., 2006), however, this required 
high overexpression of the gene. The level of FRG1 overexpression in FSHD patients is 
correlatively but not definitively related to the D4Z4 repeat length, and thus the phenotype in 
the mouse may not be directly related to FSHD. In addition the reproducibility of FRG1 
expression in biomarker assays for FSHD is low (Osborne et al., 2007; Rahimov et al., 
2012). The variability, sensitivity and, or subtlety of phenotypes in animal models generated 
for FSHD, underscores the complexity of the disease. The lineage specificity of the D4Z4 
repeats, the subtelomeric location of the FSHD locus, the variable expression of several 
candidate genes (gene present within the D4Z4 repeats – Dux4, or adjacent to the D4Z4 
repeats – ANT1, FRG1, and FRG2) as well as the epigenetics all contribute to making the 
development of an animal model for FSHD technically challenging.  
 
Dux4: Leading Candidate Gene of FSHD 
Double Homeobox 4, Dux4, has emerged as the leading candidate gene of FSHD 
and is the singular, highly conserved open reading frame located in the D4Z4 repeats. 
Previously, stated to be primate specific, it has been shown that the D4Z4 repeats are found 
in several placental mammals, however, the topology of the 3.3kb D4Z4 repeat with the 
Dux4 ORF (with two homeodomains and an activation domain) is nearly perfectly aligned in 
higher primates, humans, chimpanzees and orangutans (Clapp et al., 2007; Giussani et al., 
2012). Despite the high degree of ORF conservation of the Dux4 gene (Clapp et al., 2007), 
the precise biological role of Dux4 is unclear. Dux4 protein can be detected in muscle 
biopsies of fetuses with FSHD and the Dux4 mRNA can be detected in the patients with 
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FSHD but is not typically found in somatic cells of healthy individuals (Ferreboeuf et al., 
2014; Snider et al., 2010). Recent studies employing overexpression of Dux4 in mouse 
derived myoblasts do not replicate the transcriptome changes of Dux4 expression in human 
cell lines (Sharma et al., 2013); and in FSHD mice models that feature Dux4 expression only 
~22% of the genes differentially regulated overlap with human genes (Krom et al., 2013). 
This is likely due to the Dux4 targets not being present in mice, as Dux4 mainly binds to 
retroelements and LTR regions (Sharma et al., 2013). Nonetheless, transgenic mice bearing 
randomly integrated D4Z4 repeats, show a human-like epigenetic topology, in that the locus 
is typically epigenetically silenced and shortened repeats bear less repressive features, 
marked with reduced CpG methylation and reduced ratio of H3K9me3:H3K4me2 (Krom et 
al., 2013). So, while the ORF (in particular the homeodomain) is conserved, suggesting a 
protein coding function, its presence in the likewise conserved D4Z4 repeats, suggests that 
the expression of Dux4 is subject to a high degree of epigenetic regulation.   
Animal models using Dux4 expression as a driver for pathogenesis have replicated 
aspects of FSHD pathology but not the full scale of the disease (Lek et al., 2015) (Lek et al., 
2015). One mouse model, integrating the Dux4 gene on the X chromosome, showed that 
the presence of the gene led to increased male lethality and the X chromosome bearing the 
gene was preferentially silenced in female offspring. Although, there was not observed 
significant muscle weakness, retinal abnormalities were reported in surviving mice 
(Dandapat et al., 2014). The retinal abnormalities were also reported in another mouse 
model (Krom et al., 2013). However, likely due to a dissimilarity in the transcriptome of Dux4 
in mice versus humans (Sharma et al., 2013), none of the mouse models fully recapitulate 
the disease. An alternative approach utilized xenograft models, in which skeletal muscle 
tissue from FSHD patients is engrafted into mice to reproduce the Dux4 expression profile 
(Zhang et al., 2014). However, this model is more suited to assaying molecular outcomes 
due to the presence of the human tissue and localized repair of the xenograft muscle, but, 
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will not be sufficient for functional studies, such as grip strength which assesses the muscle 
strength of the mouse. In zebrafish, the ectopic expression of Dux4 led to severe skeletal 
malformations, which could be rescued by morpholinos reducing Dux4 (Mitsuhashi et al., 
2012). In human cell lines it has been shown that Dux4 inhibits myogenesis – differentiation 
of myoblast to myotubes (Bosnakovski et al., 2008). However, FSHD patients present no 
difference in the apparent myogenesis and Dux4 expression appears to be enhanced by 
myogenesis (Block et al., 2013; Tsumagari et al., 2011). Collectively, the efforts to 
recapitulate aspects of FSHD using Dux4 have been accomplished with mixed success 
further reflecting the complexity of the disease. 
 
RNA Processing in FSHD 
The Dux4 ORF is located entirely in the first exon of the gene, while the 3′ 
untranslated region (UTR) has two introns. In the testis, where Dux4 is found to be 
expressed in healthy individuals, an alternatively spliced UTR results in usage of a  
polyadenylation signal in a distant downstream exon, exon 7 (Figure 2.2A). This distal PAS 
appears to be not active in normal somatic cells and, typically only in the case of FSHD is 
the Dux4 transcript expressed using a polyadenylation signal  AUUAAA found due to a SNP 
in Exon 3 on chromosome 4, exclusively (Snider et al., 2010).  Alternative splicing of Dux4, 
reportedly generates several isoforms of Dux4 (Figure 2.2 B), including a non-pathogenic 
Dux4 isoform, called Dux4-s. This splice isoform, is generated from a cryptic splice site in 
the Dux4 ORF in the first exon, and retains the homeodomain, but does not have the 
activation domain. The pathogenic Dux4 isoforms, collectively referred to as Dux4-fl retain 
the entire ORF of Dux4 containing two homeodomains and an activation domain  (Snider et 
al., 2010). There are two annotated RefSeq isoforms of the Dux4 transcript in Genbank: 
(NM_001306068.1) and variant 2 (NM_001293798.1) that differ due to intron retention in 
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variant 1 (Figure 2.2 B). The implication of the intron retention will be discussed later in this 
study, however, it is likely that splicing of the Dux4 mRNA itself is highly regulated. The 
expression of Dux4 mRNA is low and the full length mRNA is barely detectable (reviewed 
(Richards et al., 2012)). This could be due to inefficient cleavage and polyadenylation at the 
non-consensus PAS, rapid mRNA turnover or weak promoter, or due to the epigenetic 
modifications at the locus. Detection of Dux4 is technically challenging, requiring a high 
cycle number (typically 50 cycles) nested amplification by PCR.   
One possible explanation for the low abundance of Dux4 is that it undergoes splicing 
downstream of a stop codon. Moreover, the exons are short which lead to the hypothesis 
that Dux4 mRNA is subject to non-sense mediated decay (NMD) (Feng et al., 2015). Feng 
and company demonstrated using a mini-gene reporter system that the second intron of 
Dux4 makes the mRNA susceptible to NMD, and thus results in its decay. It is likely that 
both variants of Dux4 are NMD targets. The detection of the Dux4-s in patient cells and 
healthy cells, as well as numerous small transcripts from the D4Z4 repeats of patient cells 
(Snider et al., 2009) do not support the hypothesis that there is a weak promoter in the D4Z4 
repeat. Several studies have shown that there are many different RNA transcripts generated 
from the D4Z4 repeats (Snider et al., 2009), and while some of these transcripts may aid in 
increasing overall transcription activity (Cabianca et al., 2012) from the D4Z4 repeats, some 
have inhibitory effects (Lim et al., 2015). Significant efforts have been devoted to understand 
the epigenetic regulation of the D4Z4 repeats, as this may contribute to the poor expression 
of the Dux4. While the locus shows decreased repressive DNA and histone methylation 
(Hewitt, 2015), it is still unclear if this contributes to Dux4 inefficient expression.  Besides, 
the identification of the non-consensus PAS in the Dux4 transcripts from patient cells 
(Lemmers et al., 2010a), and  a myriad of studies which amplify the polyadenylated Dux4, 
not much work has been done characterizing the 3′ end processing of the Dux4 transcript.  
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In this thesis work, I explore the 3′ processing of Dux4 to determine whether inefficient 
cleavage and polyadenylation contributes to poor Dux4 expression.  
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Figure 2.2 Schematic of Dux4 transcripts. (A) Grey triangle represents terminal D4Z4 repeat, 
grey trapezoid repeats truncated D4Z4 repeat. Exons indicated by white rectangles, hatched 
diagonal line indicate the degenerate β-satellite repeats and the red square indicates 
telomeric portion of the chromosome. The Dux4 transcripts are shown indicating the exons 
detected from germline and somatic cells. Somatic tissue solely produces transcripts with 
using PAS with exon 3. (B) Dux4 ORF located in exon 1, contains two homeodomains, 
shown as yellow rectangle, and an activation domain shown as a brown square. Alternative 
splicing produces three isoforms containing exon 3, Dux4-fl variant 2, is spliced to contain 
exons 1-3 consecutively (splice pattern 1). Dux4-fl variant 1 retains the first intron (splice 
pattern 2). Dux4-s, a short isoform produced using a cryptic splice site in the Dux4 ORF, 
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Dux4-s lacks the activation domain, and can use a stop codon present in exon 2 (splice 
pattern 3). Start and stop codons are indicated by green and red circles, respectively. 
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The Dux4-regulated transcriptome 
As mentioned, Dux4 contains two homeodomains and an activation domain, and 
belongs to the family Homeobox proteins, which are typically transcription factors. 
Consistent with this idea, Dux4 can potently activate transcription at it target genes and 
preferentially binds and transcriptionally activates mutlimeric copies of TAATCTAATCA 
(Choi et al., 2016; Geng et al., 2012; Young et al., 2013; Zhang et al., 2016). The potent 
transcriptional activation capacity of Dux4 is also evident in its role in a subset of 
undifferentiated small round cell sarcomas, in which a translocation event fuses the 
activation domain in the C-terminus of Dux4 to the CIC (human homologue of the drosophila 
Capicua transcriptional repressor) gene and enhances its transcriptional activity; in addition, 
the fusion gene can transform NIH/3T3 cells (reviewed by (Antonescu, 2014; Haidar et al., 
2015)).  
Despite this clear activity, the precise biological role of Dux4 is unknown. 
Overexpression has been shown to be toxic to a variety of cell lines (Block et al., 2013; 
Bosnakovski et al., 2008; Wallace et al., 2011; Wuebbles et al., 2010) but its presence in 
germline tissue (Snider et al., 2010)  suggests a role in organismal development. Supporting 
this idea, Dux4 has been shown to activate genes that are typically involved in germline 
development (Geng et al., 2012). Interestingly, ChIP-Seq data from Dux4 transduced cells 
shows peaks over the entire body of genes targeted by Dux4, in addition many of the Dux4 
binding sites were found within intergenic regions. Further expounding on this observation, it 
was shown that Dux4 binding was enriched at repetitive elements, such as mammalian 
apparent long terminal repeat retrotransposons (MaLR) (Geng et al., 2012; Young et al., 
2013). The implication of this was that several of these elements became activated as 
promoters driving the expression of somatically silenced transcripts. While many of the 
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transcripts detected in Dux4 transduced lines were also found in the testes, the biological 
role of these changes remains elusive and speculative.  
Gene ontology and pathway analyses of Dux4 regulated gene expression changes 
have been carried out and have shed some light on how Dux4 expression may affect 
cellular behavior (Bosnakovski et al., 2008; Feng et al., 2015; Geng et al., 2012; Rickard et 
al., 2015; Young et al., 2013). Using the data generated from genome wide analysis of 
transcriptome changes, Feng et al reported that there was an increase in the population of 
mRNA that is predicted to be subject to NMD. The mechanism for this observation is that 
Dux4 is thought to cause a modest reduction in the NMD regulator UPF1. This report is 
particularly intriguing because given that Dux4 is regulated by NMD, due to the presence of 
its second intron, the authors posit a positive feedback loop in which Dux4 may modulate 
NMD and consequently modulate itself. However, the exact mechanism through which Dux4 
regulates NMD remains to be verified. In particular they do not see an overall decrease in a 
NMD genes, and only show a modest change in UPF1 protein itself. However, others have 
shown that Dux4 overexpression does lead to changes in relative abundance of splicing 
proteins (Geng et al 2012). Intriguingly one may speculate that dysregulation of NMD may 
account for some of the splicing changes observed in patient cells. However, there is likely 
more at play, consequently it is imperative to understand the splicing dysfunction in FSHD 
populations compared to control populations. 
Toward the goal of further understanding transcriptome changes in FSHD patient 
cells caused by Dux4 expression, Rickard and colleagues use a Dux4 responsive reporter to 
enrich for FSHD cells that express Dux4 (Rickard et al., 2015).They and others (Snider et 
al., 2010; Tassin et al., 2012) show asynchronous expression of Dux4, and demonstrate a 
diffusion gradient of Dux4 within the syncytia. The asynchronous Dux4 expression, may 
suggest circadian regulation wherein the gene oscillates between high and low expression, 
however this has not been tested. Using Dux4 positive cells identified by sorting of reporter 
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positive cells, a population of cells that would have a transcriptome representative of Dux4 
action was enriched (Rickard et al., 2015). It was found that ~20% of the transcriptome is 
directly changed as a consequence of expression of Dux4. Pathway analysis of the RNA-
seq data suggest that one the major pathways affected is RNA metabolism – in particular 
splicing, surveillance and export. The dysregulation in RNA metabolism is thought to occur 
through up-regulation of several proteins that belong to either mRNA splicing, surveillance 
and export pathways. Interestingly amongst these genes are splicing factors SRSF2, 
STAU1, DDX39B which either skip an exon or retain an intron within their own mRNA 
transcripts. It must be noted that others have observed that culture conditions likely also 
affect the degree of Dux4 expression (Block et al., 2013; Pandey et al., 2015) thus the 
impact of Dux4 on the transcriptome may also be connected to the microenvironment. 
To resolve the paradigm of how a low abundance protein like Dux4 that may be 
expressed asynchronously can have meaningful impact on the transcriptome, a model has 
been put forward where expression in one nucleus is sufficient to trigger activation of Dux4 
target genes in a temporal and spatial manner within the syncytia. The model here posits 
that Dux4 is stochastically expressed, and it may activate genes in “sentinel” nuclei, or may 
diffuse across the syncytia and activate genes in other nuclei. Stochastic expression or 
pulsed expression from sentinel nuclei is typical of myotubes (Newlands et al., 1998). To 
date, there has been no in-depth study on the half-life of the Dux4 protein, although it is 
predicted to be unstable and decayed by the proteasome (Tassin et al., 2012). It had 
previously been demonstrated, in a model interrogating Dux4 expression with respect to 
telomere shortening (which serves as a proxy for aging due to aging related onset of FSHD 
symptoms) there is likely 1 in 2000 nuclei expressing Dux4. Upon telomere shortening, this 
number significantly increased to 1 in 200 nuclei (Stadler et al., 2013). Dux4 mRNA 
transcribed in one nucleus is exported to the cytoplasm where it is translated and returns to 
the nuclei closest to its translation site, but it may also diffuse within the syncytia and 
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activate transcription in distal nuclei. However, the length of time and the distance it diffuses 
is dependent upon its stability and the proximity of nuclei, thus a careful determination of 
Dux4 protein stability is necessary to develop this model further. 
But questions still remain, what is the permissive amount of Dux4 protein before it 
becomes toxic to the cells? Overexpression can lead to cell death, and can contribute to 
deformation effects in animal models. However, what happens when Dux4 is expressed at 
low level? At what point does the threshold exist? Also, how frequently, and what quantity of 
RNA is produced in the event of productive transcription of the Dux4? What are the relative 
stabilities of Dux4 mRNA and protein, and to what extent could the Dux4 mRNA itself play a 
role in the pathogenicity of the Dux4 mediated disease? 
 
Cell Physiology of FSHD and Correlation to Dux4 
There is a decrease in the histone and DNA methylation of the D4Z4 repeats in 
FSHD patients, which leads to transcriptional derepression. While the skeletal muscle is the 
primary tissue type affected in FSHD, Dux4 can be detected in the non-skeletal muscle cells 
in FSHD patients (Snider et al., 2010). The hypomethylation of the D4Z4 repeats in FSHD is 
attributed to the action of several different factors which will be discussed here.   
One longstanding theory underlying the association of hypomethylation of the D4Z4 
repeats with FSHD, as well as the subtelomeric localization of the repeats is that disease 
presents due to dysregulated heterochromatin (van der Maarel et al., 2012).  Several lines 
of evidence support a model in which silenced genomic DNA is being reactivated in somatic 
cells in FSHD patients.  
In a subset of individuals, mutations in SMCHD1 occurring with 4qA permissive 
haplotype result in FSHD2, even in the absence of contractions/reduction of the D4Z4 
repeats (Lemmers et al., 2012). The monosomy or mutations identified resulted in 
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haploinsuffiency of SMCHD1 due to the presence of less than 50% of the protein. 
Consequently, FSHD2 patients with SMCHD1 mutations, showed reduced occupancy of the 
protein on the D4Z4 repeats (Lemmers et al., 2012, 2015). SMCHD1 is an essential gene, 
and in mice it is embryonic lethal, although in certain genetic backgrounds reduce male 
lethality (Mould et al., 2013). This apparent gender disparity in embryonic lethality is a 
consequence of the essential role of SMCHD1 in X-chromosome inactivation. SMCHD1 is 
recruited at sites with H3K9me3 or H3K9me2 (Brideau et al., 2015), and is potentially a DNA 
methylase or essential cofactor for acquired and sustained DNA methylation (Blewitt et al., 
2008; Gendrel et al., 2012). However, not all FSHD2 patients have haploinsuffiency 
mutations in SMCHD1, and it has only been recently demonstrated that mutations in 
DNMT3B also modify the disease in another set of FSHD2 patients, thus there are likely 
other modifiers. It was previously shown that depletion SUV39H1 specifically reduces 
H3Kme3 on the D4Z4 repeats (Zeng et al., 2009). Given that SMCHD1 recruitment at the 
D4Z4 repeats is H3Kme3 dependent (Zeng et al., 2014), mutations in histone methylase or 
demethylase may also modify disease.   
Other work has provided some indication that a feed forward mechanism may be at 
play to allow for increased derepression of the locus, and thus only a subtle change is 
necessary to start a destabilizing cascade. An example that supports this model is DBE-T, 
which is a long non-coding RNA detected in FHSD patients that originates from the D4Z4 
repeat (Cabianca et al., 2012). DBE-T is likely polyadenylated because of detection in 
polyA+ fraction, and thus, is likely an RNA Polymerase II transcript. Fluorescence in situ 
hybridization (FISH), shows a faintly nuclear localized, chromatin associated DBE-T and it is 
posited to bind the D4Z4 repeats causing derepression. Evidence that supports this model is 
that depletion of DBE-T reduces transcription of D4Z4 proximal genes like Ant1 and Frg1, as 
well as Dux4. Notably, the function of the RNA in de-repressing the locus cannot be 
accomplished in trans. The action of DBE-T is likely mediated through its recruitment of 
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histone-lysine N-methyltransferase, ASHL1. ASHL1, a member of the Trithorax complex 
was found enriched on non-deleted element (NDE) which lies upstream of the first D4Z4 
repeat. In a heterologous host, treated with inhibitors of DNA methylation and histone 
acetylation (here referred to as enforced transcriptionally permissive conditions), DBE-T 
associates with ASH-L determined by RNA-IP, moreover knockdown of DBE-T reduces 
ASHL1 presence at the NDE. 
There is potentially a positive feedback effect, wherein, DBE-T production enhances 
ASHL-1 recruitment at the NDE, which increases H3K36me2 and thus enhances its own 
transcription. In essence creating a trickle effect wherein occasional transcription, which is 
enhanced upon deletion of D4Z4 repeats due to more accessibility, allows for more DBE-T 
to be produced, which in turn recruits ASHL-1 to further derepress the locus.  
However questions remain. First, how is DBE-T processed? Without enforcing 
transcriptional permissive conditions, the most abundant transcripts originating for the region 
appear discontinuous, therefore is the DBE-T processed to generate smaller RNA species? 
Second, what is the timing for the recruitment or the sequence of events that occur to permit 
a feedback loop? 
At present, a compelling model of FSHD is one in which the D4Z4 repeat locus on 
chromosome 4 is a metastable epiallele (Himeda et al., 2014; Jones et al., 2015; Lemmers 
et al., 2012), where modified expression of genes at the locus contributes to the etiology of 
the disease (Figure 2.3). Key in this model is that, derepression of the somatically repressed 
locus in certain chromosomal backgrounds (giving haplotype specificity) allows the 
production of a homeodomain transcription factor, Dux4.  
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Figure 2.3 Model of Dux4 in FSHD: A Metastable Epiallele. (Top) D4Z4 depicted as 
heterochromatin region with negligible transcription due to the histone methylation and DNA 
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methylation by DNMT3B, SMCDH1, SUV39H amongst other factors. (Bottom) Dux4 is 
derepressed, and the pathogenic splice isoform is enriched due to contractions of the 
repeats which alleviate some of the repressive heterochromatin signals or mutations which 
impair the function of DNMT3B or SMCDH1. Transcription of lncRNA DBE-T recruits ASHL1 
to further derepress the locus. Dux4 is expressed and activates a transcriptional cascade 
that includes dysregulated RNA processing – NMD, which stabilizes Dux4-fl mRNA and 
potentially increases production of the pathogenic protein product.  
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Current State 
Genetic variants, epigenetic modifications and RNA splicing contribute to complex 
diseases (Li et al., 2016). The transcriptome changes as a consequence of Dux4 
expression, the genetic variation modifying disease onset and severity, and the epigenetic 
contributions to disease pathology, demonstrate that FSHD may be characterized as a 
complex disease.   
The current therapies for treatment of FSHD are physiotherapy, dietary 
supplementation, corticosteroids and T-cell infiltration (Sacconi et al., 2015; Tawil et al., 
2015) and have resulted in variable success rates. The unclear molecular etiology had long 
impaired therapeutic progress. However, the recent advances into the molecular basis of the 
disease shows a mosaicism that may not be suitable for a simple panacea and may require 
varying strategies for treating and, or preventing the disease. For example, recent reports 
have demonstrated in cell culture models, the utility of RNA therapeutics (Lim et al., 2015; 
Marsollier et al., 2016), and CRISPR/CAS9 technology (Himeda et al., 2015, 2016) in 
suppressing Dux4.  
The productive transcription of the Dux4 mRNA in FSHD patients is because of a 
SNP which generates a non-consensus PAS. However, beyond the identification of the 
PAS, the requirements for efficient 3′ end processing of the Dux4 mRNA have not been 
examined. Here, we extend upon these efforts to investigate and characterize the Dux4 3′ 
end processing signals required for cleavage and polyadenylation. Further, we investigate 
the use of utility of RNA therapeutics, in particular cleavage and polyadenylation inhibiting 
antisense oligonucleotides to impair processing at the Dux4 polyadenylation signal.   
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Chapter 3 : Materials and Methods 
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Cloning 
Plasmids used in the study are described in Table 3.1. In the majority of constructs 
traditional restriction enzyme cloning was used to generate reporters. Primers and 
oligonucleotides used for cloning are described in Table 3.2.  Inserted DNA was amplified 
using Pfu polymerase (purified by the Wagner Laboratory), and gel purified using GeneJet 
Gel Purification System (Thermo Fisher Scientific, Massachusetts USA). The SV40 late 
polyadenylation signal was amplified using the pGL4.13 (Promega, Wisconsin USA). 
Putative Dux4 processing signals were amplified from p2loxDux4 that was kindly provided 
by the Kyba Laboratory (Bosnakovski et al., 2008). Dux4 3′ UTRs and cDNA sequences 
were obtained from ensembl.org and cross referenced with Ref Seq. The Dux4 UTR 
constructs and the Dux4 cDNA were artificially synthesized by GenScript (New Jersey, USA) 
and subcloned into the appropriate vector.  All clones were sequenced to confirm identity.  
In the remaining constructs, annealed oligonucleotide cloning was used and 
proceeded as follows: unphosphorylated polyacrylamide gel electrophoresis (PAGE) purified 
oligonucleotides were mixed equimolar at 20µM in annealing buffer (100mM Tris pH 7.5, 1M 
NaCl, 10mM EDTA). The mixture was heated to 95˚C and then using a thermocycler the 
temperature was ramped down 5˚C per cycle for three minutes per cycle, to a final 
temperature of 25˚C. 5µL of the annealed oligonucleotides was then incubated at 37˚C for 
30 minutes with T4 Polynucleotide Kinase (New England Biolabs, Massachusetts USA) and 
10µM ATP (Thermo Fisher Scientific) for phosphorylation. The phosphorylated annealed 
oligonucleotide was diluted 1:1000 and ligated to the appropriate alkaline phosphatase 
treated vector. Ligation reactions were carried out using T4 Ligase (purified by the Wagner 
Laboratory). Ligations were transformed into XL-1 Blue Competent cells (Stratagene, 
California USA). 
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In some constructs site-directed mutagenesis was performed to remove cryptic start 
codons, or introduce defects in the polyadenylation cis elements. In brief, to perform site-
directed mutagenesis 10-25 ng of template plasmids were used for PCR using 
oligonucleotides for site directed mutagenesis listed in Table 3.2 in a total volume of 25µL 
using Pfu polymerase. Methylated template DNA was digested with 1µL DpnI (Thermo 
Fisher Scientific) for thirty minutes. Following Dpn I digestion, 1µL of the PCR product was 
transformed in XL1-Blue Competent Cells. 
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Table 3.1. Table of Plasmids 
Name Source/Reference 
pcDNA3.1(+) Courtesy of the Jayaraman Lab, University of Texas 
McGovern Medical School 
p2loxDux4 Courtesy of the Kyba Lab, Lillehei Heart Institute, 
University of Minnesota 
pLentiDuxBSntGFP Acquired from the Miller Lab, University of Washington  
pcDNA6tr Invitrogen 
pcDNA3 Invitrogen 
pdp20 Derived by Dr. Eric J. Wagner from pdp19 vector 
initially purchased from Ambion 
pTZHIVdGless Suñe Lab,  Instituto de Parasitología y Biomedicina 
“López Neyra”, Consejo Superior de Investigaciones 
Científicas (IPBLN-CSIC), PTS, Granada, Spain 
psiCheck2 Promega 
pgl4.13 Promega 
pUC19 NEB 
pGINT Addgene 
pUC57-Kan-Dux4ORF Genscript 
pUC57-Kan-Dux4UTR1 Genscript 
pUC57-Kan-Dux4UTR2 Genscript 
pUC57-Kan-Dux4UTR-Int2minus Genscript 
pUC57-Kan-Dux4UTRunspliced Genscript 
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Table 3.2. Table of DNA Oligonucleotides for Cloning 
Name Purpose Sequence 
N060 Annealled Oligo Cloning of 
Hammerhead ribozyme 
GCCGGCGTCCTGGTATCCAATCCT
TCGGGATGTACTACCAGCTGATGA
GTCCCAAATAGGACGAAACGCCGG
A 
N061A Annealled Oligo Cloning of 
Hammerhead ribozyme 
AGCTTCCGGCGTTTCGTCCTATTTG
GGACTCATCAGCTGGTAGTACATC
CCGAAGGATTGGATACCAGGACGC
CGGCTGCA 
N078 Cloning CMV Promoter GCCGAATTCGCGTTGACATTGATTA
TTGAC 
N079 Cloning CMV Promoter GGCCGAATTCGAGCTCTGCTTATAT
AGACCT 
N0D19 Cloning Dux4PAS GGCCGCGGCCGCTACATATCTCTA
CACTGATCACGTAAGTGATGTA 
N0D20 Cloning Dux4PAS GGCCAAGCTTCTTCCGTGAAATTCT
GGCTGAATGTCTCC 
N0D21 Cloning Dux4PAS GGCCGCGGCCGCTACCAATTTCAG
GCTTTTTGTACAGGGGATA 
N0D22 Cloning Dux4PAS GGCCAGATCTCTTCCTGGCTAGAC
CTGCGC 
N0D23 Cloning Dux4PAS GGCCAGATCTTTCTATAGGATCCAC
AGGGAGGG 
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N0D18B Cloning Dux4PAS GGCCAAGCTTTAGACCTGCGCGCA
GTGCGCACCCC 
N0D24 Cloning Dux4PAS GGCCAGATCTCGAGTAGACCTGCG
CGCAGTGCGCACCCC 
N0D25 Cloning Dux4PAS GGCCAGATCTACATATCTCTACACT
GATCAC 
N0D26 Cloning Dux4PAS GGCCAGATCTCGAGCTTCCGTGAA
ATTCTGGCTGAATGTCTCC 
N0D27 Cloning Dux4PAS GGCCAGATCTACCAATTTCAGGCTT
TTTCTACAGGGGATA 
N0D28 Cloning Dux4PAS CATCTCCTGGATGATTACTTCAGAG
ATATATTAAAATGCCC 
N0D29 Cloning Dux4PAS GGGCATTTTAATATATCTCTGAAGT
AATCATCCAGGAGATG 
N0D30 Cloning Dux4PAS GTCACAATATCCCCTGTACAAAAAG
CCTGAAATTGG  
N0D31 Cloning Dux4PAS CCAATTTCAGGCTTTTTGTACAGGG
GATATTGTGAC  
N0D32 Cloning Dux4PAS GGCCAGATCTATCGATTGCCTACA
CTCTGCCTACAGGAGGC 
N0D33 Cloning Dux4PAS GGCCAGATCTCGAGATCGATTAGA
CCTGCGCGCAGTGCGCAC  
N0D34 Cloning Dux4PAS GGCCGCGGCCGCTTTAAGTGATGT
AACCATTCTC 
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N0D35 Cloning Dux4PAS GGCCGCGGCCGCTTAGGTTCAGTC
TACTATGG 
N0D36 Cloning Dux4PAS GGCCGCGGCCGCTGAGTTCTGAAA
CACATCTGC 
N0D37 Cloning Dux4PAS GGCCGCGGCCGCTGCACTGATCAC
CGAAGTTATG 
N0D34B Cloning Dux4PAS GGCCGCGGCCGCTGTAAGTGATGT
AACCATTCTC 
N0D92 Cloning Dux4PAS GGCCTCTAGATTAAGTGATGTAACC
ATTCTC 
N0D93 Cloning Dux4PAS GGCCTATAGATAGGTTCAGTCTACT
ATGG 
N0D94 Cloning Dux4PAS GGCCTCTAGAGAGTTCTGAAACAC
ATCTGC 
N0D95 Cloning Dux4PAS GGCCTCTAGAGCACTGATCACCGA
AGTTATG 
N0D96 Cloning Dux4PAS GGCCTCTAGAACCAATTTCAGGCTT
TTTGTACAGGGGATA 
N0D97 Cloning Dux4PAS GGCCCTCGAGTAGACCTGCGCGCA
GTGCGCACCCC  
N0D98 Cloning Dux4PAS GGCC GGATCC 
TAGACCTGCGCGCAGTGC 
N0D106 Cloning Dux4PAS GGCCGAATTCTAGACCTGCGCGCA
GTGCGCAC 
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N0D107 Cloning Dux4PAS GGCCCTCGAGACATATCTCTACACT
GATCAC 
N0D108 Cloning Dux4PAS GGCCCTCGAG 
CTATAGGATCCACAGGGAG 
N0D109 Cloning Dux4PAS GGCCCTCGAGGCACTGATCACCGA
AGTTATG 
N0D111 Cloning Dux4PAS GGCCGAATTCCTTCCGTGAAATTCT
GGCTGAATGTCTCC 
N0D120 Cloning Dux4PAS CATGCGGCCGCTCACGCGCTCTAC
ACTGATCACGTAAGTGATG 
N0D121 Cloning Dux4PAS CATGCGGCCGCTACATATAGAGCA
ACTGATCACGTAAGTGATG 
N0D122 Cloning Dux4PAS GGCCGCGGCCGCTACTGATCACGT
AAGTGATGTAAC 
N0D145 Cloning Dux4PAS CATGCGGCCGCTAAATATCTCTACA
CTGAT 
N0D125 Cloning Dux4PAS GGCCGCGGCCGCTCTCTACACTGA
TCACGTAAGTG 
N0D144 Cloning Dux4PAS CATGCGGCCGCTCCATATCTCTAC
ACTGAT   
N0D146 Cloning Dux4PAS CATGCGGCCGCTACCTATCTCTAC
ACTGAT 
N0D147 Cloning Dux4PAS CATGCGGCCGCTACAGATCTCTAC
ACTGATCAC 
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N0D148 Cloning Dux4PAS CATGCGGCCGCTACATCTCTCTAC
ACTGATCAC 
N0D149 Cloning Dux4PAS CATGCGGCCGCTACATAGCTCTAC
ACTGATCAC 
N0D150 Cloning Dux4PAS GGCCGCGGCCGCTACATATATCTA
CACTGATCACGTAAGT 
N0D151 Cloning Dux4PAS GGCCGCGGCCGCTACATATCGCTA
CACTGATCACGTAAGT 
N0D152 Cloning Dux4PAS GGCCGCGGCCGCTACATATCTGTA
CACTGATCACGTAAGT 
N0D153 Cloning Dux4PAS GGCCGCGGCCGCTACATATCTCTA
CCCTGATCACGTAAGTGAT 
N0D154 Cloning Dux4PAS GGCCGCGGCCGCTACATATCTCTA
CAATGATCACGTAAGTGAT 
N0D155 Cloning Dux4PAS GGCCGCGGCCGCTACATATCTCTA
CACGGATCACGTAAGTGAT 
N0D156 Cloning Dux4PAS GGCCATCGATTAGACCTGCGCGCA
GTGCGCACCCC 
N0D157 Cloning Dux4PAS GGCCATCGATCTTCCGTGAAATTCT
GGCTGAATGTCTCC 
NOD163 Cloning Dux4PAS GGCCAAGCTTACATATCTCTACACT
GATCACGTAAGTGATGTA 
NOD164 Cloning Dux4PAS GGCCAAGCTTACCAATTTCAGGCTT
TTTGTACAGGGGATA 
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NOD165 Cloning Dux4PAS GGCCAAGCTTTGCCTACACTCTGC
CTACAGGAGGC 
NOD36B  Cloning Dux4PAS GGCCGCGGCCGCTGAGTTCTGAAA
CAGATCTGC 
NOD167 Cloning Dux4PAS GGCCAAGCTTAGGGGCTTTGTGAG
ATATCTCTG 
NOD168 Cloning Dux4PAS GGCCAAGCTTATTTCCACTGCTCAA
ACAGGTGATG 
NOD169 Cloning Dux4PAS GGCCAAGCTTGAGATGTAAAAATTG
TCTGGGCTTTGTC 
NOD170 Cloning Dux4PAS GGCCAAGCTTAAGCTCTGCCTACA
GGGGCATTG 
NOD173 Cloning Dux4PAS GGCCGCGGCCGCTTCGGTTCAGTC
TACTATGGAGTTC 
NOD174 Cloning Dux4PAS GGCCGCGGCCGCTTAGTGGCAGT
CTACTATGGAGTTC 
NOD175 Cloning Dux4PAS GGCCGCGGCCGCTTAGGTTACTTC
TACTATGGAGTTC 
NOD176 Cloning Dux4PAS GGCCGCGGCCGCTTAGGTTCAGGA
GACTATGGAGTTC 
NOD177 Cloning Dux4PAS GGCCGCGGCCGCTTAGGTTCAGTC
TCAGATGGAGTTC 
NOD178 Cloning Dux4PAS GGCCGCGGCCGCTTAGGTTCAGTC
TACTCGTGAGTTC 
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NOD179 Cloning Dux4PAS GGCCGCGGCCGCTTAGGTTCAGTC
TACTATGTCTTTC 
NOD181 Cloning Dux4PAS GGCCGCGGCCGCTGCTTGGCAGT
CTACTATGGAGTTCTGAAAC 
NOD182 Cloning Dux4PAS GGCCGCGGCCGCTTAGGTTACTGA
GACTATGGAGTTCTGAAAC 
NOD183 Cloning Dux4PAS GGCCGCGGCCGCTTAGGTTCAGTC
TCAACGTGAGTTCTGAAAC 
NOD178B Cloning Dux4PAS GGCCGCGGCCGCTTAGGTTCAGTC
TACTCGTGAGTTC TGAAAC 
NOD179B Cloning Dux4PAS GGCCGCGGCCGCTTAGGTTCAGTC
TACTATGTCTTTCTGAAAC 
NOD189 Cloning Dux4PAS GGCCAGATCTAGGGGCTTTGTGAG
ATATCTCTG 
NOD195 Cloning Dux4PAS GGCCGCGGCCGCTAAATATCTCTA
CCAGACGCACGTA 
NOD196 Cloning Dux4PAS GGCCGCGGCCGCTAAATATAGAGC
AACTGATCACGTA 
NOD197 Cloning Dux4PAS GGCCGCGGCCGCTCGCGCGCTCT
ACACTGATCACGTA 
NOD225 Cloning Dux4PAS GGCCGCGGCCGCTCACGCTCTCTA
CACTGATCACGTA 
NOD223a Cloning Dux4PAS GGCCGCGGCCGCTAAATATCTCTC
ACAGGATCACGTA 
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NOD224a Cloning Dux4PAS GGCCGCGGCCGCTAAATAGAGAGA
CACTGATCACGTA 
NOD226 Cloning Dux4PAS GGCCGCGGCCGCTGAACTAATCAT
CCAGGAGATG 
NOD227 Cloning Dux4PAS GGCCCTCGAGACCTGCGCGCAGT
GCGCACC 
NOD228 Cloning Dux4PAS GGCCCTCGAGCTTCCGTGAAATTC
TGGC 
N0D08 Cloning Dux4PAS Exon3 GGCCAGATCTTTCTATAGGATCCAC
AGGGAGGG 
N0D17 Cloning Dux4PAS Exon3 GGCCGCGGCCGCTTGCGTACACTC
TGCCTACAGGAGGC 
N0D01B Cloning Dux4PAS pLAM GGCCAAGCTTCGGTCAAAAGCATA
CCTCTGTCTGTCT  
N054 Cloning HAmCherry GGCCGGTACCATGTACCCATACGA
TGTTCCTGACTATGCGGGCGTGAG
CAAGGGCGAG 
N055 Cloning HAmCherry GGCCGGATCCTTACTTGTACAGCT
CGTCCATG 
N081 Cloning Random Sequences from 
pUC19 
GGCCAAGCTTGTGATGACGGTGAA
AACCTC 
N082 Cloning Random Sequences from 
pUC19 
GGCCGGATCCGTACAATCTGCTCT
GATGCC 
N083 Cloning Random Sequences from 
pUC19 
GGCCAAGCTTGAGAGTGCACCATA
TGCGGT 
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N084 Cloning Random Sequences from 
pUC19 
GGCCGGATCCCAACGTCGTGACTG
GGAAAACCCTGGCGTT 
N085 Cloning Random Sequences from 
pUC19 
GGCCAAGCTTATGTTGTGCAAAAAA
GCGGTTAGCTCCTTC 
N086 Cloning Random Sequences from 
pUC19 
GGCCGGATCCGAATGACTTGGTTG
AGTACT 
N087 Cloning Random Sequences from 
pUC19 
GGCCAAGCTTATGATACCGCGAGA
CCCACG 
N088 Cloning Random Sequences from 
pUC19 
GGCCGGATCCGGCAACAACGTTGC
GCAAACTATTAACTGG 
N089 Cloning Random Sequences from 
pUC19 
GGCCGGATCCTTTAAAAGTGCTCAT
CATTG 
N090 Cloning Random Sequences from 
pUC19 
GGCCAAGCTTATGAGTATTCAACAT
TTCCGTG 
N091 Cloning Random Sequences from 
pUC19 
GGCCAAGCTTGGGTGCCTAATGAG
TGAGCT 
N092 Cloning Random Sequences from 
pUC19 
GGCCGGATCCGAGGAAGCGGAAG
AGCGCCCAATACGCAAA 
N081p Cloning Random Sequences from 
pUC19 
GGCCAGATCTGTGATGACGGTGAA
AACCTC 
N083p Cloning Random Sequences from 
pUC19 
GGCCAGATCTGAGAGTGCACCATA
TGCGGT 
N085p Cloning Random Sequences from 
pUC19 
GGCCAGATCTATGTTGTGCAAAAAA
GCGGTTAGCTCCTTC 
60 
 
N087p Cloning Random Sequences from 
pUC19 
GGCCAGATCTATGATACCGCGAGA
CCCACG 
N089p Cloning Random Sequences from 
pUC19 
GGCCAGATCTTTTAAAAGTGCTCAT
CATTG 
N091p Cloning Random Sequences from 
pUC19 
GGCCAGATCTGGGTGCCTAATGAG
TGAGCT   
N050 Cloning SV40LPAS  GGCCAAGCTTGCCGTGTAATAATTC
TAGAGTC 
N051 Cloning SV40LPAS  GGCCGGATCCGAAAACCTCCCACA
CCTCCCC 
N0120 Cloning SV40LPAS  GGCCATCGATGCCGTGTAATAATTC
TAGAGT C 
N0121 Cloning SV40LPAS  GGCCGGATCCGAAAACCTCCCACA
CCTCCCC 
N0122 Cloning SV40LPAS  GGCCGGATCCCGATTTTACCACATT
TGTAGAGG 
N0145  Cloning SV40LPAS  GGCCATCGATGAGTTTGGACAAAC
CACAAC 
N0146 Cloning SV40LPAS  GGCCATCGATGCAGCTTATAATGG
TTACAAAT 
N0147 Cloning SV40LPAS  GGCCAAGCTTCAACAATTGCATTCA
TTTTATGTTTC 
N099 Cloning SV40LPAS  GGCCAGATCTGAAAACCTCCCACA
CCTCCCC 
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N0121B Cloning SV40LPAS  GGCCAAGCTTGAAAACCTCCCACA
CCTCCCC 
N0122B Cloning SV40LPAS  GGCCAAGCTTCGATTTTACCACATT
TGTAGAGG 
N080 Cloning SV40LPAS DSE null GGCCGTCGACATTGTTGTTGTTAAC
TTGTTTATTGC 
N069 Cloning SV40LPAS DSE null GGCCGGATCCATTGTTGTTGTTAAC
TTGTTTATTGC 
N0150A Site directed mutagenesis create ClaI 
restriction site in Dux4PAS 
CTCCTGGATGATTAGTTCATCGATA
TATTAAAATGCCCCCTCCCT 
N0150B Site directed mutagenesis create ClaI 
restriction site in Dux4PAS 
AGGGAGGGGGCATTTTAATATATC
GATGAACTAATCATCCAGGAG 
N0149A Site directed mutagenesis create 
HindIII restriction site in Dux4PAS 
GTGGATCCTATAGAAGATTTGAAGC
TTTTGTGTGATGAGTGCAG 
N0149B Site directed mutagenesis create 
HindIII restriction site in Dux4PAS 
CTGCACTCATCACACAAAAGCTTCA
AATCTTCTATAGGATCCAC 
N076 Site directed mutagenesis create 
SV40L clvnull short oligo 
GCAATAAACAAGTTAACGGCGGCG
GTTGCATTCATTTTATG 
N077 Site directed mutagenesis create 
SV40L clvnull short oligo 
CATAAAATGAATGCAACCGCCGCC
GTTAACTTGTTTATTGC 
N074 Site directed mutagenesis create 
SV40L PASNull short oligo 
GTAACCATTATAAGCTGCGGGAAA
CAAGTTAACAAC 
N075 Site directed mutagenesis create 
SV40L PASNull short oligo 
GTTGTTAACTTGTTTCCCGCAGCTT
ATAATGGTTAC 
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N0D113A Site directed mutagenesis Dux4PAS CTCCATAGTAGACTGAACCTATCTC
CTGGTTACATCACTTAC 
N0D113B Site directed mutagenesis Dux4PAS GTAAGTGATGTAACCAGGAGATAG
GTTCAGTCTACTATGGAG 
N0D114A Site directed mutagenesis Dux4PAS GTAGACTGAACCTAGAGAAGTTGG
ACATCACTTACGTGATCAG 
N0D114B Site directed mutagenesis Dux4PAS CTGATCACGTAAGTGATGTCCAACT
TCTCTAGGTTCAGTCTAC 
N0D115A Site directed mutagenesis Dux4PAS CTGAACCTAGAGAATGGTTCACGA
ACTTACGTGATCAGTGTAGAG 
N0D115B Site directed mutagenesis Dux4PAS CTCTACACTGATCACGTAAGTTCGT
GAACCATTCTCTAGGTTCAG 
N0D116A Site directed mutagenesis Dux4PAS CTAGAGAATGGTTACATCCAGGCC
GTGATCAGTGTAGAGATATG 
N0D116B Site directed mutagenesis Dux4PAS CATATCTCTACACTGATCACGGCCT
GGATGTAACCATTCTCTAG 
N0D117A Site directed mutagenesis Dux4PAS GAGAATGGTTACATCACTTAATGTC
TCAGTGTAGAGATATGTAGC 
N0D117B Site directed mutagenesis Dux4PAS GCTACATATCTCTACACTGAGACAT
TAAGTGATGTAACCATTCTC 
N0D117C Site directed mutagenesis Dux4PAS GAGAATGGTTACATCACTTATTGTC
TCAGTGTAGAGATATGTAGC 
N0D117D Site directed mutagenesis Dux4PAS GCTACATATCTCTACACTGAGACAA
TAAGTGATGTAACCATTCTC 
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N0D118A Site directed mutagenesis Dux4PAS GGTTACATCACTTACGTGAGACTG
GTAGAGATATGTAGC 
N0D118B Site directed mutagenesis Dux4PAS GCTACATATCTCTACCAGTCTCACG
TAAGTGATGTAACC 
NOD166A Site directed mutagenesis Dux4PAS GTTACATCTCCTGGAGGATTACTTC
AGAGATATATTAAAATCCCC 
NOD166B Site directed mutagenesis Dux4PAS GGGGATTTTAATATATCTCTGAAGT
AATCCTCCAGGAGATGTAAC 
NOD112C Site directed mutagenesis Dux4PAS CATTACTTCAGAGATATATTTAAATC
CCCCCTCCCTGTG 
NOD112D Site directed mutagenesis Dux4PAS CACAGGGAGGGGGGATTTAAATAT
ATCTCTGAAGTAATG 
NOD180A Site directed mutagenesis Dux4PAS GATCATTACTTCAGAGATATAGGGA
AATCCCCCCTCCCTGTG 
NOD180B Site directed mutagenesis Dux4PAS CACAGGGAGGGGGGATTTCCCTAT
ATCTCTGAAGTAATGATC 
NOD190A Site directed mutagenesis Dux4PAS CAGAACTCCATAGTAGACTGCCAA
GCGAGAATCGTTACATCTACGTGAT
C 
NOD190B Site directed mutagenesis Dux4PAS GATCACGTAGATGTAACGATTCTCG
CTTGGCAGTCTACTATGGAGTTCTG 
NOD191A Site directed mutagenesis Dux4PAS CTCCATAGTAGACTGAACCTATCTC
CGCGTTACATCACTTACGTGATCAG 
64 
 
NOD191B Site directed mutagenesis Dux4PAS CTGATCACGTAAGTGATGTAACGC
GGAGATAGGTTCAGTCTACTATGG
AG 
NOD192A Site directed mutagenesis Dux4PAS CCATAGTAGACTGAACCTAGAGAAT
ATCTACATCACTTACGTGATCAGTG 
NOD192B Site directed mutagenesis Dux4PAS CACTGATCACGTAAGTGATGTAGAT
ATTCTCTAGGTTCAGTCTACTATGG 
NOD192C Site directed mutagenesis Dux4PAS CCATAGTAGACTGAACCTAGAGAAT
ATCGCAATCACTTACGTGATCAGTG 
NOD192D Site directed mutagenesis Dux4PAS CACTGATCACGTAAGTGATTGCGAT
ATTCTCTAGGTTCAGTCTACTATGG 
NOD193A Site directed mutagenesis Dux4PAS GTAGACTGAACCTAGAGAATCGTTA
CCGACAGTACGTGATCAGTGTAGA
G 
NOD193B Site directed mutagenesis Dux4PAS CTCTACACTGATCACGTACTGTCGG
TAACGATTCTCTAGGTTCAGTCTAC 
NOD194A Site directed mutagenesis Dux4PAS CCTAGAGAATCGTTACATCACTGCA
GTGATCAGTGTAGAGATATTTTG 
NOD194B Site directed mutagenesis Dux4PAS CAAAATATCTCTACACTGATCACTG
CAGTGATGTAACGATTCTCTAGG 
NOD194C Site directed mutagenesis Dux4PAS CCTAGAGAATCGTTACATCACTGCA
TATATCAGTGTAGAGATATTTTG 
NOD194D Site directed mutagenesis Dux4PAS CAAAATATCTCTACACTGATATATG
CAGTGATGTAACGATTCTCTAGG 
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NOD214A Site directed mutagenesis Dux4PAS CAGATCTGTTTCAGAACTCACGCTT
AGACTGAACCTAGAGAATC 
NOD214B Site directed mutagenesis Dux4PAS GATTCTCTAGGTTCAGTCTAAGCGT
GAGTTCTGAAACAGATCTG 
NOD215A Site directed mutagenesis Dux4PAS CTGTTTCAGAACTCCATAGGCTCGT
GAACCTAGAGAATCGTTAC 
NOD215B Site directed mutagenesis Dux4PAS GTAACGATTCTCTAGGTTCACGAGC
CTATGGAGTTCTGAAACAG 
NOD216A Site directed mutagenesis Dux4PAS CAGAACTCCATAGTAGACGTCCACT
AGAGAATCGTTACATCAC 
NOD216B Site directed mutagenesis Dux4PAS GTGATGTAACGATTCTCTAGTGGAC
GTCTACTATGGAGTTCTG 
NOD217A Site directed mutagenesis Dux4PAS CTCCATAGTAGACTGAACAGCTCG
AATCGTTACATCACTTACGTG 
NOD217B Site directed mutagenesis Dux4PAS CACGTAAGTGATGTAACGATTCGA
GCTGTTCAGTCTACTATGGAG 
NOD218A Site directed mutagenesis Dux4PAS CTCCATAGTAGACTGAACCTAGATC
CTAGTTACATCACTTACGTG 
NOD218B Site directed mutagenesis Dux4PAS CACGTAAGTGATGTAACTAGGATCT
AGGTTCAGTCTACTATGGAG 
NOD219A Site directed mutagenesis Dux4PAS GTAGACTGAACCTAGAGAATCTGG
CAATCACTTACGTGATCAGTG 
NOD219B Site directed mutagenesis Dux4PAS CACTGATCACGTAAGTGATTGCCA
GATTCTCTAGGTTCAGTCTAC 
66 
 
NOD220A Site directed mutagenesis Dux4PAS GAACCTAGAGAATCGTTACCGACAT
TACGTGATCAGTGTAGAG 
NOD220B Site directed mutagenesis Dux4PAS CTCTACACTGATCACGTAATGTCGG
TAACGATTCTCTAGGTTC 
NOD221A Site directed mutagenesis Dux4PAS CTAGAGAATCGTTACATCACGGCAT
TGATCAGTGTAGAGATATC 
NOD221B Site directed mutagenesis Dux4PAS GATATCTCTACACTGATCAATGCCG
TGATGTAACGATTCTCTAG 
NOD222A Site directed mutagenesis Dux4PAS GAATCGTTACATCACTTACGGTCGA
AGTGTAGAGATATCTAGCG 
NOD222B Site directed mutagenesis Dux4PAS CGCTAGATATCTCTACACTTCGACC
GTAAGTGATGTAACGATTC 
N066 Site-directed mutagenesis remove 
start codon in SV40LPAS 
CCGCTTCGAGCAGACGTGATAAGA
TACATTGATGAGTTTGG 
N067A Site-directed mutagenesis remove 
start codon in SV40LPAS 
CCAAACTCATCAATGTATCTTATCA
CGTCTGCTCGAAGCGG 
N064 Site-directed mutagenesis remove 
stop codon in SV40LPAS 
CCACAACTAGAATGCAGGGAAAAA
AATGCTTTATTTGTG 
N065A Site-directed mutagenesis remove 
stop codon in SV40LPAS 
CACAAATAAAGCATTTTTTTCCCTG
CATTCTAGTTGTGG 
N093 Site-directed mutagenesis remove 
stop codon in SV40LPAS 
GGACAAACCACAACTAGAGTGCAG
GGA AAAAAATGC 
N094 Site-directed mutagenesis remove 
stop codon in SV40LPAS 
GCATTTTTTTCCCTGCACTCTAGTT
GTGGTTTGTCC 
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N095 Site-directed mutagenesis remove 
stop codon in SV40LPAS 
TGCATTCATTTTGTGTTTCAGGTTC
AGGGGGAGGTG  
N096 Site-directed mutagenesis remove 
stop codon in SV40LPAS 
CACCTCCCCCTGAACCTGAAACAC
AAAATGAATGCA 
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Cell Culture  
All cell lines used in this study are described in Table 3.3. Patient cell lines were 
obtained from University of Rochester and University of Massachusetts Wellstone Center for 
FSHD. Patient cells were supplied as de-identified lines by the aforementioned institutes. 
HeLa, HEK293T and RD cells were cultured in Dulbecco’s modified Eagle medium (DMEM) 
(Lonza, Maryland USA) containing L-Glutamine and Sodium pyruvate and supplemented 
with 1% penicillin-streptomycin (Thermo Fisher Scientific) and 10% fetal bovine serum 
(Hyclone, Utah USA). Hereafter, referred to as DMEM Complete. Cells were passaged 1:10 
and grown in 5% CO2.  
Immortalized myoblast cells obtained from the Wellstone Center for FSHD were 
culture in LHCN , Medium (4:1 DMEM: Medium 199, supplemented with 20% fetal bovine 
serum, 30 mg/L ZnSO4 (Sigma, Missouri USA), 1.4 mg/mL Vitamin B12 (Sigma, Missouri 
USA), 55µg/mL dexamethasone (Sigma, Missouri USA), 2.5 µg/mL hepatocyte growth factor 
(Sigma), 25 µg/mL basic fibroblast growth factor (Promega, Wisconsin, USA) and 1% 
antibiotic/antimycotic (Thermo Fisher Scientific, Massachusetts USA).  For differentiation, 
cells at ≥90% confluence were fed 4:1 DMEM:Medium 199 supplemented with 2% horse 
serum (Hyclone, Utah USA) or 15% Knock-Out Serum Replacer (Thermo Fisher Scientific, 
Massachusetts USA), 2 mM L-glutamine (Thermo Fisher Scientific, Massachusetts USA), 
1% antibiotics/antimycotics, 20 mM HEPES (Sigma, Missouri USA) and 1 mM sodium 
pyruvate (Thermo Fisher Scientific, Massachusetts USA). Immortalized human myoblast 
cells were grown on plates treated with 0.1% gelatin.  
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Table 3.3. Table of Cell Lines 
Cell Line Supplier Descriptor Reference 
HeLa  ATCC Immortalized human 
cervical cancer cell line 
HeLa (ATCC® CCL-2™) 
HEK293T ATCC Immortalized human 
embryonic kidney cells 
containing the SV40 large T 
antigen 
293T (ATCC® CRL-3216™) 
RD  ATCC Immortalized human 
rhabdomyosarcoma striated 
muscle cell line  
RD (ATCC® CCL-136™) 
15Abic 
Ct#24 
University of 
Massachusett
s Wellstone 
Program 
Immortalized human 
skeletal muscle cell line: 
myoblasts. FSHD line 
derived from proband with 
~8 D4Z4 repeats.  
(Homma et al., 2012; 
Rahimov et al., 2012; Stadler 
et al., 2011) 
15Vbic 
CT#9 
University of 
Massachusett
s Wellstone 
Program 
Immortalized human 
skeletal muscle cell line: 
myoblasts. Control line 
derived from unaffected 
sibling of 15Abic line. 
Normal D4Z4 repeat length 
>11. 
(Homma et al., 2012; 
Rahimov et al., 2012; Stadler 
et al., 2011) 
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Stable Line Development 
A kill curve was performed on HEK293T cells and the optimal dose for selecting 
resistance within 6 days using blasticidin (Thermo Fisher Scientific, Massachusetts USA) 
was 10 mg/mL. HEK239T cells were plated at 6x105 cells per well in 6 well dish, and 
transfected the following day with the reporter plasmid and selection plasmid (10:1 ratio) 
using Polyethylenimine (PEI). After a period of 24 hrs after transfection, visual confirmation 
of the expression of the selection plasmid (mCherry) and the reporter plasmid (GFP) was 
done. The medium was then removed from the cells and replaced with DMEM complete 
containing blasticidin at 10 µg/mL. Cells were allowed to grow in selection in six-well dish for 
a week with medium replenished every other day. After day six, cells were moved to 10 cm2 
dish, while still maintaining selection. Cells were allowed to grow to generate sufficient 
plates for freezing down and cell sorting. Within two days of moving to 10 cm2 dish, cell 
selection was maintained using a lower dose of Blasticidin (5 µg/ml) with each passage in 
DMEM complete. Cells plated for transfection with ASOs or siRNAs were seeded in DMEM 
complete without blasticidin. Polyclonal cells were sorted at the University of Texas Medical 
Branch Flow Cytometry and Cell Sorting Core Facility for GFP positive cells. To select clonal 
cells, cells were seeded at a density of 0.5 cell/ well in 96 well dish in the absence of 
blasticidin. After sufficient growth, indicated by a change in the color of the medium clones 
were moved to a 24-well dish and supplemented with 5 µg/mL blasticidin. The clonal identity 
was determined by sequencing of nested PCR products amplified from the genomic DNA of 
the clones.  
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Transfections 
All cells were transiently transfected with Lipofectamine 2000 (Thermo Fisher 
Scientific, Massachusetts USA) or with Polyethylenimine (PEI) (Sigma, Missouri USA). Cells 
were transfected at 70-80% confluence.  
Small Interfering RNA (siRNA) transfections 
All siRNAs used in this study are listed in Table 3.4, and were purchased from 
Sigma-Aldrich. A two hit protocol (Albrecht and Wagner, 2012; Wagner and Garcia-Blanco, 
2002) was used for transfection of siRNAs (Figure 3.1A). Briefly, cells were seeded the day 
before transfection to ensure 80% confluence on day of transfection in a 24-well plate. A 
total of 3 µL of Lipofectamine 2000 was incubated with 50µL of OptiMEM (Thermo Fisher 
Scientific) for seven minutes at room temperature. After seven minutes elapsed, the 
Lipofectamine/OptiMEM mixture was mixed with an equal volume of OptiMEM containing 3 
µL of 20 µM siRNA. The siRNA:lipid complexes were allowed to form during a 25 minute 
incubation at room temperature. After which, the complexes were added to cells. Final 
concentration of siRNA on cells 100 nM. The medium was changed four hours after 
transfection. Twenty-four hours after transfection, the cells were trypsinized and moved to a 
six-well plate. Following an additional twenty-four hours of growth, cells were once more 
transfected with siRNA as described earlier for final concentration of 100 nM siRNA. In some 
instances at the second transfection, siRNA was co-transfected with DNA plasmids that 
were typically 100 ng of reporter plasmid with 50ng transfection control plasmid. Cells were 
lysed for protein or RNA 24-48 hrs after second transfection.  
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Table 3.4. Table of siRNAs 
Name Sequence Reference 
C2 GGUCCGGCUCCCCCAAAUG[dT][dT] (Wagner et al., 2005) 
XRN1 GUAACUGAACUUUCUCGAA[dT][dT] Sigma-Aldrich #1  
Exosc4 GACCGUAAGUCCUGAGA[dT][dT] Sigma-Aldrich #1  
siGFP CAAGCUGACCCUGAAGUUC[dT][dT] (Tschuch et al., 2008) 
Dicer1 CAUUGAUCCUGUCAUGGAU[dT][dT] Sigma-Aldrich #1  
CPSF160 GCUUUAAGAAGGUCCCUCA[dT][dT] Sigma-Aldrich #1  
UPF1 GAGAUAUGCCUGCGGUACA[dT][dT] Sigma-Aldrich #1  
CstF64 GGCUUUAGUCCCGGGCAGA[dT][dT] Sigma-Aldrich #1  
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Figure 3.1. Schematic of transfection protocol with co-transfection of siRNA or ASO with 
Reporter. A and B are two hit protocols, C is a single hit protocol for transfections 
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Antisense Oligonucleotide (ASO) transfections 
All ASO are listed in Table 3.5, and were purchased from Sigma-Aldrich with either a 
phosphorothioate or phosphodiester backbone. ASOs were transfected with a two-hit 
protocol as described above for siRNA transfection. Lipofectamine 2000 volume was 
typically kept constant at 3 µL and ASO volume maintained below 5 µL, and if necessary 
diluted in ultrapure water for the required concentration. Modifications to the ASO 
transfections include only a single transfection of ASO in 24 well plated cells, with cells lysed 
for RNA or protein or visualized for fluorescence 24-120 hrs (120 hrs post transfection used 
for myoblast transfected ASOs which were induced to differentiate). Another modification of 
the ASO transfection protocol (Figure 3.1B/C) occurs when reporter and transfection control 
plasmid are first transfected into cells plated in a 24-well dish, described below. Plasmid 
transfected cells are moved to a 6-well dish and transfected with ASO at the appropriate 
concentration. 
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Table 3.5. Table of Antisense Oligonucleotides 
Name Sequence Bac
kbone 
Targ
et 
Refe
rence 
NPASO -1 
[mG][mU][mU][mA][mA][mC][mU][mU][mG][mU][mU][mU][mA][mU]
[mU][mG][mC][mA] 
PS, PO 
SV40PAS  This study 
NPASO -2 
[mG][mC][mA][mA][mU][mU][mA][mG][mU][mA][mA][mA][mU][mU][
mC] 
PS, PO 
ASO 
Control 
Short  This study 
NPASO-2F 
[Flc][mG][mC][mA][mA][mU][mU][mA][mG][mU][mA][mA][mA][mU][
mU][mC] 
PS 
ASO 
Control 
Short 
'5Fluorecein 
Tag This study 
NPASO -3 
[mU][mU][mG][mC][mA][mA][mU][mU][mA][mG][mU][mA][mA][mA][
mU][mU][mC][mA] 
PS, PO 
ASO 
Control 
Long  This study 
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NPASO -4 
[mG][mC][mA][mU][mU][mU][mU][mA][mA][mU][mA][mU][mA][mU][
mC] 
PS 
Dux4PAS at 
PAS This study 
NPASO -5 
[mG][mG][mA][mU][mU][mU][mU][mA][mA][mU][mA][mU][mA][mU][
mC] 
PS 
Dux4PAS at 
PAS single 
mismatch This study 
NPASO -6 
[mG][mU][mU][mA][mA][mC][dT][dT][dG][dT][dT][dT][dA][dT][mU][
mG][mC][mA][mG][mC] 
PS 
SV40PAS  This study 
NPASO -7 
[mG][mU][mA][mU][mC][mU][dA][dC][dT][dG][dG][dT][dT][dC][mG][
mU][mA][mU][mA][mU] 
PS 
ASO 
Control 
Long  This study 
NPASO - 8  GTTAACTTGTTTATTGCAGC PS SV40PAS  This study 
NPASO - 9 
GTATCTACTGGTTCGTATAT PS 
ASO 
Control 
Long  This study 
NPASO - 10 
[mA][mG][mG][mG][mG][mG][dC][dA][dT][dT][dT][dT][dA][dA][mU][
mA][mU][mA][mU][mC] 
PS 
Dux4PAS at 
PAS This study 
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NPASO - 12 
[mC][mU][mA][mG][mG][mU][mU][mC][mA][mG][mU][mC][mU][mA]
[mC] 
PS 
Dux4PAS at 
~+160 This study 
NPASO - 13 
[mA][mC][mA][mU][mA][mU][mC][mU][mC][mU][mA][mC][mA][mC][
mU][mG] 
PS 
Dux4PAS 
at~+200 This study 
NPASO - 14 
[mU][mC][mU][mA][dG][dG][dT][dT][dC][dA][dG][dT][mC][mU][mA][
mC][mU] 
PS 
Dux4PAS 
at~+160 This study 
NPASO - 15 
[mG][mC][mA][mA][mA][mU][mC][mU][mU][mC][mU][mA][mU][mA][
mG] 
PS 
Dux4PAS at 
Cleavage 
site This study 
NPASO - 16 
[mC][mU][mA][mU][mA][mG][mG][mA][mU][mC][mC][mA][mC][mA][
mG] 
PS 
Dux4PAS 
Cleavage 
site This study 
NPASO - 21 
[mA][mG][mG][mG][mG][dG][dC][dA][dT][dT][dT][dT][dA][dA][dT][m
A][mU][mA][mU][mC] 
PS 
Dux4PAS at 
PAS This study 
NPASO - 22 
[mA][mG][mG][mG][mG][mG][mC][mA][mU][mU][mU][mU][mA][mA]
[mU][mA][mU][mA][mU][mC] 
PS, PO 
Dux4PAS at 
PAS  This study 
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NPASO - 23 
[mU][mG][mC][mG][mC][mG][mC][mA][mG][mG][mU][mC][mU][mA
][mG][mC][mC][mA][mG][mG] 
PS, PO 
Dux4  Exon 
3 Splice 
Acceptor This study 
NPASO - 24 
[mU][mG][mU][mA][mA][mC][mC][mA][mU][mU][mC][mU][mC][mU]
[mA][mG][mG][mU][mU][mC] 
PS, PO 
Dux4PAS 
~160 This study 
NPASO - 25 
[mC][mC][mU][mA][mA][mG][mU][mG][mA][mU][mG][mU][mA][mA]
[mC][mC][mA][mU][mU][mC] 
PS, PO 
Dux4PAS 
~160 This study 
NPASO - 26 
[mC][mU][mA][mC][mA][mC][mU][mG][mA][mU][mC][mA][mC][mC][
mU][mA][mA][mG][mU][mG] 
PS, PO 
Dux4PAS 
~200 This study 
NPASO - 27 
[mC][mG][mA][mG][mA][mA][mU][mU][mU][mU][mA][mA][mC][mA][
mU][mA][mU][mC][mU][mC] 
PS, PO 
Dux4PAS 
~200 This study 
NPASO-
Dicer1A1 
[mG][mC][mU][mG][mA][dC][dC][dT][dT][dT][dT][dT][dG][dC][dT][m
U][mC][mU][mC][mA]  
PS 
Dicer 
Gapmer1 5-
10-5 
Positive 
Control 
(Lim et al., 
2015) 
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NPASO-
Dicer1B1 
[mA][mG][mG][mA][mG][dG][dA][dA][dG][dC][dC][dA][dA][dT][dT][
mC][mA][mC][mA][mG] 
PS 
Dicer 
Gapmer1 5-
10-5 
Positive 
Control 
(Lim et al., 
2015) 
NPASO-
Dicer1C1 
[mA][mG][mA][mC][mG][dA][dT][dA][dA][dC][dT][dT][dT][dA][dT][m
U][mG][mG][mA][mG] 
PS 
Dicer 
Gapmer 
PAS 
Targeting This study 
NPASO-
Dicer1C2 
[mA][mG][mA][mC][mG][mA][mU][mA][mA][mC][mU][mU][mU][mA][
mu][mU][mG][mG][mA][mG] 
PS 
Dicer PAS 
Targeting 
non-gapmer This study 
NPASO - 28 
[mU][mA][mU][mC][mU][mC][mU][mA][mC][mA][mC][mU][mG][mA][
mU][mC] 
PS 
Dux4PAS 
~200 This study 
NPASO - 29 
[mG][mA][mU][mC][mA][mC][mC][mU][mA][mA][mG][mU][mG][mA]
[mU][mG] 
PS 
Dux4PAS 
~200 This study 
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NPASO - 30 
[mC][mA][mU][mC][mU][mG][mC][mA][mC][mU][mG][mA][mU][mC]
[mA][mC][mC][mG] 
PS 
Dux4PAS 
~120 This study 
NPASO-
INTS4-1 
[mU][mC][mA][mA][mC][dT][dT][dT][dA][dT][dT][dG][dT][dG][dG][m
A][mC][mA][mG][mG] 
PS 
Integrator4 
PAS  This study 
NPASO-
INTS4-2 
[mU][mC][mA][mA][mC][mU][mU][mU][mA][mU][mU][mG][mU][mG]
[mG][mA][mC][mA][mG][mG] 
PS 
Integrator4 
PAS This study 
NPASO - 
4+22 
[mG][mG][mC][mA][mU][mU][mU][mU][mA][mA][mU][mA][mU][mA][
mU][mC][mU][mC][mU][mG][mA][mA][mC] PS, PO 
Dux4PAS at 
PAS This study 
NPASO - 
15+16 
[mG][mC][mA][mA][mA][mU][mC][mU][mU][mC][mU][mA][mU][mA][
mG][mG][mA][mU][mC][mC][mA][mC][mA] PS, PO 
Dux4PAS at 
Cleavage 
site This study 
NPASO - 
22MS 
[mA][mA][mG][mU][mG][mG][mA][mA][mA][mU][mG][mU][mG][mU]
[mU][mA][mU][mC][mU][mC] 
PO 
Dux4PAS at 
PAS with 
mismatch This study 
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Plasmid transfections  
To prepare DNA for transfection, 0.1 -1.0 µg of DNA was mixed with 50µL of 
OptiMEM. 0.5-2µL Lipofectamine 2000 was mixed with 50µL of OptiMEM and incubated 
seven minutes, after which the DNA diluted in OptiMEM was mixed with Lipofectamine 
Reagent diluted in OptiMEM. Lipid DNA complexes were allowed to for during a 25-minute 
incubation at room temperature. The lipid:DNA complexes were then added to cells.  
 
Microscopy 
Cell Fixation and Fluorescence Microscopy. 
15Abic CT#24 cells were plated at 25000cells/cm2. Cells were transfected with 
fluorescein tagged ASO (ASO-2F) at concentrations 2.5 µM, 2 µM, 1.5 µM, 1 µM, 500 nM 
and 100 nM using Lipofectamine 2000. 24 hrs after transfection cells were shifted to 
differentiation medium (DM). Day 3 after switch to DM cells were washed once with 
phosphate buffered saline (PBS), and then fixed with 4% paraformaldehyde (Electron 
Microscopy Sciences, Pennsylvania USA) for 10 minutes. Cells were washed once with PBS 
and nuclei were stained with a solution of 1:10000 4',6-diamidino-2-phenylindole (DAPI) in 
PBS for 10 minutes at 37 ˚C. After DAPI staining, cells were washed twice with PBS and 
visualized with the Leica DM IL LED Fluorescence Microscope. 
Alternatively, cells were visualized without DAPI staining, and bright field/phase 
contrast and GFP fluorescence images were taken of live cells.  
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Western Blotting and Immunoprecipitation 
General Cell Lysis  
HEK293T cells were lysed in low salt lysis buffer (150mM NaCl, 100mM Tris pH 7.5, 
1%NP-40). Patient cell lines and HeLa cells were lysed in high salt lysis buffer (500mM 
NaCl, 100mM Tris pH 7.5, 1%NP-40). Patient cell lines and RD cells were lysed in RIPA 
buffer (50mM Tris pH 8, 150mM NaCl, 1% NP-40, 0.5% Sodium Deoxycholate, and 0.1% 
sodium dodecyl sulfate (SDS)). All cells were washed once with PBS and then incubated 
with rocking at 4˚C for 15 minutes with appropriate lysis buffer. Cell lysis was completed with 
one round of freeze-thaw. Protein centration of either low- or high-Salt lysed cells was 
quantified using the Bradford assay and 10µg-20µg of cell lysate was loaded and resolved 
using either a 10% or 12.5 %SDS-PAGE. Protein samples were prepared in 4X SDS loading 
buffer (200mM Tris pH 6.8, 0.8%SDS, 20% glycerol, 400mM Dithiothreitol) and boiled for 
5mins at 95˚C prior to loading on SDS-PAGE. 
Immunoprecipitation of Dux4 
Protein G Dynabeads (Thermo Fisher Scientific) was washed twice with Phosphate 
Buffered Saline with Tween 20 (PBS-T), and once with RIPA buffer. Beads were then bound 
to 10mg of mAB raised to Dux4 in PBS-T, by rotating 10 minutes at room temperature, 
followed by 1hr at 4˚C. After antibody adsorption to the beads, the supernatant was 
removed and beads were resuspended in 100µL of PBS-T. Immortalized human myoblasts 
and myotubes in grown on 35mm dishes were washed once with PBS and were then lysed 
with 500µL of RIPA buffer. 400µL of RIPA lysate of was added to the 20µL of mAB Dux4 
labelled beads. The slurry was rotated overnight at 4˚C. The supernatant was removed and 
cells were washed once with RIPA buffer, and twice with PBS-T. To elute the protein bound 
to the beads, after removal of PBS-T at final wash, beads were resuspended in 0.1M 
83 
 
Glycine pH 2.7. To which, equal volume of 2X Laemilli buffer (Biorad) was added. After 
boiling the sample for 5 minutes, the sample was resolved using SDS-PAGE. 
Electrophoresis and Immunoblotting   
For all SDS-PAGE experiments, lysates were initially resolved using 90V through the 
stacking gel, and then the voltage was increase to 140V and the gel was run until the 17kDa 
marker (PageRuler Plus Prestained Marker, Thermo Fisher Scientific) ran off the gel. The 
proteins were transferred to PVDF membrane.  The membrane was blocked 20 minutes in 
5% milk PBS-T, then incubated with primary antibody diluted in 5%milk PBS-T for 1hr with 
rocking at room temperature or overnight with rocking at 4˚C. After three, 10-minute washes 
with 5%milk PBS-T, the membrane was incubated 1hr with 1:5000 dilution of secondary 
antibody in 5% milk PBS-T. Membrane was washed thrice for 10 minutes each, then rinsed 
once with PBS. The membrane was then incubated for 5 minutes with 4-IBPA ECL. 
Chemiluminescent signal was visualized by exposing film in autoradiograph cassette or with 
the Bio-Rad ChemiDoc Touch Imaging System.  Western blots were quantified using Image 
J software (imagej.nih.gov/ij/) or Image Lab (Biorad). 
Antibodies 
Primary antibodies used in this project were: mouse αGFP, JL-8 (632380, Clontech, 
California USA), mouse αCherry, 1C51 (ab125096, Abcam, Massachusetts, USA), mouse α-
GAPDH (AM4300, Thermo Fisher Scientific), HRP conjugated αHA (A190-107P, Bethyl, 
Texas, USA), HRP Conjugated αFlag-M2 (A8592, Sigma), mouse α-Flag-M2  (A9469, 
Sigma), rabbit α-Exosc4 (A303-774A, Bethyl), mouse α-MHC (MAB4470, R&D Systems, 
Minnesota, USA), mouse α-Dux4, 9A12 (MABD116, Millipore, California USA), rabbit 
αDux4, E55 (ab124699, Abcam), rabbit α-Tubulin (ab15246, Abcam), and α-myc. 
Secondary antibodies were Horse Radish Peroxidase conjugated α mouse (715-053-150, 
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Jackson Immuno Research, Pennsylvania, USA), and Horse Radish Peroxidase conjugated 
α rabbit (NA934V, GE Healthcare, Buckinghamshire, UK)  
 
Plate Reader Assays 
Luciferase Assay 
HEK293T cells or RD cells were seeded in a 24 well plate at 1.25x105 and 3.5 x104 
cells/well respectively. The following day, the cells were transfected with 100 ng of 
psiCheck2 reporter plasmid using Lipofectamine 2000 as described above. 48 hrs after 
transfection cells were lysed in passive lysis buffer (Promega) for 15 minutes at room 
temperature. Firefly and Renilla luciferase activities were determined using the Dual 
Luciferase Reporter Assay System (Promega) in the Enspire 2300 Multilabel Reader. 
Renilla luciferase activity was normalized to Firefly luciferase activity.   
Fluorescence Plate Reader Assay 
HeLa cells were seeded in a 24 well plate at 8.5x104 cells/well. HEK293T cells were 
seeded in a 96 well plate at 1.3x104 cells/well. The following days, cells were transfected 
with 500ng or 100ng of reporter plasmid, with 100 or 20 ng of transfection control plasmid 
using Lipofectamine 2000 as described above. Fluorescence intensity was measure at 24 or 
48 hrs post-transfection in the Enspire 2300 Multilabel Reader or the Tecan Infinite 200 Pro 
Plate Reader. Excitation and emission wavelengths of eGFP was selected as 488/509 and 
the excitation and emission wavelengths of mCherry selected was 575/610.  
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Nucleic Acid Preparation Analysis and Methodology: 
Total RNA Extraction  
RNA was extracted from cells using TriZol Reagent (Thermo Fisher Scientific). 
Briefly, cells were incubated with rocking for 15 minutes at room temperature with TriZol. 
Chloroform was added to the TriZol reagent and the mixture was vortexed 10 seconds. The 
samples were incubated for 10 minutes on ice, then centrifuged at 4˚C for 20 minutes at 
15,000rpm. The aqueous layer was mixed with isopropanol and 10 µg glycogen (AM9510, 
Thermo Fisher Scientific), and incubated overnight at -20˚C or 30 minutes at -80˚C. The 
samples were then centrifuged at 15,000 rpm for 20 minutes at 4˚C. The isopropanol was 
removed without disturbing the RNA pellet, and the pellet was washed once with 75% 
ethanol. The samples were centrifuged at 4˚C for 20 minutes at 15000rpm and then the 
ethanol was removed. After drying, the pellet was resuspended in 30µL of DEPC treated 
water (Thermo Fisher Scientific). 
Complementary DNA (cDNA) synthesis 
RNA for RT-PCR and qPCR were DNAse treated as follows. Briefly, 3 – 10ug of 
RNA was treated with Turbo DNAse (Thermo Fisher Scientific) for 30 minutes at 37˚C. After 
the 30 minutes elapsed the DNAse was inactivated with the addition of Turbo DNAse 
inactivation buffer, and the mixture was incubated 10 minutes at 25˚C with agitation. 
Following the incubation, the mixture was briefly centrifuged to pellet the DNAse. 1 µg of 
DNAse treated RNA was used for cDNA synthesis with M-MLV Reverse Transcriptase 
(Thermo Fisher Scientific). Reverse transcription reaction was allowed to proceed for 1hr at 
37°C, followed by incubation at 95°C for 5 minutess. In the event, where RNA from 
myoblasts was being prepared to assay Dux4 mRNA expression, 2 – 3 µg of DNAse treated 
RNA was used for cDNA synthesis with Superscript III Reverse Transcriptase (Thermo 
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Fisher Scientific). cDNA synthesis for RT PCR and qPCR were primed with OligodT12-18, 
OligodT20 (Thermo Fisher Scientific), or OligodT18 (New England Biolabs). cDNA for 3′ RACE 
was primed with SP6 OligodT or T7 OligodT. 
Rapid Amplification of Complementary DNA Ends (RACE) 
Primers used for 3′RACE are listed in Table 3.6. The polyadenylated cDNA pool was 
subjected to two consecutive rounds of PCR at 20 cycles each to amplify the 3′ RACE 
product. 1µL of cDNA was used as template for the 1st cycle of PCR, with Pfu polymerase, 
primed with appropriate forward primer and SP6 OligodT or T7 OligodT, as reverse primer in 
a 50µL reaction. The cycling conditions are 95˚C for 3 minutes, 20 cycles of 95˚C for 30s, 
55˚C for 30s, 72˚C for 30s, and final elongation at 72˚C for 5minutes. After the 1st PCR 
cycle, 5 µL of PCR product was run on 1-3% agarose gel. 2 µL of the product from the 1st 
PCR cycle, was used as template for a second round of PCR, using cycling conditions as 
above. After 2nd round of PCR, 5 uL of the PCR product was run on 1-3% agarose gel. To 
determine the site of polyadenylation, 20 µL of the final PCR product was run on 1% 
agarose gel and bands were excised and purified and submitted for sequencing (Genewiz, 
NJ USA or Lonestar Labs, TX USA with a nested primer.   Alternatively, 4 µL of the PCR 
product was ligated to the Zero Blunt Topo PCR Vector (Thermo Fisher Scientific) according 
to manufacturer’s recommendation. XL1-Blue competent cells were transformed with 1 µL of 
the ligation reaction and plated on Luria Broth-Kanamycin Agar plates. Amplified clones that 
contained inserts as determined by EcoRI restriction digest screen were submitted for 
sequencing with M13F and M13R primers. 
RT-PCR 
Primers used for RT-PCR are listed in Table 3.6.  2 µL of cDNA was used as 
template for PCR with Pfu polymerase. The final PCR product was run on 2-3% agarose gel. 
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PCR products were ligated and transformed as described above, and clones amplified were 
submitted for sequencing as above. 
qPCR 
Primers used for qPCR are listed in Table 3.6. 2 µL of the undiluted cDNA was used 
in the reaction with SYBR Green master mix (KAPA Biosystems or Biorad) and appropriate 
primers. Data were acquired using the Stratagene Agilient MX3000P or Biorad CFX 
Connect, and calculated using ΔΔCT method.  
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Table 3.6. Table of DNA Oligonucleotides for PCR  
Name Sequence Purpose 
SP6 3'RACE R1 GGCCGGATTTAGGTGACACTATAGTTTTTTTTTTTTT
TTTTTTTTTTTT 
3′RACE Reverse primer 
SP6 3'RACE R2 CCGGATTTAGGTGACACTATAG 3′RACE Reverse primer 
TSS F1 CCCACTGCTTACTGGCTTATCG 3′RACE Transcription Start Site PASGFP 
Reporter 
TSS F2 CGAAATTAATACGACTCAC 3′RACE Transcription Start Site PASGFP 
Reporter 
TSS F3 GACCCAAGCTGGCTAGCG 3′RACE Transcription Start Site PASGFP 
Reporter 
mCHE-ORF F1 CTTCAAGTGGGAGCGCGTG 3′RACE, qRT-PCR: mCherry ORF 
mCHE-ORF F2 GGCGAGTTCATCTACAAGGTG 3′RACE, qRT-PCR: mCherry ORF 
mCHE-ORF F3 GCCTCCTCCGAGCGGATG 3′RACE pCCHAM Reporter mCherry ORF 
mCHE-ORF F4 GTCAACATCAAGCTGGACATC 3′RACE pCCHAM Reporter mCherry ORF 
mCHE-R1 GCTTCAGCCTCTGCTTGATCTC  qRT-PCR: mCherry ORF 
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T7 3'RACE R1 GGCCGGTAATACGACTCACTATAGTTTTTTTTTTTTT
TTTTTTTTTTTT 
3′RACE Reverse primer 
T7 R2 GGCCGGTAATACGACTCACTATAG 3′RACE Reverse primer 
NRO-G4A TGAGCAAGGGCGAGGAGCTGTT qRT-PCR, RTPCR: GFP ORF, Forward 
NRO-G4B AAGCACTGCACGCCGTAGGTCA  qRT-PCR, RTPCR: GFP ORF, Reverse 
NRO-G5A GGGCATCGACTTCAAGGAGGAC qRT-PCR, RTPCR: GFP ORF, Forward 
NRO-G5B ACGCTGCCGTCCTCGATGTT qRT-PCR, RTPCR: GFP ORF, Reverse 
NRO-NeoF ATTCGGCTATGACTGGGCAC qRT-PCR: Neomycin Resistance Gene ORF 
NRO-NeoR  CCAATAGCAGCCAGTCCCTT qRT-PCR: Neomycin Resistance Gene ORF 
eGFP RACE 3 GGATCACTCTCGGCATGG 3′RACE: GFP ORF 
eGFP RACE 2 GATCACATGGTCCTGCTGGAG  3′RACE: GFP ORF 
eGFP RACE 1 GACAAGCAGAAGAACGGCATC 3′RACE: GFP ORF 
NeoF2 TCGTGCTTTACGGTATCGCC RTPCR: Neomycin Resistance Gene ORF 
NeoR2 GGCGAAGAACTCCAGCATGA RTPCR: Neomycin Resistance Gene ORF 
N0143 GGCAAGCTGACCCTGAAGTT qRT-PCR; GFP ORF, Forward 
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N0144 GGTCTTGTAGTTGCCGTCGT qRT-PCR; GFP ORF, Reverse 
GAPDH F CAG GAG GCA TTG CTG ATG AT  qRT-PCR, RTPCR 
GAPDH R  GAA GGC TGG GGC TCA TTT  qRT-PCR, RTPCR 
B-GUSF  GAAAATATGTGGTTGGAGAGCTCATT qRT-PCR, RTPCR 
B-GUSR CCGAGTGAAGATCCCCTTTTTA qRT-PCR, RTPCR 
18S F CAGCCACCCGAGATTGAGCA qRT-PCR 
18S R TAGTAGCGACGGGCGGTGTG qRT-PCR 
ROCK1P1 F ACACTCTACCACTTTCCTGCCA qRT-PCR, RTPCR 
ROCK1P1 R TGTGGCACTTAACATGGCGTCT qRT-PCR, RTPCR 
N0D64 GTGAGCAAGGGCGAGGAGC qRT-PCR: GFP ORF, Forward 
N0D67 GGTCAGCTTGCCGTAGGTGG qRT-PCR: GFP ORF, Reverse 
N0129 GGACTTGAAGAAGTCGTGCTGC qRT-PCR: GFP w/intron Exon-Exon Junction, 
Forward 
N0130 GAG GGC GAT GCC ACC TAC  qRT-PCR: GFP ORF, Reverse 
N0157 CATGGTAACGCTGCCTCCAG RTPCR: Luciferase, Forward 
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N0158 GGCGATATGAGCCATTCCCG RTPCR: Luciferase, Reverse 
N0159 TCGAGCTGCTGAACCTTCCA RTPCR: Luciferase, Forward 
N0160 CGATCACGTCCACGACACTC RTPCR: Luciferase, Reverse 
N0161 TAGACGGCCTACCCTCTCCT RTPCR: Luciferase, Forward 
N0162 CCAGGGTCGGACTCGATGAA RTPCR: Luciferase, Reverse 
N0163 CCTGGGCTACCTGATTTGCG RTPCR: Luciferase, Forward 
N0164 GAAGCTGAACAGGGTTGGCA RTPCR: Luciferase, Reverse 
N0165 GCCGAGCTGGAGTCTATCCT RTPCR: Luciferase, Forward 
N0166 TCATGGTCTTGCCGTGTTCC RTPCR: Luciferase, Reverse 
N0167 TTCACCGATGCCCACATTGA RTPCR: Luciferase, Forward 
N0168 GTTCTCAGAGCACACCACGA RTPCR: Luciferase, Reverse 
NO169 CAGCGACGATCTGCCTAAGA RTPCR: Luciferase, Forward 
NO170 TCCAACGCTATTGTCGAGGG RTPCR: Luciferase, Forward 
NO171 ATCAAGAGCTTCGTGGAGCG RTPCR: Luciferase, Forward 
NO172 ACCGAGTTCGTGAAGGTGAAG RTPCR: Luciferase, Forward 
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NO173 ACGCTCCAGATGAAATGGGT RTPCR: Luciferase, Forward 
NO174 CGTGCTGAAGAACGAGCAGT  RTPCR: Luciferase, Forward 
WO851 GTTTACGTCGCCGTCCAGCTC qRT-PCR; GFP ORF, Reverse 
N0D103(RACE) AGGCGCAACCTCTCCTAGAAAC 3' RACE: Dux4 Exon 1 C-terminus 
N0D104(RACE) GAAGCACCCCTCAGCGAGGAA 3' RACE: Dux4 Exon 1 C-terminus 
N0D105(RACE) GGCTCTGCTGGAGGAGCTTTAG 3' RACE: Dux4 Exon 1 C-terminus 
NOD199 CCAGGAGATGTAACTCTAATCCAGGTTTGC RTPCR: Dux4 Exon 3, Reverse 
NOD200 GCTGGAAGCACCCCTCAGCGAGGAA RTPCR: Dux4 Exon 1 C-terminus, Forward 
NOD201 GAGCTCCTGGCGAGCCCGGAGTTTCTG RTPCR: Dux4 Exon 1 C-terminus, Forward 
NOD202 GGCCCGGTGAGAGACTCCACAC RTPCR: Dux4 Exon 2, Forward 
NOD203 GGCCCGGTGAGAGACTCCACA RTPCR: Dux4 Exon 2, Forward 
NOD204 GCGCACCCCGGCTGACGTGCAA RTPCR: Dux4 Exon 3, Forward 
NOD205 GTAACTCTAATCCAGGTTTGCCTAGACAGC RTPCR: Dux4 Exon 3, Reverse 
NOD206 CCCCGAGCCAAAGCGAGGCCCTGCGAGCCT  RTPCR: Dux4 Exon 1 N-terminus, Forward 
NOD207 CGGCCCTGGCCCGGGAGACGCGGCCCGC RTPCR: Dux4 Exon 1 N-terminus, Forward 
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NOD208A CCTGGTCTGCACTCCCCT qRT-PCR, RTPCR: Dux4 Exon1 C-terminus, 
Forward 
NOD208B  CTAAAGCTCCTCCAGCAGAGCC qRT-PCR, RTPCR: Dux4 Exon1 C-terminus, 
Reverse 
NOD208C GAGCCCGGTATTCTTCCTCG qRT-PCR, RTPCR: Dux4 Exon1 C-terminus, 
Reverse 
NOD208Anest GGCGCAACCTCTCCTAGAAA RTPCR: Dux4 Exon 1 C-terminus, Forward 
NOD208Bnest GAGCCCGGTATTCTTCCTCG RTPCR: Dux4 Exon 1 C-terminus, Reverse 
NOD209A GCTTTCGTGAGCCAGGCAGCG RTPCR: Dux4 Exon 1 C-terminus, Forward 
NOD209B CTTGAGCGGGCCCAGGCTGTG RTPCR: Dux4 Exon 1 C-terminus, Reverse 
NOD210A TCCCAGGGGAGTCCGTG RTPCR: Dux4 Exon 1 C-terminus, Forward 
NOD210B TTTCTAGGAGAGGTTGCGCC RTPCR: Dux4 Exon 1 C-terminus, Reverse 
NOD211A CTGGTCTGCACTCCCCTG RTPCR: Dux4 Exon 1 C-terminus, Forward 
NOD211B CGTCCTAAAGCTCCTCCAGC RTPCR: Dux4 Exon 1 C-terminus, Reverse 
NOD212 GTCTAGGCCCGGTGAGAGAC RTPCR: Dux4 Exon 2, Forward 
NOD213 ATCCACAGGGAGGGGGCATTTTAATATATC RTPCR: Dux4 Exon 3, Reverse 
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NOD229 GCTGGTACCTGGGCCG RTPCR: Dux4 Exon 2, Reverse 
NOD230 CTAGGCCCGGTGAGAGACT RTPCR: Dux4 Exon 2, Forward 
NOD231 GGTTTGCCTAGACAGCGTCG RTPCR: Dux4 Exon 3, Reverse 
NOD232 CGTAGCCAGCCAGGTGTTC RTPCR: Dux4 Intron 1, Reverse 
NOD233 AAGGCAGGAATCCCAGGC RTPCR: Dux4 Intron 1, Reverse 
NOD236 GAAAGGCAGTTCTCCGCGG RTPCR: Dux4 Exon 2, Reverse 
Dicer1 Common F CTCATTATGACTTGCTATGTCGCCTTG qRT-PCR 
Dicer1 Common R CACAATCTCACATGGCTGAGAAG qRT-PCR 
Dicer1 Distal F TGCTTTCCGCAGTCCTAACTATG qRT-PCR 
Dicer1 Distal R AATGCCACAGACAAAAATGACC qRT-PCR 
PRAMEF1 Biorad, PrimePCR SYBR Green: qHsaCED0057477 qRT-PCR, primer pair 
TRIM43 Biorad, PrimePCR SYBR Green: qHsaCID0038709 qRT-PCR, primer pair 
TRIM48 Biorad, PrimePCR SYBR Green: qHsaCID0022430 qRT-PCR, primer pair 
TRIM49 Biorad, PrimePCR SYBR Green: qHsaCED0046590 qRT-PCR, primer pair 
ZSCAN4 Biorad, PrimePCR SYBR Green: qHsaCID0036861 qRT-PCR, primer pair 
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Genomic DNA Extraction 
Genomic DNA was extracted from cells using the Rapid Genomic DNA Extraction 
(RGDE) method (Ali et al., 2008).  
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Chapter 4 : Development of Tools to Assay mRNA 3’end processing in cells 
 
 
 
 
 
 
This chapter is based in part upon Peart N, Wagner EJ. 2016. Gain-of-function 
reporters for analysis of mRNA 3′ end formation: Design and Optimization. BioTechniques 
60:137-140. doi 10.2144/000114390 
© 2009 BioTechniques. Used by Permission 
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Development of Tools to Assay mRNA 3′ end processing in cells. 
Introduction 
The formation of the 3′ end of mRNA is a complex and highly regulated process that 
is essential for the generation of mature mRNA (Chan et al., 2011). In eukaryotic cells, the 
process involves the recognition of cis sequence elements by several trans-acting protein 
factors (Mandel et al., 2008). A key cis element essential for this process is the 
hexanucleotide polyadenylation signal (PAS). The recognition of the PAS, typically 
AAUAAA, is aided by the presence of other cis sequence elements to stimulate cleavage 
and subsequent polyadenylation of the mRNA. These other sequences may include a 
loosely defined upstream sequence element (USE), a G/U-rich or G-rich downstream 
sequence element (DSE), and the actual cleavage site itself (Tian and Graber, 2012). The 
combination of these cis regulatory elements creates a biosynthetic context that determines 
whether an mRNA will be efficiently processed (Hu et al., 2005; Tian and Graber, 2012; 
Wilusz et al., 1990). Perturbation of this context is evident in the etiologies of a variety of 
human diseases (Danckwardt et al., 2008).  
Gain of Function Reporter 
Cell-based reporters can be used to analyze mutations in disease-causing genes for 
their effect on mRNA 3′ end formation, as well as to understand the biological mechanism of 
3′ end formation. Reporter systems have been successfully used to study the requirements 
of various RNA 3′ end formation, including the Nrd1/Nab3/Sen2 complex in Saccharomyces 
cerevisiae transcription termination (Steinmetz et al., 2001), the cis and trans requirements 
of histone mRNA 3′ end formation (Yang et al., 2009), the role of the Integrator complex in 
snRNA 3′ end formation (Albrecht and Wagner, 2012; Chen et al., 2013a), and more 
recently to investigate effects of the nuclear cap binding complex on stimulation of 3′ end 
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processing of several RNA families (Hallais et al., 2013).   In the case of snRNA or histone 
pre-mRNA processing the cis-acting signals are compact making reporter design 
straightforward, however, the processing signals required for cleavage and polyadenylation 
are much more diverse and cover larger ranges (Hu et al., 2005). Here, we describe the 
construction of an effective, gain-of-function reporter system to analyze pre-mRNA 
processing and provide an assessment of the reporter’s capabilities and limitations.  
To demonstrate the design and utility of a GFP expression-based assay to monitor 
mRNA 3′ end processing, we generated a transcriptional read-through reporter (Figure 
4.1A). This reporter (termed PAS-GFP) is constructed in the pcDNA3.1 (+) vector (Thermo 
Fisher Scientific) where sequences to be analyzed are cloned upstream of a GFP open 
reading frame (ORF), which itself is followed by a bovine growth hormone PAS. The 
expectation is that if RNAPII encounters a functional cleavage and polyadenylation signal 
prior to transcription of GFP-encoding mRNA, no fluorescence will be observed. As a 
positive control, we tested the late SV40 PAS, which has been well-characterized for 
cleavage and polyadenylation efficiency (Zarkower and Wickens, 1988). Into the PAS-GFP 
reporter, we inserted a 233-nt-long sequence that included the SV40 PAS, cleavage site, 
and a DSE.  Importantly, we also created two negative control reporters where random 
sequences devoid of defined cleavage and polyadenylation elements were inserted 
upstream of the GFP ORF (Figure 4.1A). All reporter constructs as well as an empty PAS-
GFP were each transiently transfected into HeLa or HEK293T cells and both protein and 
total RNA were isolated for analysis 48 hrs post-transfection (as described in (Albrecht and 
Wagner, 2012; Chen et al., 2013a)). An additional plasmid encoding HA-tagged mCherry 
was co-transfected to control for transfection efficiency. We observed that only the insertion 
of the SV40 PAS into the reporter prevented the expression of the GFP protein (Figure 
4.1B). Quantification of the GFP expression using ImageJ analysis correlated with qRT-PCR 
measurement of GFP mRNA (Figure 4.1C/D). It is noteworthy that both random sequences 
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slightly reduced the expression of the GFP reporter compared to the empty PAS-GFP 
vector.  This is not surprising as some level of translation inhibition would be expected from 
placement of a ~220nt insertion upstream of the GFP start codon.  Along the same lines, it 
is important to consider that not all random sequences are “inert” and may contain cryptic 
regulatory elements therefore it is recommended to test multiple negative control 
sequences. 
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Figure 4.1. PAS-GFP reporter analysis using an SV40 polyadenylation signal (PAS). (A) 
Schematic of the transcriptional read-through reporter designed to study mRNA 3´-end 
formation. The GFP open reading frame (ORF) without a native AUG start codon is placed 
downstream of either the SV40 PAS (SV40-GFP) or random sequences derived from the 
pUC vector (RSeq-GFP). (B) Western blot of lysates from HeLa cells (left) and HEK293T 
cells (right) transfected with the reporters shown in panel A. The Western blots were probed 
for GFP protein using αGFP. HAmCherry protein expressed from a co-transfected 
HAmCherry plasmid used to normalize transfection was probed with αHA, and tubulin used 
as a loading control was probed with α-tub. These controls were used in all blots throughout 
this study. (C) Quantification of the GFP signal in the Western blot of the HeLa lysates 
shown in panel B (left) was performed using Image J. (D) qRT-PCR analysis of RNA 
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isolated from the HeLa cells transfected as those analyzed by Western blotting in panel B 
(left). Error bars show standard deviation from three independent experiments. 
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To demonstrate sensitivity of the reporter to mutations of the cis regulatory element 
of 3′ end processing, we introduced a three-nucleotide mutation (AAUAAA to GGGAAA) of 
the PAS (PAS null [PN]), and deletion of the DSE (DSE null [DN]) or a mutation of the 
cleavage site (cleavage null [CN]) (Figure 4.2A) The most significant read-through was 
observed after mutation of the PAS and to a lesser extent the DSE (Figure 4.2B). It was not 
unexpected that the cleavage site mutation did not result in significant read-through as this 
is thought to be the least critical element, as alternative cleavage sites can be utilized if one 
is mutated (Tian and Graber, 2012). Importantly, we observed strong correlation between 
GFP protein expression and GFP mRNA levels demonstrating that GFP expression is 
reflective of mRNA production (Figure 4.2C/D). Finally, 3′ RACE and sequencing confirmed 
that the SV40 PAS located upstream of GFP or the BGH PAS located downstream of GFP 
represent the only two cleavage and polyadenylation events as predicted (Figure 4.2E). Our 
data show that while monitoring GFP expression is representative of transcriptional read-
through, we did observe slightly greater sensitivity measuring read-through using qRT-PCR 
analysis, where we measured the GFP mRNA levels normalized to the neomycin resistance 
mRNA encoded elsewhere within the PAS-GFP plasmid.  
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Figure 4.2 Effect of start codon context on polyadenylation signal (PAS)-GFP reporter 
analysis. (A) Schematic of SV40 mutant GFP reporter constructs with mutations of the PAS 
from AUAAAA to GGGAAA (PN), deletion of the downstream sequence element (DSE) 
(DN), and mutation of the cleavage site from CA to CG (CN). (B) Western blot of lysates 
from HeLa cells (left) and HEK293T cells (right) transfected with the reporters shown in 
panel A. (C) Quantification of the GFP signal in the Western blot of the HeLa lysates shown 
in panel B (left) performed using Image J. (D) qRT-PCR analysis of RNA isolated from the 
HeLa cells transfected with the reporters shown in panel A. Error bars show standard 
deviation from three independent experiments. (E) Ethidium bromide–stained agarose gel 
(top) showing products of 3´ rapid amplification of cDNA ends (RACE) of RNA isolated from 
HeLa cells transfected with the reporters shown in panel A. Sequence chromatogram 
(bottom) obtained by 3´ RACE showing that the SV40 PAS in the reporter uses the cleavage 
site previously reported in the literature. (F) Schematic of the transcriptional read-through 
reporter designed to study mRNA 3´-end formation. The GFP open reading frame (ORF) 
with a native AUG start codon was placed downstream of the SV40 PAS constructs. (G) 
Western blot of lysates from HeLa cells transfected with reporter constructs containing the 
SV40 PASs shown in panel A placed into the reporter plasmid with the native AUG start 
codon of GFP shown in panel F. 
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One possible concern for a transcriptional read-through reporter with large inserts 
upstream is the location and context of the start codon. The constructs shown in (Figure 
4.2A) all have the optimized GFP start codon mutated and rely on the start codon 
fortuitously located within the SV40 polyadenylation signal.  We redesigned the PAS-GFP 
reporter, such that the EGFP ORF cloned downstream of NotI maintains its native AUG 
(Figure 4.2F). The same SV40PAS and its mutants were then tested in this new context to 
determine if the presence of an optimal codon would alter the results. While we did not 
detect any difference in the effects of the SV40 mutants, however, we did observe 
preferential usage of the native AUG of the EGFP by Western Blot analysis (Figure 4.2G) 
despite the presence of an upstream start codon.  This is most likely because the NotI site 
flanking the endogenous EGFP start codon is GC rich similar to a Kozak sequence.  
Results from recent global analyses of altered RNA 3′ end formation events have 
uncovered a process that is highly dynamic and subject to regulation ((Gruber et al., 2014; 
Shepard et al., 2011; Xia et al., 2014), and reviewed in (Shi and Manley, 2015)).  However, 
these approaches must be followed up using specific reagents to provide mechanistic 
understanding on how RNA processing takes place. Typical reporters used by others to 
investigate mRNA 3′ end formation (Gehring et al., 2001; Mayr and Bartel, 2009) place the 3′ 
end processing elements downstream of a heterologous ORF (e.g. luciferase or -globin) 
and then either the protein or mRNA expression is measured. These reporters have proven 
to be robust and the primary strength of this design compared to the transcriptional read-
through reporter described in this study is that 3′ end processing occurs in a more native 
context, which is downstream of an ORF. However, the potential limitation of reporters with 
3′ end-processing signals placed downstream lies in the interpretation of loss-of-function 
events. Mutations that are introduced into these reporters that result in failure to produce the 
reporter product may be confounded by other factors such as instability of the RNA 
transcribed due altered 3′ UTR content. This concern is mitigated by the design of our 
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transcriptional read-through reporters.  However, the PAS-GFP reporter described here is 
also not without limitation. As previously mentioned, cryptic regulatory elements in the 5′ 
UTR may impair reporter expression. We addressed one of these limitations by exploring 
the importance of the start codon context (Figure 4.2). Additional considerations when 
designing a transcriptional read-through reporter are the presence of upstream ORFs 
(uORFs), secondary structures limiting start codon recognition, and the potential use of a 
non-AUG start codon (Araujo et al., 2012; Ivanov et al., 2011). These factors may affect 
translation of the downstream reporter. These constraints may also place an upper limit on 
the size of the construct investigated. 
Nonetheless, the customizable, gain-of-function PAS-GFP reporter described here 
offers an immunological and visual output to allow for a case-by-case analysis of mRNA 3′ 
end formation. Moreover, this reporter is readily adaptable for more complicated model 
systems including in vivo expression for tissue-specific analysis of mRNA 3′ end formation 
and genome-wide CRISPR screening to identify novel regulatory factors.  
Loss of Function Reporter 
While we have alluded to the weakness within loss of function reporters for assaying 
mRNA 3′ end processing in cells, these reporters are still a viable tool for assaying 3′ end 
formation if used appropriately, and the data are interpreted with an understanding of the 
reporter limitations. Here, we describe a loss of function reporter that addresses two 
limitations of traditional loss-of-function reporters that assay case specific mRNA 3′end 
formation in cells. The first limitation is the dependence upon radioactivity by means of 
northern blot or cell lysis to monitor enzymatic activity of the reporter gene. Here, we use the 
fluorescent mCherry as reporter. mCherry is a stable monomer with high brightness (Shaner 
et al., 2004) compared to other fluorescent proteins. We can detect the reporter expression 
using fluorescence intensity or by immunoblotting. The reporter is also amenable to analysis 
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of the mRNA by qPCR. The second limitation for assaying 3′end formation using loss-of-
function reporters lies in the failure to cleave and polyadenylate at the required downstream 
PAS. Instead, the polymerase may skip over what it perceives as weak PAS and the 
reporter may be subject to unintentional alternative cleavage and polyadenylation (APA). To 
address this limitation downstream of the multiple cloning site into which the interrogated 
PAS is cloned we placed the self -cleaving ribozyme Schistosoma Mansoni Hammerhead 
(Martick et al., 2008). This reporter, termed pCCHAM (Figure 4.3A) is constructed in the 
pUC19 vector. The CMV promoter was amplified and cloned in the EcoRI restriction site of 
the pUC19 vector. We then cloned using annealed oligonucleotide, as described above, the 
S. Mansoni Hammerhead, between PstI and HindIII. HA-tagged mCherry was amplified and 
cloned into the KpnI and BamHI. Polyadenylation signals interrogated with this reporter were 
cloned between BamHI and SalI. As a proof of principle, to investigate the utility of the 
reporter, we cloned the late SV40PAS as described above. We also used site-directed 
mutagenesis to generate PAS Null, Cleavage Null and DSE null SV40 constructs as 
described previously in this study for the PAS-GFP Reporter (Figure 4.3A).  
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Figure 4.3 pCCHam reporter analysis using an SV40 polyadenylation signal (PAS). A. 
Schematic of the loss of function pCCHAM reporter designed to study mRNA 3′-end 
formation. The mCherry open reading frame (ORF) is cloned in the pUC Vector, after a 
cytomegalovirus (CMV) promoter, and the self-cleaving Hammerhead ribozyme (HH) is 
placed in the 3′ terminus of the multiple cloning site of the vector. Random Sequence 
(Random Seq or RSeq) derived from elsewhere in the pUC vector or SV40PAS sequences 
are cloned between the stop codon of mCherry and the Hammerhead ribozyme. (B) qRT-
PCR analysis of RNA isolated from the HeLa cells transfected with pCCHAM SV40 or 
pCCHAM without PAS (empty). Error bars show standard deviation from two independent 
experiments. (C) Fluorescent plate reader analysis of HeLa cells transfected with pCCHAM 
SV40, pCCHAM Empty, pCCHAM RSeq. Fluorescence intensity above background was 
measured relative to untransfected cells, and normalized for transfection using GFP which 
was co-transfected. (D) Fluorescent plate reader analysis (Top) of HeLa cells transfected 
with the reporters shown in panel A.  Percentage fluorescence intensity of relative to 
pCCHAMSV40, and normalized for transfection using co-transfected GFP. Western blot 
(Bottom) of lysates from HeLa cells. The Western blots were probed for HAmCherry protein 
expressed with α-HA, and tubulin used as a loading control was probed with α-tub.  
 
  
110 
 
The reporter was transiently transfected into HeLa cells and protein and RNA were 
extracted from the cells 48 hrs post transfection. Prior to harvesting RNA or protein from the 
cells, fluorescence intensity was determined for each construct. We demonstrate that we do 
not detect reporter expression when there is no PAS, while the SV40 PAS placed 
downstream of mCherry allows for robust reporter expression (Figure 4.3B/C). Furthermore, 
we observe a reduction in the expression of the mCherry, when the hexanucleotide PAS is 
mutated (PN), and the DSE is removed (Figure 4.3D The cleavage site (CN) mutant likely 
does not show significant reduction due in part to the promiscuity in the cleavage site 
selection (Pauws et al., 2001; Tian and Graber, 2012). On the other hand, in our PAS-GFP 
reporter we still obtained a cleavage product using the CG dinucleotide as a cleavage site, 
despite its suboptimality (Chen et al., 1995; Furger et al., 1998; Jin et al., 2005). Therefore, 
these reporters may not be sensitive enough to measure the efficacy of CPA by impairing 
the cleavage site, or further supports other data (Chen et al., 1995; Furger et al., 1998; Jin 
et al., 2005) that favor promiscuity in the cleavage site selection.  
Nevertheless, this reporter still possess the limitation that reporter output, is subject 
to UTR destabilization unrelated to CPA, which can obfuscate the results. However, like 
similar reporters this can be addressed by assaying the mRNA levels in conjunction with the 
protein output. Nonetheless, it can be useful as a complement to the PAS-GFP reporter to 
interrogate CPA in a more native context, provided validation in the PAS-GFP reporter 
supports the interrogated element as a PAS.  
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Chapter 5 : Exploring the 3′ end processing of Dux4 mRNA 
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FSHD, a disease of the dysregulated 3′ end processing? 
The importance of the context of the cis regulatory elements is evident in disease 
pathology. Several human diseases can be attributed to dysregulation of 3′ end processing 
of mRNA. Two common human diseases attributed to changes in cis regulatory elements 
that result in disease include β-thalassemia and thrombophilia. Loss-of-function mutation 
within the PAS of the β-globin gene decreases the efficiency of cleavage and 
polyadenylation and thereby mRNA production, which consequently impairs accumulation of 
the β-globin protein and leads to the development of β-thalassemia (Orkin et al., 1985). In 
contrast, gain-of-function mutations due to CG to CA mutation within the prothrombin gene 
creates an optimal cleavage site and increases the production of prothrombin mRNA by 
enhancing cleavage and polyadenylation of the pre-mRNA. This event greatly increases the 
predisposition toward thromboembolic disorders (Danckwardt et al., 2008; Gehring et al., 
2001). 
In addition to these well-characterized human pathologies, several other lesser-
understood diseases are  also associated with changes in the efficiency of 3′ end processing 
of mRNA.  Recently, it has been demonstrated that Facioscapulohumeral Dystrophy (FSHD) 
can also be linked to single nucleotide polymorphisms that generate cis elements mediating 
3′ end formation that affect the CPA of a pathogenic mRNA (Lemmers et al., 2010a). 
Individuals with FSHD inappropriately express Dux4. The expression of Dux4 in 
FSHD muscle cells is not only contingent on D4Z4 derepression, but also requires the 
presence of a stable collection of single nucleotide polymorphisms (SNPs), or haplotype, in 
a region of DNA downstream of the D4Z4 repeats. In the general population, there are two 
equally common haplotypes of chromosome 4, namely A and B. Haplotype A, with which 
FSHD is associated, is distinguished from haplotype B by the presence of a segment of 
DNA called pLAM and a 6.2kb degenerate β-satellite repeat immediately downstream of the 
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D4Z4 repeat (van Geel et al., 2002; Lemmers et al., 2004) (Figure 5.1). Concomitant with 
the transcriptional depression at the FSHD locus, a SNP in the pLAM creates a functional 
but non-canonical PAS (AUUAAA) that allows for the production of the Dux4 mRNA 
(Lemmers et al., 2010a, 2012; Snider et al., 2010). Dux4, a homeodomain gene, is not 
normally expressed in somatic cells but is robustly expressed in testes and is thus posited to 
play a role in development (Dixit et al., 2007; Snider et al., 2010; Young et al., 2013). In 
germline cells, Dux4 is alternatively spliced and uses a PAS distal to that which may be 
created by SNPs in pLAM (Snider et al., 2010) .The inappropriate expression of Dux4 is 
believed to contribute to muscle damage caused by various mechanisms including defects 
in myogenesis via induction of apoptosis, immune response stimulation, and inappropriate 
activation of germline transcription (van der Maarel et al., 2012). 
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Figure 5.1. Schematic of Chromosome 4qA chromosome. Chromosome 4qA depicted with 
hypermethylated transcriptionally silenced D4Z4 repeats (gray triangles) upstream of pLAM 
and the β-satellite repeat region. Reduction in the number of repeats leads to 
hypomethylation and transcriptional derepression. The image on the bottom magnifies the 
terminal D4Z4 repeat and downstream sequences, and shows the Dux4 ORF in the D4Z4 
repeats. The downstream sequences specific to the haplotype A, shows pLAM with a SNP 
creating a PAS and the β-satellite repeats defined by recurring sites for the restriction 
enzyme Sau3A. 
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In patients with FSHD, the productive transcription of Dux4 mRNA is facilitated by 
SNPs within certain haplotypes on chromosome 4 that supply a PAS. However, beyond the 
non-canonical PAS, the cis sequence elements that define the context for 3′ end formation 
of Dux4 are undefined. The purpose of this study was to identify cis sequence elements that 
aid in the efficiency of cleavage and polyadenylation of Dux4 mRNA. We anticipated that the 
Dux4 PAS would be weak because of its non-canonical nature and that it would require 
additional regulatory elements to mediate 3′ end processing. Here, we use a transcriptional 
read-through reporter (PAS-GFP) described previously in Chapter 4 to interrogate the cis 
requirements of Dux4 cleavage and polyadenylation. With use of this tool, we identified a 
previously uncharacterized element that is required to mediate Dux4 mRNA 3΄ end 
formation. Surprisingly, this element, although potent in enhancing processing, is located 
more than 100 nucleotides downstream of the PAS and is present within the β-satellite 
region. This finding underscores the complexity of Dux4 expression and uncovers a 
potentially new therapeutic target to inhibit Dux4 expression. 
β-Satellite Sequences Contribute to Dux4 mRNA 3’ End Formation.  
The pLAM sequence, which contains the SNP creating the PAS for Dux4, is ~240 
base pairs and includes a portion of the terminal intron as well as the terminal exon 3 
(Figure 5.1). To test the relative efficiency of this sequence to act as a CPA element, we 
cloned pLAM into the PAS-GFP reporter (described in Chapter 4) and transfected this 
construct into HeLa cells and HEK293T (Figure 5.2A). Surprisingly, despite a functioning, 
albeit non-consensus, PAS present within pLAM, we observed a significant amount of GFP 
expression relative to the SV40-GFP reporter. This could indicate that (1) the Dux4 PAS is 
significantly weaker than SV40, (2) other sequence elements are required for efficient CPA, 
(3) Neither HEK293T nor HeLa cells can recapitulate Dux4 CPA to the extent of muscle 
tissues, or (4) the small portion of the terminal intron that was included in the pLAM-GFP 
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reporter somehow disrupts recognition of the Dux4 PAS (Figure 5.2B/C, lane 2).To address 
this last point, we also generated a PAS-GFP reporter containing only exon 3 upstream of 
GFP. We observed that removal of the partial intron resulted in a slight decrease in GFP 
expression; however, GFP protein was still readily detectable (Figure 5.2B/C, lane 3). 
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Figure 5.2. Identifying the minimal region necessary to suppress GFP. (A). Schematic of the 
terminal D4Z4 repeat pLAM and β-satellite to show the Dux4 constructs cloned upstream of 
118 
 
the GFP ORF. (B and C). Western blots of cell lysates for HEK293T (left) and HeLa cells 
(right). Loading control was α-tubulin, transfection control was αHA to recognize co-
transfected HAmCherry.  
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We then generated two more Dux4 reporters into which we inserted genomic 
fragments containing increasing amounts of DNA flanking the pLAM PAS to include either 
~100 nucleotides on either side of the PAS or ~200 nucleotides (Figure 5.2A). We observed 
a total suppression of GFP expression only when ~200 nucleotides of sequence flanking on 
either side of the pLAM PAS was included in the PAS-GFP reporter (Figure 5.2B/C, lanes 3-
4). Finally, we conducted 3′ RACE on RNA isolated from the pLAM-GFP, Exon3-GFP, P100-
GFP or P200-GFP transfected cells. We observed that the primary product was due to 
transcriptional read-through for the pLAM, Exon 3 and P100 sequence; however, when the 
P200 sequence was used, we observed a small upstream cleavage product (Figure 5.3). 
Sequencing of this smaller fragment confirmed that the Dux4 PAS is used, although the 
cleavage site mapped to 1-2 nucleotides upstream of the annotated sequence. 
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Figure 5.3. 3′ RACE of Dux4 constructs in PAS-GFP Reporter. On top, ethidium bromide 
stained agarose gel with PCR products, amplified from HeLa cells transfected with Dux4 
constructs, resolved to show upstream cleavage product and read-through product. On 
bottom, sequence chromatogram of upstream cleavage product from clone P200, the PAS 
and cleavage site are underlined. 
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On the basis of the observation that additional sequences located on either side of 
the Dux4 PAS are required for its efficient CPA, we sought to increase the resolution of our 
analysis by using deletions. To first determine whether cis elements lie upstream or 
downstream of the Dux4 PAS, we created two additional reporter constructs. The ΔD-GFP 
reporter lacked 100 nucleotides from the 3′ terminus of P200, thereby removing the second 
β-satellite repeat, whereas the ΔU-GFP reporter retained only 100 nucleotides upstream of 
the PAS (Figure 5.4A). In agreement with results presented in Figure 5.2, we observed GFP 
expression from the P100-GFP reporter but not from the P200-GFP reporter; moreover, we 
noted GFP expression from the ΔD-GFP reporter but not from the ΔU-GFP reporter (Figure 
5.4B/C). These results demonstrate that sequences that were removed in the ΔU-GFP 
reporter are dispensable for Dux4 CPA, whereas sequences within the second β-satellite 
repeat are required for Dux4 CPA. Altogether, these results indicate that sequences 
downstream of the Dux4 PAS are required for its efficient use. 
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Figure 5.4. Elements for Dux4 CPA lie downstream of PAS. (A). Schematic of Dux4 CPA 
constructs cloned upstream of GFP. (B and C). Western blot of lysates from HEK293T and 
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HeLa cells transfected with the constructs in (A). Loading control and transfection control 
are α-tubulin and αHA respectively.  
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Downstream Auxiliary Elements aids in cleavage and polyadenylation of Dux4. 
To further delineate the location of the downstream element, we performed deletion 
mutagenesis, in 20-nucleotide increments, of the terminal 100 nucleotides of the P200 
sequence (henceforth called full-length, FL) (Figure 5.5A). By Western blot analysis, we 
observed that we gained GFP expression when the last 40 nucleotides were removed from 
the FL Dux4 CPA construct (Figure 5.5B). Following up with a fluorescence plate reader 
assay to increase sensitivity, we observe that there is complete loss of GFP fluorescence 
only in the FL construct, suggesting that an element lies within the last ~20 nucleotides. This 
discrepancy may be as a result of the amount of protein loaded, and/or the sensitivity of the 
GFP antibody used.    
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Figure 5.5. Deletion series identifies element in the extreme 3′ terminus of the Dux4 CPA 
construct. (A). Schematic of deletion constructs of Dux4 FL cloned upstream of GFP (B). 
Western blot of lysates from HEK293T cells transfected with reporter containing Dux4 PAS 
constructs shown in A. Loading control and transfection control are α-tubulin and αHA 
respectively. (C). Quantification of data from plate reader assay of GFP fluorescence 
normalized to co-transfected HA tagged mCherry. Hatched vertical line indicates where the 
sensitivity of the Western blot is diminished. Error bars calculated from standard deviation of 
biological triplicates. 
 
  
127 
 
To achieve even greater resolution of the regulatory element, we compared the 
constructs Δ40 and Δ60, and further made transversion mutations in six-nucleotide clusters 
within the region that the Δ40 possess and the Δ60 lacks (Figure 5.6, left). We observed that 
there is an increase GFP expression, when mutations of the last six nucleotides are made, 
which reproduced using a fluorescence plate reader (data not shown).  
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Figure 5.6. Point mutation analysis in construct Δ40 compared with Δ60. (Left) Schematic of 
the Dux4PAS constructs showing Δ40 and Δ60, transversion mutations of six nucleotides 
were made in the 3′terminus of the Δ40 construct. Wild type sequence depicted in lower 
case, mutations are shown in upper case. (Right) Western blot of Dux4PAS constructs 
depicted on left. Loading control and transfection control are α-tubulin and αHA respectively. 
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We further assessed the validity of our data, by making transversion mutations in the 
context of our full-length Dux4 CPA (Figure 5.7, left). Due to the weak signal we quantified 
the expression of the GFP from three different experiments, and our analysis of the western 
blots (Figure 5.7, right) re-identifies the cis regulatory element (mutant C) identified in the 
context of the Δ40 mutants in (Figure 5.6). In addition, we identify near the 3′ end of the full 
length Dux4 CPA another element (mutant K), wherein mutation of this sequence resulted in 
increased GFP expression. In the second instance we mutated AGAGA to CTCTC, while the 
first element identified in both point mutation analyses share an overlap of the nucleotide 
AAC mutated to CCA. Mutated sequences that increase GFP expression were over 150 -
130 nucleotides downstream of the Dux4 polyadenylation signal and cleavage site, 
respectively. Here we identify downstream sequences that are required to suppress GFP 
expression which we correlate with facilitating cleavage and polyadenylation at the Dux4 
PAS. Nonetheless, we acknowledge that confirmation of their importance for 3′ end 
processing requires the analysis of the RNA levels. A limitation of the PAS-GFP reporter is a 
consequence of the immunoblotting or fluorescent readout for the analysis of CPA events. 
To ensure that the reporter protein is produced, it is imperative that the upstream PAS: (1) is 
cloned in frame, (2) contains no in frame stop codons or start codons if the native reporter 
start codon is used, and (3) contains no start codons out of frame with the reporter protein 
ORF. All these consideration as well as those discussed in Chapter 3, limit the scope of the 
PAS-GFP reporter while site-directed mutagenesis to remove these elements may interrupt 
or create alternative cis regulatory elements.   
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Figure 5.7.  Effects of mutation in Dux4 Downstream Auxiliary Element (DAE). (Left) Schematic of the Dux4PAS constructs 
depicting transversion mutations of five nucleotides made in the DAE of Dux4. (Right) Representative western blot of Dux4PAS 
constructs depicted on left. Quantification of western blots from 3 experiments performed using Biorad Image Lab software, and 
mutants with reproducible increases in GFP expression shown. Loading control and transfection control are α-tubulin and αHA 
respectively. 
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Evaluating Dux4 3′ end processing “natively” 
To further assay Dux4 processing we placed the Dux4 P200 construct downstream 
of the mCherry ORF. Surprisingly, we did not detect robust mCherry expression, although 
we observed a 3′ RACE product from the P200 construct (not shown).To determine if the 
UTR is destabilizing we used the dual luciferase reporter system and placed the terminal 
exon of pathogenic Dux4, Exon 3, into the psiCheck 2 vector (Figure 5.8). However, we did 
not see any decrease in luciferase expression. Consequently, we switched models, and 
moved the 3’ UTR into a splicing capable reporter (Figure 5.9A). As a consequence of 
frequent PCR errors and recombination events due to the repetitive nature of the Dux4 
sequence, we opted to further modify the region cloned downstream of the GFP ORF such 
that we retained 100 nucleotides upstream of the Dux4 polyadenylation signal and 500 
nucleotides downstream of the of the PAS, as we previously showed that elements 
downstream of the PAS were critical for 3′ end processing (Figure 5.2). When the Dux4 CPA 
elements were placed downstream of an intron containing GFP, we observed robust protein 
expression, similar to SV40. Moreover, the strength of the GFP expression was directly 
related to presence of downstream auxiliary elements of Dux4 (Figure 5.9B). 3′RACE of the 
reporter containing solely the Dux4CPA produced a polyadenylated product cleaved as 
reported in the literature and as observed with our PAS-GFP reporter. However, we also 
observed that there was another band present which when sequenced showed a cleavage 
product due to utilization of a PAS (not identified) in the vicinity of the GFP stop codon. This 
product would correspond to GFP transcript with a short UTR (Figure 5.9C). Due to the lack 
of any destabilizing elements in the Dux4 UTR cloned as determined by luciferase assay, 
we speculate that the upstream splicing aided in cleavage and polyadenylation with the 
Dux4 PAS. Alternately, the usage of an alternate polyadenylation signal in the reporter 
containing the full Dux4 CPA, may result in a robust protein production not dependent on an 
132 
 
mRNA cleaved and polyadenylated at the Dux4 CPA element. However, this is unlikely, as 
we observe that substituting the 100 nucleotides upstream of the Dux4 polyadenylation 
signal with the minimal SV40PAS upstream sequence elements, also produced robust GFP 
expression and we detect only a single band in the 3′ RACE (Figure 5.9C). Moreover, 
sequencing of the PCR product showed that the cleavage and polyadenylation event 
occurred at the same location as used by the full intact Dux4PAS. In contrast, creating a 
reciprocal construct, in which the downstream sequence elements (DSE) of SV40PAS are 
placed after the Dux4 polyadenylation signal, we observed that the primary cleavage and 
polyadenylation event occurs downstream of the SV40 DSE, suggesting the use of another 
unidentified polyadenylation signal (Figure 5.9). 
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Figure 5.8. Histogram of terminal Exon 3 of pathogenic Dux4 in dual luciferase reporter. 
Exon 3 cloned downstream of Renilla luciferase and transfected into HEK293T cells. Renilla 
luciferase expression was normalized to Firefly luciferase. Error bars shown depict standard 
deviation of biological triplicates. 
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Figure 5.9. Reporter gene expression as a result of Dux4PAS. (A). Schematic of reporter 
showing intron-containing GFP, cloned downstream are the SV40PAS, Dux4PAS and 
chimeric constructs which retain the Dux4 hexanucleotide polyadenylation signal, but have 
either sequence upstream or downstream of the  polyadenylation signal substituted for the 
complementary elements in the SV40PAS. Blue boxes represent SV40 sequences and 
green boxes represent Dux4 sequences. In pictogram of SV40 gray rectangle denotes 
polyadenylation signal and red line indicates cleavage site. In the pictogram of the Dux4 
construct, black rectangle indicates the polyadenylation signal, and red line shows the 
cleavage site used. The chimeric construct DUSD contains 100 nucleotides of Dux4 UTR 
sequences upstream (green box) of the Dux4 PAS (black rectangle), and extends to the 
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cleavage site (dotted line).The 96 nucleotide SV40DSE is immediately downstream of the 
cleavage site. Red line denotes the cleavage site used. The chimeric construct SUDD 
contains 100 nucleotides of SV40 upstream sequence elements (blue bar), the Dux4PAS 
(black rectangle) and the Dux4 DAE (green bar). The cleavage site used is indicated by the 
red line. (B). Representative western blot HEK293T cells transfected with constructs shown 
in A.  Transfection control depicts co-transfected myc tagged mCherry. Loading control and 
transfection control are α-GAPDH and α-myc respectively. (C). Ethidium bromide stained 
2% agarose gel showing 3′ RACE products obtained from the HEK293T cells transfected 
with constructs depicted in A. RT denotes reverse transcriptase, and + or -, represents the 
presence or absence of reverse transcriptase in the cDNA synthesis. Untransfected 
HEK293T cells were also included in the 3′RACE. 
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Design and Use of ASO targeting CPA 
The utility of RNA as both a target and a modality to influence gene expression is 
rapidly becoming mainstream. This has been spurred by recent advances in nucleic acid 
based technology such as clustered regularly-interspaced short palindromic repeats 
(CRISPR), and improvement in commercially availability of chemically modified nucleic acids  
(Haussecker, 2016). One of the broadest methods to target RNA and modify gene 
expression uses antisense mechanisms (reviewed (Kole et al., 2012; Potaczek et al., 
2016)).  This is exemplified by the increasingly common place use of RNA interference 
(RNAi) and antisense oligonucleotides (ASOs). The simplest definition of an ASO would 
describe a short polymer of the nucleotides A, T, U, C or G as a ribose or deoxyribose 
sugar, which is used to bind RNA or DNA molecules through base pairing. ASOs are 
typically modified to increase affinity, stability and accessibility. Increases in the stability, that 
is resistance to nucleases, can be accomplished by modifying the backbone chemistry; for 
example, using phosphorothioate bonds in lieu of a phosphodiester bonds for polymer 
conjugation. However, while a phosphorothioate backbone increases ASO stability, it also 
reduces the affinity of the ASO for the target and introduces chirality (Koziolkiewicz et al., 
1995), and indeed alternative backbones have been investigated to achieve increased 
nuclease resistance without loss of affinity (Freier and Altmann, 1997).  Additional 
modifications, when an RNA template ASO is in use, include substituting the reactive 2′ 
hydroxyl group with a more stabilizing or neutral group. With such substitutions, the loss of 
binding affinity caused by using a phosphorothioate backbone can be rescued (and further 
improved). Likewise, in the context of a phosphodiester backbone, substitution of the 2′ 
hydroxyl group can increase  nuclease resistance of ASOs (Monia et al., 1993, 1996) . 
Common substitutions are 2′-O-methyl or 2′-O-fluoro. Alternatively, nucleoside analogues 
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such as peptide nucleic acids (PNA), locked nucleic acids (LNAs), phosphorodiamidate 
morpholino oligomers (PMOs) may be used.  
Antisense strategies, can be exploited in many ways for example, RNAi is a routinely 
used antisense strategy and employs small RNAs (short interfering RNAs, microRNAs) 
incorporated in the RNA induced silencing complex (RISC) machinery to decrease 
translation of target mRNA and degrade the RNA (reviewed by (Iwakawa and Tomari, 2015; 
Jonas and Izaurralde, 2015)). In the case of ASOs, the chemistry and design affects the 
behavior when it interacts with the target substrate. One such application ASOs is to 
degrade the RNA and downregulate gene expression. This method takes advantage of the 
nuclease, RNase H, which cleaves RNA molecules in RNA:DNA hybrids (reviewed (Bennett 
and Swayze, 2010; Crooke, 2004)). However, not all ASOs are meant to degrade RNA. 
Fully modified antisense oligonucleotides which do not induce RNase H action ASOs can be 
and have been used to repurpose the molecule by affecting how it is processed (reviewed 
(Bennett and Swayze, 2010; Kole et al., 2012)). The best studied application in modulating 
RNA processing, is the use of ASOs to change splicing events. In this instance, the ASOs 
are designed to bind RNA and sterically impair protein:RNA interactions, such as those 
between splicing factors and exonic splicing silencer or enhancers, thus promoting exon 
inclusion or skipping. The application of ASOs in redirecting splicing has been widely 
explored, however, there are other RNA processing events which can be interrogated by 
splicing (Kole et al., 2012; Sazani and Kole, 2003).  
Cleavage and polyadenylation of mRNA is a tenable target for application of ASOs, 
and others have shown that using CPA targeting ASO can redirect polyadenylation signal 
choice or impair CPA altogether (Marsollier et al., 2016; Vickers et al., 2001). Moreover, they 
have been used to elucidate molecular mechanisms behind RNAPII termination events 
(Zhang et al., 2015). Here, we design steric blocking ASOs targeting CPA elements of 
endogenous genes and reproduce a redirection of polyadenylation signal choice. In addition, 
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we use steric blocking and RNase H sensitive (gapmer) ASOs to interrogate the elements 
critical for 3′ end formation of Dux4 mRNA in a reporter system, and to downregulate the 
endogenous expression of the gene.  
 
Short Antisense Oligonucleotide shows primarily nuclear localization 
We designed a short, 15 nucleotide ASO, with a fluorescein moiety at the 5′ end, 
ASO-2F (Table 3.5) and transfected this nucleotide into RD cells, HEK293T, HeLa, and an 
immortalized FSHD patient myoblast cell line, 15Abic CT#24. HEK293T cells were 
transfected with ASO 2F at concentration ranging from 100nM to 2.5µM, and cells were 
visualized by microscopy twenty four hours after transfections. The immortalized patient 
myoblast cell line was transfected at the same concentrations of ASO. Twenty four hours 
after transfection the cells were shifted to differentiation medium, and cells were ultimately 
visualized by microscopy five days after inducing differentiation (see Chapter 3, methods).  
 While there was minimal toxicity to HEK293T cells to even the highest dose of ASO 
used, we did observe that the 15Abic cells were less resilient. The toxicity of the higher 
doses (>500nM) of ASO-2F to 15Abic cells is likely to account for the decreased myotube 
formation observed (Figure 5.10). Furthermore, we observed that in addition to the toxicity, 
the localization of ASO-2F in 15Abic cells was primarily cytoplasmic at lower concentrations, 
however, the ASO was enriched in the nucleus with increasing concentrations. In contrast, 
ASO-2F was primarily nuclear (Figure 5.11) at low concentrations in HeLa, HEK293T and 
RD cells. However, as the ASO concentration increased, the localization became more 
diffuse and punctate (Figure 5.12). Differences in ASO behavior dependent on the cell line 
has been previously reported (Crooke, 2004). Another consideration, that after six days the 
fluorescein group on the ASO may have been hydrolyzed and the observed fluorescent 
signals were the consequence of free fluorescein. However, we do observe that there 
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appears to be diffuse localization of the ASOs in the cells even after changing the medium 
at 4 hrs post transfection. 
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Figure 5.10. Fluorescein labelled Antisense Oligonucleotide transfected into immortalized 
FSHD patient cells. Images of 20X magnification of 15Abic CT#24 cells, five days after 
initiating differentiation, six days after transfection with fluorescent ASO. Phase contrast 
images (BF), DAPI and green fluorescence images shown, for cells transfected with 
increasing concentrations of fluorescent ASO. Toxicity observable at higher concentrations 
(1µM) where there is an increase in the balled cells as well as decreased cell density. 
Transfection of lower concentrations (0.1 and 0.500µM) had less toxicity and cell 
morphologies were consistent with healthy growing cells upon verge of differentiation, 
although we do not observe robust myotube formation (multinucleated cells). Increasing 
concentration of ASO resulted in more diffuse localization of ASO, as well as the 
appearance of punctate spots. Exposure times were kept constant.  
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Figure 5.11.  Merged Images of cells transfected with low concentration of Fluorescein 
labelled ASO. (Top) Merged bright field (BF) and green channel images (GFP) of HeLa, 
HEK293T and RD cells transfected with 100nM fluorescein labelled ASO at 10X 
magnification. Localization of the ASO is primarily nuclear. (Bottom) Merged images (bright 
field with DAPI and bright field with GFP) of immortalized FSHD patient cells transfected 
with 100nM fluorescein labelled ASO at 10X magnification. Localization heterogeneous, 
majority of cells show cytoplasmic localization, but some cells show both nuclear and 
cytoplasmic localization.  
  
142 
 
 
Figure 5.12. Microscope images at HEK293T cells transfected with increasing 
concentrations of fluorescein labelled ASO. Bright field (BF) images show little cellular 
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toxicity, in the green channel (fluorescein) increasing concentration of ASO in more visibly 
fluorescent cells and more diffuse localization of ASO in the cell. Exposure times were kept 
constant.  
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Determining the utility of ASOs with use a reporter 
As a proof of principle and to investigate the utility of CPA targeting ASOs to 
decrease protein expression we designed ASOs targeting the SV40 polyadenylation signal. 
We generated a reporter in which the SV40PAS is placed downstream of an intron 
containing GFP ORF. The HEK293T cells were first transfected with antisense 
oligonucleotides, and later transfected with reporter (see Chapter 3 Methods). After 48 hrs, 
the cells were harvested for protein. Western blot analysis and quantification demonstrates 
that the different approaches have different levels of efficiency, and also that the chemistry 
employed has different levels of antagonistic effects for protein expression. Using this 
protocol we observed that both steric and gapmer ASOs resulted in ~70% decrease in 
protein expression, however, the decrease was modest and not significant with the steric 
blocking ASO (Figure 5.13). 
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Figure 5.13.  Western blot of HEK293T cells transfected using with SV40 PAS directed 
ASOs using a two hit protocol. Cells were first treated with ASOs, subsequently cells were 
simultaneously transfected with ASOs plasmid containing SV40PAS downstream GFP. 
Control ASO is a scrambled version of the SV40PAS directed ASO. Loading control and 
transfection control are α-GAPDH and α-Cherry respectively. Quantification performed using 
Bio-Rad Image Lab on western blots from biological triplicates. Error depicts standard 
deviation of biological triplicates. (A). Western blot of HEK293T cells transfected using 2hit 
protocol with 100nM SV40PAS directed gapmer ASO. (B). Western blot of HEK293T cells 
transfected using 2hit protocol with 100nM SV40PAS directed steric ASO.  
  
146 
 
Two limitations of the two-hit protocol used above are pretreatment of the ASOs, as 
well as co-transfection with the reporter. It is conceivable in the latter instance, that co-
transfecting the ASO with the reporter may be biased toward either the plasmid DNA or the 
ASO. Another possibility is that there is segregation of plasmid and ASO upon transfection 
such that cells which are transfected with ASOs do not necessarily take up the plasmid 
DNA, and vice versa. The first caveat in which the cells are pre-treated with ASO prior to the 
addition of the reporter, may influence the data in that cells do not have a pre-existing pool 
of the target substrate, so the data would have a limited range of applicability. Similar 
protocols have been employed by others in which cells are induced to produce the gene of 
interest subsequent to addition of the antisense (Bennett et al., 1992; Chiang et al., 1991; 
Vickers et al., 2001). To address these limitations, we first transfected the reporter, and 
following transfection of the reporter we treated the cells once or twice with antisense 
oligonucleotides (see Chapter 3 Methods). To deplete the preexisting pool as well as 
decrease subsequent production we transfected a higher concentration of both steric and 
gapmer ASO. Once more we observe a ~70% reduction in GFP protein expression with a 
PAS directed gapmer ASO (Figure 5.14). Although, we do see a reduction in the GFP 
protein expression with PAS directed steric ASO, there was high degree of variability which 
resulted in a loss of significance. A pertinent consideration in this approach would be the 
consideration of the half-life of the reporter protein (estimated to be 26 hrs) (Corish and 
Tyler-Smith, 1999)and mRNA, however, cells are harvested for protein 48 hrs post 
transfection which should provide sufficient time to observe an effect. 
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Figure 5.14. Western blot of HEK293T cells transfected using with SV40 PAS directed 
ASOs. Cells transiently transfected with plasmid containing SV40PAS downstream GFP, 
and subsequently transfected with 1.25µM of ASO. Control ASO is a scrambled version of 
the SV40PAS directed ASO. Loading control and transfection control are α-GAPDH and α-
myc respectively. Quantification performed using Biorad Image Lab on western blots from 
biological triplicates. Error depicts standard deviation of biological triplicates. (A). Western 
blot of HEK293T cells transfected with1.25µM SV40PAS directed gapmer ASO. (B). 
Western blot of HEK293T cells transfected using 2hit protocol with 1.25µM SV40PAS 
directed steric ASO. 
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Having cloned the Dux4PAS and DAE downstream of the intron-containing GFP, we 
attempted to use CPA targeting ASOs to decrease the reporter protein expression. In our 
pilot experiments we first transfected HEK293T cells with the reporter containing the 
Dux4PAS, and subsequently transfected the cells with increasing concentrations of ASO, 
targeting the PAS and DAE. Using gapmer ASOs, we were not able to achieve reproducible 
depletion in GFP expression when cells were transfected with the PAS directed ASO 
compared to the control treated cells (not shown). Likewise, changes in the GFP expression 
in cells transfected with steric ASO, were highly variable. One cause for concern is the 
usage of alternate PAS in the reporter when Dux4 CPA elements are placed downstream 
(Figure 5.9) this could prevent the detection of any changes in the protein expression, due to 
inducing alternative cleavage polyadenylation. As such, we feel that further optimization is 
necessary. One method to address this concern, would be the development of a stable 
clonal line with a reporter using the Dux4PAS. However, care would have to be taken to 
ensure that GFP expression detected is as a consequence of Dux4PAS usage, and not due 
random integration into the genome supplying alternative polyadenylation signals. Using an 
analogous reporter in which we have the chimeric SV40UTR/Dux4PASDAE (Figure 5.9) 
placed downstream of the intron-containing GFP we generated clonal stable cell lines. 
Although amplification of genomic DNA suggested that all the elements Dux4CPA 
downstream of the intron containing GFP were present as desired (Figure 5.15) we 
observed the difficulty in identifying clones that solely use the Dux4 CPA (Figure 5.15). 
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Figure 5.15. Ethidium Bromide stained agarose gels of stable GFP positive clonal lines. 
(Top) 2% agarose gel with products of nested PCR amplification of genomic DNA to identify 
GFP positive clones that had the GFP ORF and Dux4PAS and CPA elements downstream. 
PCR products were excised and purified, then submitted for sequencing and restriction 
digest screen. The * (positive control) indicates the parental plasmid used to generate the 
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stable cell line amplified by PCR. (Middle) Clones which were positive in the nested PCR 
amplification, were digested with BamHI and EcoRI and resolved on 3% agarose gel. The * 
indicates the control positive control PCR product digested also with BamHI and EcoRI. 
(Bottom) 3′ RACE on clonal lines which contained GFP upstream of the Dux4PAS.   
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Redirecting CPA 
We next turned our attention to an endogenous gene in HeLa cells. Dicer has 
multiple polyadenylation signals (Masamha et al., 2014). We designed both steric and 
gapmer ASOs targeting the distal PAS of Dicer. A double transfection of 100nM dicer siRNA 
using the standard two hit protocol (see Chapter 3 Methods) was able to give robust 
knockdown ~80% compared to a non-targeting siRNA (Figure 5.16). Comparatively, we 
performed a single transfection of both steric and gapmer ASOs targeting Dicer1 at a final 
concentration of 100nM, and observe that a PAS directed gapmer ASO produced a ~40-
50% decrease in the Dicer1 mRNA levels, when measured using a primer within the ORF 
and a primer which detects Dicer1 transcripts using a distal polyadenylation signal. In 
contrast, using the PAS directed steric blocking ASO, we did not detect a significant 
decrease in the overall Dicer1 mRNA levels, and instead, we observed ~ 60% decrease in 
usage of distal polyadenylation signal. We interpret the data presented here, as redirection 
of the polyadenylation signal choice by a PAS directed steric ASO. The availability of more 
than one polyadenylation signal likely, limits the extent of knockdown that can be achieved 
with the steric blocker. In contrast, the gapmer ASO allows for degradation of the mRNA due 
to the action of RNase H, regardless of whether or not there is an alternative 
polyadenylation signal. In addition, the gapmer ASO is not restricted to working during the 
process of CPA, but can also lead to degradation of the processed mRNA in both the 
cytoplasm and nucleus. Increasing the concentration of gapmer ASO or following a two hit 
protocol similar to the siRNA transfection may increase the level of knockdown. Although the 
depletion would be most observable in transcripts using the distal polyadenylation signal. 
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Figure 5.16. PAS directed ASO redirect PAS or reduce gene expression. (Top) Schematic of 
Dicer1 open reading frame (ORF) and untranslated region (UTR), head to head arrows 
indicate the location of the primers used to amplify Dicer. Vertical bars in the UTR denote 
position of the proximal (pPAS) and distal (dPAS) polyadenylation signal. Horizontal lines 
with diagonal hatches indicate location of siRNA and PAS-Directed ASO. (Bottom) qRT-
PCR analysis of HeLa cells transfected with control or Dicer1 siRNA (siD1#1), and both 
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steric and gapmer ASOs directed toward the distal polyadenylation signal of Dicer1.Control 
ASOs are derived from a scramble of the SV40PAS directed ASO.  Error bars calculated 
from standard deviation of biological triplicates. Distal and proximal polyadenylation signal 
indicated are as previously described by Masamha et al. 2014. Primers to amplify Dicer1 
common and distal previously described by Masamha et al. 2014.  
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Dux4 in 15Abic cells 
One of our primary goals was to decrease the Dux4 protein expression. Dux4 is 
typically poorly expressed, and detection is difficult. Nonetheless, we attempted to detect 
Dux4 protein in the 15Abic immortalized cell line. We immunoprecipitated with a Dux4 
antibody (9A12) that recognizes the Dux4 (but is reported to cross hybridize with other 
Dux4-like proteins) and then subsequently performed a western blot to detect Dux4 using an 
antibody which uniquely recognizes the Dux4 C-terminus (Geng et al., 2011). Consistent 
with previous reports that Dux4 is induced upon differentiation (Block et al., 2013), we 
observe a strong signal at ~55kDa (likely Dux4) (Figure 5.17A), due to the predicted size of 
the Dux4 protein being 45-52kDa. However, contrary to previous reports (Pandey et al., 
2015), substitution of knockout serum replacer (KOSR) in place of horse serum (HS) in the 
differentiation medium, did not enrich or stimulate for Dux4 protein detection (Figure 5.17B). 
Knockout serum replacer is posited to enhance myotube formation, which would 
consequently promote Dux4 expression (Block et al., 2013). However, it is notable that, at 
the time of lysis, both the horse serum and knockout serum replacer differentiated cells had 
roughly the same amount of multinucleated cells (not shown). 
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Figure 5.17. Detecting Dux4 Protein in Immortalized FSHD patient lines. (A). Western blot 
probed with α-Dux4 (E5-5) of 5Abic myoblasts (MB) and myotubes (MT) immunoprecipitated 
with α-Dux4(9A12). Protein marker shown. (B). Western blot of 15Abic myoblasts (MB) and 
myotubes (MT). Myoblasts were differentiated over 5 days in either 20% Knockout Serum 
Replacer (KOSR) or 2% Horse Serum. Blots probed for differentiation marker myosin heavy 
chain (α-MHC) and Dux4 protein with αDux4 (E5-5). Loading control is α-GAPDH.  
156 
 
Conclusions 
Here, I identified that additional cis regulatory elements, besides the non-consensus 
PAS are required for cleavage and polyadenylation of Dux4.  Previous bioinformatics 
analyses posit that RNA elements critical for cleavage and polyadenylation optimally lie 
within 100 nucleotides of cleavage site and are typically Uridine rich (Hu et al. 2005; 
Legendre and Gautheret 2003). The location of these cis regulatory elements for Dux4 
cleavage and polyadenylation are outside the optimal 100 nucleotide window downstream of 
both the polyadenylation signal and the cleavage site. Moreover, this element lies within a 
degenerate repeat regions, which leads us to form two hypotheses to model Dux4 cleavage 
and polyadenylation. The cis elements identified are not enriched for uridines, and the 
degeneracy of the repeats impairs the identification of similar motifs, although the 
commonality between the regions identified to increase GFP expression seems to be biased 
toward purines. 
In the context of our reporter, we identify a DAE that appears to enhance Dux4 
mRNA 3′ end processing from the non-consensus PAS. Thus, we present the following 
models for how the DAE identified enhances CPA of Dux4 (Figure 5.18). We propose that 
the DAE facilitates efficient cleavage and polyadenylation by one of two potential 
mechanisms.  The first involves the recognition of the DAE within the nascent pre-mRNA by 
a yet-to-be identified RNA binding factor that would enhance the recognition of the PAS by 
the CPSF machinery.  
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Figure 5.18. Model of Dux4 Processing. (A.) RNA binding proteins interacting with the 
downstream auxiliary element (DAE) identified may facilitate Dux4 cleavage and 
polyadenylation by aiding in the recruitment of CPSF machinery to the non-consensus PAS. 
Alternatively, (B). The DAE may be a DNA element that induces RNA pauses due either to 
sequence identity of protein blockage. The stalled polymerase kinetically favors cleavage 
and polyadenylation at the non-consensus Dux4 PAS. 
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An alternative explanation, is that the DAE aids in the 3’ end formation of Dux4 
mRNA by pausing (or terminating) of the RNA polymerase. Polymerase pausing is well 
defined in terms of its role in transcription initiation, particularly for stress response genes 
(Kwak and Lis 2013), however, less is known about the role of RNAPII pausing to facilitate 
mRNA maturation. One of the best understood pausing elements, which can influence 
mRNA 3’end processing, is the MAZ sequence (Yonaha and Proudfoot 1999, 2000). It has 
been shown that placement of MAZ elements downstream of the of poorly defined exons 
such as α-tropomyosin exon 3 or Fibroblast Growth Factor Receptor II exon IIIb, increases 
their inclusion presumably through providing additional time for splice site recognition 
(Roberts et al. 1998; Robson-Dixon and Garcia-Blanco 2004). 
Upon cloning the Dux4 CPA downstream of mCherry we disappointingly did not 
observe robust expression. However, as we found increasing the β-satellite repeats 
sequences downstream increased reporter expression. Significantly, we also observed that 
introduction of splicing upstream of the Dux4CPA increased our detection of the Dux4 
mRNA. However, due to the presence of additional cleavage products in the 3′RACE we 
cannot exclude that the Dux4CPA elements may result in a lower production of mRNA 
compared to the upstream PAS.  
Finally, using the knowledge acquired we designed Dux4 CPA targeting ASOs to 
prevent protein expression.  We undertook proof of principle experiments and demonstrate 
that CPA targeting ASOs can decrease gene expression or redirect cleavage and 
polyadenylation. Unfortunately, we have not yet been able to directly impair gene expression 
using Dux4PAS targeting ASOs in either our reporter system or in patient cell lines. In the 
immortalized patient cell line we observed a wide range of toxicity in response to several of 
the ASOs tested in 15Abic cells. In our reporter system, we do not get reproducible 
decrease in reporter protein expression. Analysis of the RNA would illuminate whether we 
are observing alternative polyadenylation in the reporter system. Further, in the patient cell 
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lines optimization of the ASO delivery, with due consideration for the ASO chemistry that we 
have accessible, is required.  
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Chapter 6 : Conclusions, Perspectives and Future Directions 
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Downstream Auxiliary Sequences aid cleavage and polyadenylation of Dux4PAS 
Using a transcriptional read-through reporter, we confirm that additional cis elements 
are required for cleavage and polyadenylation (CPA) of Dux4 besides the non-consensus 
polyadenylation signal (PAS). Moreover, this element is not located within a 100 nucleotides 
of either the Dux4 PAS, or the cleavage site.  Interestingly, the downstream auxiliary 
element lies within a degenerate repeat region, called β-satellite DNA. Moreover using the 
RegRNA2.0 tool (http://regrna2.mbc.nctu.edu.tw/index.html) (Chang et al., 2013), we do not 
observe an enrichment for any known RNA motifs associated with cleavage and 
polyadenylation within this region. 
 
Testing a Model: Are the Dux4PAS auxiliary sequences RNA or DNA? 
In Chapter 6, we propose two models describing how the downstream auxiliary 
sequence elements (DAE) may aid in CPA of Dux4. While the models are not necessarily 
mutually exclusive, we can interrogate the downstream sequences to examine the extent to 
which either DNA or RNA elements facilitates CPA of the Dux4PAS. To interrogate the 
model that the DAE is a DNA element we may use two complementary methods: Nuclear 
Run-On assay and transcriptional pausing assay. Previously, we attempted to use a non-
radioactive Nuclear Run-On assay to interrogate Dux4 PAS sequence elements for 
transcriptional pausing in PAS-GFP reporter transfected cells, however, our available cell 
lines proved refractory to labelling with 5-Bromouridine. The Nuclear Run On/Off Assay (Li 
and Chaikof, 2002; Smale, 2009), provides a cell based method to assay nascent and active 
transcription on genes. However, we can use also use the assay to comparatively 
demonstrate the absence of transcription in the regions that are anticipated to not have 
robust transcriptional activity due to termination events (Skourti-Stathaki et al., 2011), such 
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as cleavage and polyadenylation of the mRNA and the subsequent removal of the RNA 
Polymerase II (RNAPII) from the template. However, this assay does not prove pausing, and 
as such the complementary cell-free transcriptional pausing assay, such as the G-Less 
Cassette Assay (Carey et al., 2010) is also useful to investigate this hypothesis of 
transcriptional pausing.  
To address the hypothesis that the DAE functions primarily as an RNA element, 
antisense oligonucleotides (ASO) may serve as a useful tool. The utility of ASOs for 
therapeutic intervention is slowly growing (Kole et al., 2012; Potaczek et al., 2016), however, 
we can also use ASOs in cell-free RNase protection assays and cleavage and 
polyadenylation assays to interrogate the relevance of the RNA DAE for processing. Steric 
impairment  of DAE:Protein interaction (Zhang et al., 2015) or removal of the DAE by RNase 
H activating ASO may reveal whether the DAE in the pre-mRNA is critical for cleavage and 
polyadenylation.  
 
The significance of non-canonical cis elements for cleavage and polyadenylation and 
their interactions with cleavage and polyadenylation trans factors  
The size and complexity of protein factors required to cleave the mRNA transcript 
from transcribing RNAPII and DNA template underscores the importance of cis regulatory 
elements to facilitate accurate and correct cleavage and subsequence polyadenylation ((Shi 
et al., 2009)and reviewed in part (Chan et al., 2011; Wahle and Rüegsegger, 1999; Yang 
and Doublié, 2011)). It has been shown that WDR33 and CPSF30, as part of the cleavage 
and polyadenylation specificity factor (CPSF) recognize and bind to the consensus PAS, 
AAUAAA (Chan et al., 2014; Schönemann et al., 2014). WDR33 appears to preferentially 
associate with Uridines immediately downstream of the PAS, while the CPSF30 shows a 
preference toward the AU PAS (Schönemann et al., 2014; Shimberg et al., 2016). However, 
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in the case of non-consensus PAS, the tolerance for the divergence from the AAUAAA and 
low Uridine enrichment is unclear (Chan et al., 2014; Schönemann et al., 2014; Shimberg et 
al., 2016). Interestingly, although AUUAAA is fairly frequently used as a PAS, (~17% 
compared to >50% for the AAUAAA, and <20% for other variants) (Tian and Graber, 2012), 
WDR33 enrichment at AUUAAA PAS was low compared to the AAUAAA and other variants 
(Schönemann et al., 2014). In the case of pathogenic expression of Dux4, the PAS used is 
AUUAAA; and although there is a short stretch of containing two small Uridine tracks (<4 
nucleotides) and intermittent presence of UG, immediately downstream of the cleavage site, 
there is no apparent enrichment elsewhere. Additionally, using our PAS-GFP reporter, we 
demonstrate that a cleavage product with Dux4PAS is detected when we place more than 
100 nucleotides downstream of the PAS, the additional sequences do not show an 
enrichment for Uridine stretches.  
Cleavage and polyadenylation assays suggests that cleavage after a non-adenosine 
nucleotides is poor (Sheets et al., 1990).  In the literature the reported cleavage site of Dux4 
is AG (Lemmers et al., 2010a; Snider et al., 2009). The RNA template within this region 
reads AGA and so could be cleaved at either the G or A. In our hands, we reproducibly 
detect a cleavage product within the TATA region a single nucleotide upstream of the GA. 
However, an important observation here is that the cleavage site is close to the upper limit 
downstream of the PAS; cleavage and polyadenylation typically occurs within 30 nucleotides 
of the PAS (Chan et al., 2011). While there is a known micro-heterogeneity in cleavage site, 
the significance is unclear (Chan et al., 2011). However, we believe that an additional 
consideration should be whether there is a relevance between PAS consensus (that is the 
sequence of the PAS as well as the presence and strength of USE and DSE) and the 
distance of cleavage site from the PAS. Mutation of the cleavage site does not significantly 
impair processing, because the endonuclease, CPSF73, can simply cleave the RNA at an 
alternate location, these observations were reported in the context of a RNA substrates 
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modelled on the late SV40 polyadenylation signal or L3 adenovirus-2 polyadenylation signal 
that bare the consensus, PAS, AAUAAA (this study and (Mandel et al., 2006; Sheets et al., 
1990)).  
We propose that the Dux4 PAS, with its paucity of notable motifs for CPA, would be 
a good substrate to interrogate the factors that bind to a non-consensus PAS. By developing 
a stable cell line with the gain of function reporter (such as the PAS-GFP) using the 
Dux4PAS, a large scale CRISPR/Cas9 screen (Shalem et al., 2014) can be then employed 
to identify genes which cause of loss of cleavage and polyadenylation of Dux4. Identified 
genes can then be investigated using RNA immunoprecipitation or RNA binding assays to 
determine interaction with Dux4PAS. Likely such a screen would provide a lot of candidates; 
thus to narrow the investigation, combining unbiased RNA immunoprecipitation and mass 
spectrometry to identify proteins interacting with the Dux4PAS with the aforementioned 
CRISPR/Cas9 screen to identify genes that result in loss of cleavage and polyadenylation of 
Dux4 would be ideal. 
Chromosome 10 contains D4Z4 repeats, and pLAM and is nearly identical to the 
D4Z4 repeats and pLAM on chromosome 4, however FSHD is exclusively associated with 
the hypomethylation of D4Z4 repeats on chromosome 4 (van Geel et al., 2002; Lemmers et 
al., 2010b; van Overveld et al., 2003; Wijmenga et al., 1992).Non-pathogenic single 
nucleotide polymorphisms (SNPs) generate ATTTAA or ATCAAA, which are not recognized 
as PAS on chromosome 10. Interestingly, placing the pathogenic SNP (generating ATTAAA) 
in the context of a non-permissive chromosome 10 supported cleavage and polyadenylation, 
albeit inefficiently (Lemmers et al., 2010a).  Nonetheless, we posit that the context of the 
SNP that generates the PAS is critical for CPA of Dux4. It is imperative to consider what 
additional SNPs are present that allow for the AUUAAA to be used as a PAS for Dux4, and 
also to what extent does the degeneracy of the β-satellite repeats affect the CPA? While 
overwhelming evidence supports the hypothesis that poor expression of Dux4 expression is 
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a consequence of dysregulated epigenetic silencing (resulting in a leaky and stochastic 
event), it is also possible that cleavage and polyadenylation at this non-consensus PAS is 
impaired due to the degeneracy of the downstream β-satellite repeats. There have been 
dissenting data presented that discounted the importance of the pathogenic SNP, there exist 
individuals who fit the molecular criteria for FSHD, but who do not present with disease 
(Ricci et al., 2013; Scionti et al., 2012). The molecular criteria being contracted D4Z4 
repeats on chromosomal haplotype 4qA161. As such we recommend additional sequencing 
of patient DNA, with due consideration to the sequence identity and arrangement of the β-
satellite to determine if there is a correlation between severity of disease, disease onset, or 
disease presence or absence (asymptomatic FSHD). This may indicate differential efficiency 
in the CPA of Dux4, and thus production of the somatically toxic gene. 
Downstream Auxiliary Sequences aid cleavage and polyadenylation of Dux4PAS, but 
is there more? 
Although, we identify downstream sequences critical for production of a cleavage 
product using the PAS-GFP reporter we failed to detect robust mRNA and protein 
expression when the identified Dux4 CPA is placed downstream of the a reporter such as 
mCherry. This suggests that there are additional requirements beyond the PAS and the 
downstream auxiliary sequences. This is likely, because although the P200 construct 
suppresses detection of the reporter protein in the PAS-GFP, we still detect an upstream 
read-through product. However, it is unlikely that this read-through product is abundant as it 
was detected only in the second round of PCR in the 3′ RACE. Moreover, the read-through 
transcript, unlike the short upstream cleavage transcript, contains a stop codon and as such 
is not susceptible non-stop decay (reviewed by (Klauer and van Hoof, 2012)) which would 
reduce abundance. Further supporting low abundance of the read-through transcript in the 
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P200 constructs, the P100, Exon 3 and pLAM constructs all produced a detectable read-
through transcripts in the first round of PCR.   
While cloning the Dux4 PAS sequences required for CPA and reporter protein 
expression we made an interesting observation: splicing upstream enhanced reporter 
expression from the Dux4PAS. The observation that splicing affects CPA is not novel 
(Kaida, 2016), however, when considering the architecture of the Dux4 gene, the 
observation is intriguing. The Dux4 pre-mRNA has two introns in the untranslated region 
(UTR). It had been previously demonstrated that the second intron causes the transcript to 
be subject to nonsense mediated decay (Feng et al., 2015). However, the relevance of the 
first intron which is retained in Dux4 isoform, Dux4Fl-1, had not been investigated. As 
previously mentioned (see Chapter 2), a cryptic splice site within the first exon reportedly 
generates a short isoform, Dux4-s which if translated would lack the C-terminal domain, and 
may act as a dominant negative (Geng et al., 2012). Additionally, it has been observed by 
others during an attempt to generate a transgenic Dux4 mouse containing the terminal D4Z4 
repeat and abutting pLAM that there was frequent missplicing (Ansseau et al., 2015). Upon 
analysis, we observe that the 5′ splice site after Dux4 exon 1 deviates 50% from the 
consensus sequence bound by the U1snRNP. This poor splice site is likely in competition 
with alternative sequences that have higher complementarity with the U1snRNP, and 
consequently make better substrates for exon ligation, and we further posit that missplicing, 
should it happen in patient cells, may contribute to the poor detection/expression of the 
Dux4 mRNA.  
 
Antagonizing Dux4 mRNA 3′ end formation 
One of the primary goals of our investigation is to use Dux4PAS directed ASOs to 
downregulate gene expression. One consideration for using ASOs is the accessibility of the 
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target sequence. RNA molecules are not naked single stranded moieties in the cell, instead, 
they adopt intricate secondary and tertiary structures by forming intra- and inter- molecular 
bonds. Alternatively, or simultaneously RNA may be bound by proteins and packed into 
ribonucleoproteins (RNPs). The result of this propensity to adopt secondary, tertiary and 
quaternary structural conformations is that sequence elements targeted by antisense 
oligonucleotides may be inaccessible. Consequently, the application and utility of ASO is 
dependent on the stability and affinity of the interaction between RNA targets and non-ASO 
molecules (proteins, RNA etc.). In addition, ASO utility and application is dependent on the 
kinetics of the interactions. There are various strategies to limit these restrictions, but, for 
use in therapeutics some of these options may be inapplicable. For example, increasing the 
concentrations of ASO, increases the probability of ASO:RNA interactions, but may prove 
toxic to patients. In another example, pretreating with ASOs prior to the activation of the 
targeted event increases the likelihood of modulating the gene expression, however, this 
would be a preventative measure rather than corrective. 
Apart from consideration of accessibility to target by ASO, we should also consider 
the implication of escape of targeted RNA from ASO. Here we use diphtheria toxin as an 
example, wherein low expression of the diphtheria toxin (purportedly a single molecule) is 
enough to cause toxicity (Murphy, 1996). By extension, we must address if this observation 
is pertinent to Dux4, and to what extent must we reduce Dux4 for there to be a beneficial 
effect. Dux4 expression is toxic to a wide variety of cells, with the possible exception of germ 
cells (given the robust detection of Dux4 in the testicular tissue) (Kowaljow et al., 2007; 
Snider et al., 2010). Given the stochastic and low expression of Dux4, we must ask how 
many molecules of Dux4 are required to trigger Dux4-dependent pathologies. Although, 
Dux4 mice do not recapitulate the full scope of FSHD, it has been shown that even leaky 
expression of the protein can be lethal, and that surviving mice preferentially had the Dux4 
gene silenced (Dandapat et al., 2014).  
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Recently, others have demonstrated that Dux4PAS directed antisense 
oligonucleotides can impair Dux4 expression in patient cells (Marsollier et al., 2016). 
However, a global assessment of the effects of PAS directed ASOs, has not yet been 
performed. The rationale for global assessment are (1) ASOs are generally very stable, and 
stay in the cells for prolonged period and thus may have off-target effects (Bennett and 
Swayze, 2010; Crooke, 2004).  ASOs have also been shown to activate innate immunity 
pathways (Agrawal and Kandimalla, 2004; Burel et al., 2012; Crooke, 2004; Senn et al., 
2005; Watts and Corey, 2012). 
Successfully modulating gene expression with ASOs is empirical in both the clinic 
and laboratory. Considerations for when using ASOs must include dosage frequency and 
concentration and chemical modifications on the ASO to decrease toxicity while maintaining 
efficacy (Crooke, 2004) amongst other thing. Yet another consideration, it that the clinical 
response to use of antisense oligonucleotide therapies may be independent and distinct 
from the response observed in the laboratory setting (reviewed by(Watts and Corey, 2012)). 
As previously mentioned, ASOs can activate immune response pathways, due to triggering 
interferon and extracellular signal–regulated kinases (ERKs) signaling (Burel et al., 2012; 
Senn et al., 2005) and thus the utility of ASOs in mitigating the debilitating effects of one 
disease is cancelled by the induction of acute inflammation. Furthermore, ASO delivery may 
result in inappropriate organ targeting, and often hepatoxicity (Burel et al., 2016; Watts and 
Corey, 2012). There is increased commercial availability of a variety of chemical 
modifications for RNA or DNA based antisense oligonucleotides as well as the availability of 
nucleoside analogues. Together with new modalities of ASO delivery the off target effects in 
the clinical setting may be further reduced (Watts and Corey, 2012).  
Using a reporter system where the Dux4 CPA is placed downstream of an intron-
containing GFP, we have not been able to reproducibly deplete Dux4. 3′ RACE of the 
reporter shows that there is another cleavage event upstream of the Dux4PAS which would 
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still generate GFP protein. In contrast, the SV40PAS only shows one cleavage event. 
Others have shown that steric blocking ASOs can be used to redirect polyadenylation signal 
choice and cleavage site (Marsollier et al., 2016; Vickers et al., 2001), and we reproduce 
this effect. As such it is possible, that Dux4PAS-directed ASOs may redirect cleavage and 
polyadenylation. However, the irreproducible decrease in reporter expression was observed 
for both steric and gapmer ASO. 
Continued investigation of the use of Dux4PAS directed ASOs is required, not only to 
reproduce decrease in the gene expression, but also to address specificity. This would be 
broadly applicable to any PAS-directed ASO therapeutic especially with the consideration of 
causing alternative cleavage and polyadenylation. 
 
Significance  
Here we study the non-consensus PAS, AUUAAA, of Dux4 and interrogate the 
adjacent sequences to identify cis elements that enhance cleavage and polyadenylation 
from the Dux4PAS. The identification of downstream sequences in a degenerate repeat 
(regardless of the distance from the PAS) is intriguing because of the implication that a lack 
of consensus elements would allow for great variability in how this element mechanistically 
aids cleavage and polyadenylation.   
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